

1228867

THE UNITED STATES OF AMERICA

TO AND TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

September 22, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/495,172

FILING DATE: *August 14, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/26338

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label N . EV342494129US

19704 U.S. PTO
60/495172
08/14/03

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Helen Christopher G.	Francis -Lang Winter	San Francisco, California Palo Alto, California
<input checked="" type="checkbox"/> Additional inventors are being named on the 1 separately numbered sheets attached hereto		
TITLE OF THE INVENTION (500 characters max)		
MBCATs as Modifiers of the Beta-Catenin Pathway and Methods of Use		
CORRESPONDENCE ADDRESS		
Direct all correspondence to: <input checked="" type="checkbox"/> Customer Number 23500 → Place Customer Number Bar Code Label here OR Type Customer Number here		
<input type="checkbox"/> Firm or Individual Name		
Address		
Address	State	ZIP
City		
Country	Telephone	Fax
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages	104	<input type="checkbox"/> CD(s), Number
<input type="checkbox"/> Drawing(s) Number of Sheets		<input checked="" type="checkbox"/> Other (specify) return receipt postcard
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	FILING FEE AMOUNT (\$) 	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees		
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:	50-1108	160
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No.		
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____.		

Respectfully submitted,
SIGNATURE 
[Page 1 of 2] Date 8/14/2003
TYPED or PRINTED NAME Laleh Shayesteh REGISTRATION NO. 47,937
TELEPHONE 650.837.8223 Docket Number: EX03-053P

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO : Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROVISIONAL APPLICATION COVER SHEET

Additional Page

PTO/SB/16 (05-03)

Approved for use through 4/30/2003. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number	EX03-053P
---------------	-----------

INVENTOR(S)/APPLICANT(S)

Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Richard Benn Abegania	Ventura	Daly City, California
Lynn Margaret	Bjerke	San Francisco, California
Kim	Lickteig	San Francisco, California
Joanne I.	Adamkewicz	San Francisco, California
HaiGuang	Zhang	El Sobrante, California
Bing	Hai	Redwood City, California

[Page 2 of 2]

Number 1 of 1

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE

BACKGROUND OF THE INVENTION

The *Drosophila Melanogaster* Armadillo/beta-catenin protein is implicated in multiple cellular functions. The protein functions in cell signaling via the Wingless (Wg)/Wnt signaling pathway. It also functions as a cell adhesion protein at the cell membrane in a complex with E-cadherin and alpha-catenin (Cox et al. (1996) J. Cell Biol. 134: 133-148; Godt and Tepass (1998) Nature 395: 387-391; White et al. (1998) J Cell Biol. 140:183-195). These two roles of beta -catenin can be separated from each other (Orsulic and Peifer (1996) J. Cell Biol. 134: 1283-1300; Sanson et al. (1996) Nature 383: 627-630).

In Wingless cell signaling, beta -catenin levels are tightly regulated by a complex containing APC, Axin, and GSK3 beta /SGG/ZW3 (Peifer et al. (1994) Development 120: 369-380).

The Wingless/ beta -catenin signaling pathway is frequently mutated in human cancers, particularly those of the colon. Mutations in the tumor suppressor gene APC, as well as point mutations in beta -catenin itself lead to the stabilization of the beta -catenin protein and inappropriate activation of this pathway.

The ability to manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 108: 19-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; and Booth DR. 1999 Cancer

Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a “genetic entry point”) that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a “modifier” involved in the same or overlapping pathway as the genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as beta-catenin, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in their entireties.

SUMMARY OF THE INVENTION

We have discovered genes that modify the beta-catenin pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as modifier of beta catenin (MBCAT). The invention provides methods for utilizing these beta-catenin modifier genes and polypeptides to identify MBCAT-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired beta-catenin function and/or MBCAT function. Preferred MBCAT-modulating agents specifically bind to MBCAT polypeptides and restore beta-catenin function. Other preferred MBCAT-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MBCAT gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

MBCAT modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with an MBCAT polypeptide or nucleic acid. In one embodiment, candidate MBCAT modulating agents are tested with an assay system comprising a MBCAT polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate beta-catenin modulating agents. The assay system may be cell-based or

cell-free. MBCAT-modulating agents include MBCAT related proteins (e.g. dominant negative mutants, and biotherapeutics); MBCAT -specific antibodies; MBCAT -specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with MBCAT or compete with MBCAT binding partner (e.g. by binding to an MBCAT binding partner). In one specific embodiment, a small molecule modulator is identified using a binding assay. In specific embodiments, the screening assay system is selected from an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

In another embodiment, candidate beta-catenin pathway modulating agents are further tested using a second assay system that detects changes in the beta-catenin pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the beta-catenin pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

The invention further provides methods for modulating the MBCAT function and/or the beta-catenin pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a MBCAT polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated the beta-catenin pathway.

DETAILED DESCRIPTION OF THE INVENTION

In a screen to identify enhancers and suppressors of the Wg signaling pathway, we generated activated beta -catenin models in *Drosophila* based on human tumor data (Polakis (2000) Genes and Development 14: 1837-1851). We identified modifiers of the Wg pathway and identified their orthologs. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, MBCAT genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a

defective beta-catenin signaling pathway, such as cancer. Table 1 (Example II) lists the modifiers and their orthologs.

In vitro and in vivo methods of assessing MBCAT function are provided herein. Modulation of the MBCAT or their respective binding partners is useful for understanding the association of the beta-catenin pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for beta-catenin related pathologies. MBCAT-modulating agents that act by inhibiting or enhancing MBCAT expression, directly or indirectly, for example, by affecting an MBCAT function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. MBCAT modulating agents are useful in diagnosis, therapy and pharmaceutical development.

Nucleic acids and polypeptides of the invention

Sequences related to MBCAT nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) or RefSeq number), shown in Table 1 and in the appended sequence listing.

The term “MBCAT polypeptide” refers to a full-length MBCAT protein or a functionally active fragment or derivative thereof. A “functionally active” MBCAT fragment or derivative exhibits one or more functional activities associated with a full-length, wild-type MBCAT protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of MBCAT proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan *et al.*, eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. In one embodiment, a functionally active MBCAT polypeptide is a MBCAT derivative capable of rescuing defective endogenous MBCAT activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of an MBCAT, such as a kinase domain or a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). Methods

for obtaining MBCAT polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of an MBCAT. In further preferred embodiments, the fragment comprises the entire functionally active domain.

The term "MBCAT nucleic acid" refers to a DNA or RNA molecule that encodes a MBCAT polypeptide. Preferably, the MBCAT polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human MBCAT. Methods of identifying orthologs are known in the art. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA *et al.*, Genome Research (2000) 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD *et al*, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse species (e.g., retrieved through BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species, such as *Drosophila*, may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term "orthologs" encompasses paralogs. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a

specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, Advances in Applied Mathematics 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, J. of Molec.Biol., 147:195-197; Nicholas *et al.*, 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, Genomics 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring

matrix developed by Dayhoff (Dayhoff: Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 Nucl. Acids Res. 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of an MBCAT. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (e.g., Current Protocol in Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of an MBCAT under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100 µg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).

In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100

$\mu\text{g}/\text{ml}$ salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

Alternatively, low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 $\mu\text{g}/\text{ml}$ denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

Isolation, Production, Expression, and Mis-expression of MBCAT

Nucleic Acids and Polypeptides

MBCAT nucleic acids and polypeptides, are useful for identifying and testing agents that modulate MBCAT function and for other applications related to the involvement of MBCAT in the beta-catenin pathway. MBCAT nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes.

Expression of proteins to be purified for screening or antibody production may require the addition of specific tags (*e.g.*, generation of fusion proteins).

Overexpression of an MBCAT protein for assays used to assess MBCAT function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (*e.g.*, Higgins SJ and Hames BD (eds.) *Protein Expression: A Practical Approach*, Oxford University Press Inc., New York 1999; Stanbury PF et al., *Principles of Fermentation Technology*, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) *Protein Purification Protocols*, Humana

Press, New Jersey, 1996; Coligan JE et al, Current Protocols in Protein Science (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant MBCAT is expressed in a cell line known to have defective beta-catenin function. The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

The nucleotide sequence encoding an MBCAT polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native MBCAT gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (*e.g.* baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

To detect expression of the MBCAT gene product, the expression vector can comprise a promoter operably linked to an MBCAT gene nucleic acid, one or more origins of replication, and, one or more selectable markers (*e.g.* thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the MBCAT gene product based on the physical or functional properties of the MBCAT protein in *in vitro* assay systems (*e.g.* immunoassays).

The MBCAT protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (*i.e.* it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, *e.g.* by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

Once a recombinant cell that expresses the MBCAT gene sequence is identified, the gene product can be isolated and purified using standard methods (e.g. ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native MBCAT proteins can be purified from natural sources, by standard methods (e.g. immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of MBCAT or other genes associated with the beta-catenin pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (e.g. by gene knock-out or blocking expression that would otherwise normally occur).

Genetically modified animals

Animal models that have been genetically modified to alter MBCAT expression may be used in *in vivo* assays to test for activity of a candidate beta-catenin modulating agent, or to further assess the role of MBCAT in a beta-catenin pathway process such as apoptosis or cell proliferation. Preferably, the altered MBCAT expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal MBCAT expression. The genetically modified animal may additionally have altered beta-catenin expression (e.g. beta-catenin knockout). Preferred genetically modified animals are mammals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is

introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford *et al.*; for transgenic *Drosophila* see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic Zebrafish see Lin S., Transgenic Zebrafish, Methods Mol Biol. (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for transgenic rats see Hammer *et al.*, Cell (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) Nature 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

In one embodiment, the transgenic animal is a “knock-out” animal having a heterozygous or homozygous alteration in the sequence of an endogenous MBCAT gene that results in a decrease of MBCAT function, preferably such that MBCAT expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse MBCAT gene is used to construct a homologous

recombination vector suitable for altering an endogenous MBCAT gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, *Science* (1989) 244:1288-1292; Joyner *et al.*, *Nature* (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, *Science* (1989) 244:1281-1288; Simms *et al.*, *Bio/Technology* (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH *et al.*, (1994) *Scan J Immunol* 40:257-264; Declerck PJ *et al.*, (1995) *J Biol Chem*. 270:8397-400).

In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the MBCAT gene, e.g., by introduction of additional copies of MBCAT, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the MBCAT gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*, *PNAS* (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.*, (1991) *Science* 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X *et al* (2000) *Nat Genet* 25:83-6).

The genetically modified animals can be used in genetic studies to further elucidate the beta-catenin pathway, as animal models of disease and disorders implicating defective beta-catenin function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered MBCAT function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered MBCAT expression that receive candidate therapeutic agent.

In addition to the above-described genetically modified animals having altered MBCAT function, animal models having defective beta-catenin function (and otherwise normal MBCAT function), can be used in the methods of the present invention. For example, a beta-catenin knockout mouse can be used to assess, *in vivo*, the activity of a candidate beta-catenin modulating agent identified in one of the *in vitro* assays described below. Preferably, the candidate beta-catenin modulating agent when administered to a model system with cells defective in beta-catenin function, produces a detectable phenotypic change in the model system indicating that the beta-catenin function is restored, i.e., the cells exhibit normal cell cycle progression.

Modulating Agents

The invention provides methods to identify agents that interact with and/or modulate the function of MBCAT and/or the beta-catenin pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the beta-catenin pathway, as well as in further analysis of the MBCAT protein and its contribution to the beta-catenin pathway. Accordingly, the invention also provides methods for modulating the beta-catenin pathway comprising the step of specifically modulating MBCAT activity by administering a MBCAT-interacting or -modulating agent.

As used herein, an "MBCAT-modulating agent" is any agent that modulates MBCAT function, for example, an agent that interacts with MBCAT to inhibit or enhance MBCAT activity or otherwise affect normal MBCAT function. MBCAT function can be affected at any level, including transcription, protein expression, protein localization, and

cellular or extra-cellular activity. In a preferred embodiment, the MBCAT - modulating agent specifically modulates the function of the MBCAT. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the MBCAT polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the MBCAT. These phrases also encompass modulating agents that alter the interaction of the MBCAT with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of an MBCAT, or to a protein/binding partner complex, and altering MBCAT function). In a further preferred embodiment, the MBCAT- modulating agent is a modulator of the beta-catenin pathway (e.g. it restores and/or upregulates beta-catenin function) and thus is also a beta-catenin-modulating agent.

Preferred MBCAT-modulating agents include small molecule compounds; MBCAT-interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19th edition.

Small molecule modulators

Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight less than 10,000, preferably less than 5,000, more preferably less than 1,000, and most preferably less than 500 daltons. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the MBCAT protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can

also be identified by screening compound libraries for MBCAT-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the beta-catenin pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

Specific MBCAT-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the beta-catenin pathway and related disorders, as well as in validation assays for other MBCAT-modulating agents. In a preferred embodiment, MBCAT-interacting proteins affect normal MBCAT function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, MBCAT-interacting proteins are useful in detecting and providing information about the function of MBCAT proteins, as is relevant to beta-catenin related disorders, such as cancer (e.g., for diagnostic means).

An MBCAT-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with an MBCAT, such as a member of the MBCAT pathway that modulates MBCAT expression, localization, and/or activity. MBCAT-modulators include dominant negative forms of MBCAT-interacting proteins and of MBCAT proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous MBCAT-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. &

Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3rd, Trends Genet (2000) 16:5-8).

An MBCAT-interacting protein may be an exogenous protein, such as an MBCAT-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). MBCAT antibodies are further discussed below.

In preferred embodiments, an MBCAT-interacting protein specifically binds an MBCAT protein. In alternative preferred embodiments, an MBCAT-modulating agent binds an MBCAT substrate, binding partner, or cofactor.

Antibodies

In another embodiment, the protein modulator is an MBCAT specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify MBCAT modulators. The antibodies can also be used in dissecting the portions of the MBCAT pathway responsible for various cellular responses and in the general processing and maturation of the MBCAT.

Antibodies that specifically bind MBCAT polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of MBCAT polypeptide, and more preferably, to human MBCAT. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')_n.2 fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of MBCAT which are particularly antigenic can be selected, for example, by routine screening of MBCAT polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Natl. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89;

EX03-053P

Sutcliffe et al., (1983) *Science* 219:660-66) to the amino acid sequence of an MBCAT. Monoclonal antibodies with affinities of 10^8 M⁻¹ preferably 10^9 M⁻¹ to 10^{10} M⁻¹, or stronger can be made by standard procedures as described (Harlow and Lane, *supra*; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of MBCAT or substantially purified fragments thereof. If MBCAT fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an MBCAT protein. In a particular embodiment, MBCAT-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

The presence of MBCAT-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MBCAT polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

Chimeric antibodies specific to MBCAT polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further

reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 *Nature* 351: 501-501; Morrison SL. 1992 *Ann. Rev. Immun.* 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

MBCAT-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, *Science* (1988) 242:423-426; Huston et al., *Proc. Natl. Acad. Sci. USA* (1988) 85:5879-5883; and Ward et al., *Nature* (1989) 334:544-546).

Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., *Science* (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., *Int J. Biol Markers* (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg -to

about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml.

Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Specific biotherapeutics

In a preferred embodiment, an MBCAT-interacting protein may have biotherapeutic applications. Biotherapeutic agents formulated in pharmaceutically acceptable carriers and dosages may be used to activate or inhibit signal transduction pathways. This modulation may be accomplished by binding a ligand, thus inhibiting the activity of the pathway; or by binding a receptor, either to inhibit activation of, or to activate, the receptor. Alternatively, the biotherapeutic may itself be a ligand capable of activating or inhibiting a receptor. Biotherapeutic agents and methods of producing them are described in detail in U.S. Pat. No. 6,146,628.

When the MBCAT is a ligand, it may be used as a biotherapeutic agent to activate or inhibit its natural receptor. Alternatively, antibodies against MBCAT, as described in the previous section, may be used as biotherapeutic agents.

When the MBCAT is a receptor, its ligand(s), antibodies to the ligand(s) or the MBCAT itself may be used as biotherapeutics to modulate the activity of MBCAT in the beta-catenin pathway.

Nucleic Acid Modulators

Other preferred MBCAT-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit MBCAT

activity. Preferred nucleic acid modulators interfere with the function of the MBCAT nucleic acid such as DNA replication, transcription, translocation of the MBCAT RNA to the site of protein translation, translation of protein from the MBCAT RNA, splicing of the MBCAT RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the MBCAT RNA.

In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to an MBCAT mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. MBCAT-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

Alternative preferred MBCAT nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are

known in the art (Fire A, et al., 1998 *Nature* 391:806-811; Fire, A. *Trends Genet.* 15, 358-363 (1999); Sharp, P. A. *RNA interference* 2001. *Genes Dev.* 15, 485-490 (2001); Hammond, S. M., et al., *Nature Rev. Genet.* 2, 110-1119 (2001); Tuschl, T. *Chem. Biochem.* 2, 239-245 (2001); Hamilton, A. et al., *Science* 286, 950-952 (1999); Hammond, S. M., et al., *Nature* 404, 293-296 (2000); Zamore, P. D., et al., *Cell* 101, 25-33 (2000); Bernstein, E., et al., *Nature* 409, 363-366 (2001); Elbashir, S. M., et al., *Genes Dev.* 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 *Nature* 411:494-498).

Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, *et al.*, *Current Concepts in Antisense Drug Design*, *J Med Chem.* (1993) 36:1923-1937; Tonkinson JL *et al.*, *Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents*, *Cancer Invest.* (1996) 14:54-65). Accordingly, in one aspect of the invention, an MBCAT-specific nucleic acid modulator is used in an assay to further elucidate the role of the MBCAT in the beta-catenin pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, an MBCAT-specific antisense oligomer is used as a therapeutic agent for treatment of beta-catenin-related disease states.

Assay Systems

The invention provides assay systems and screening methods for identifying specific modulators of MBCAT activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the MBCAT nucleic acid or protein. In general, secondary assays further assess the activity of a MBCAT

modulating agent identified by a primary assay and may confirm that the modulating agent affects MBCAT in a manner relevant to the beta-catenin pathway. In some cases, MBCAT modulators will be directly tested in a secondary assay.

In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising an MBCAT polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. kinase activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates MBCAT activity, and hence the beta-catenin pathway. The MBCAT polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.

Primary Assays

The type of modulator tested generally determines the type of primary assay.

Primary assays for small molecule modulators

For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (e.g., receptor-ligand binding), transcriptional activity (e.g., using a reporter gene), enzymatic activity (e.g., via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive,

colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

Cell-based screening assays usually require systems for recombinant expression of MBCAT and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when MBCAT-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the MBCAT protein may be assayed by various known methods such as substrate processing (e.g. ability of the candidate MBCAT-specific binding agents to function as negative effectors in MBCAT-expressing cells), binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), and immunogenicity (e.g. ability to elicit MBCAT specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a MBCAT polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The MBCAT polypeptide can be full length or a fragment thereof that retains functional MBCAT activity. The MBCAT polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The MBCAT polypeptide is preferably human MBCAT, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the screening assay detects candidate agent-based modulation of MBCAT interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has MBCAT -specific binding activity, and can be used to assess normal MBCAT gene function.

Suitable assay formats that may be adapted to screen for MBCAT modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput

and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, *Curr Opin Chem Biol* (1998) 2:597-603; Sundberg SA, *Curr Opin Biotechnol* 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (e.g., Selvin PR, *Nat Struct Biol* (2000) 7:730-4; Fernandes PB, *supra*; Hertzberg RP and Pope AJ, *Curr Opin Chem Biol* (2000) 4:445-451).

A variety of suitable assay systems may be used to identify candidate MBCAT and beta-catenin pathway modulators (e.g. U.S. Pat. No. 6,165,992 (kinase assays); U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); and U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described in more detail below.

Protein kinases, key signal transduction proteins that may be either membrane-associated or intracellular, catalyze the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. Radioassays, which monitor the transfer from [γ -³²P or ³³P]ATP, are frequently used to assay kinase activity. For instance, a scintillation assay for p56 (lck) kinase activity monitors the transfer of the gamma phosphate from [γ -³³P] ATP to a biotinylated peptide substrate. The substrate is captured on a streptavidin coated bead that transmits the signal (Beveridge M *et al.*, *J Biomol Screen* (2000) 5:205-212). This assay uses the scintillation proximity assay (SPA), in which only radio-ligand bound to receptors tethered to the surface of an SPA bead are detected by the scintillant immobilized within it, allowing binding to be measured without separation of bound from free ligand. Other assays for protein kinase activity may use antibodies that specifically recognize phosphorylated substrates. For instance, the kinase receptor activation (KIRA) assay measures receptor tyrosine kinase activity by ligand stimulating the intact receptor in cultured cells, then capturing solubilized receptor with specific antibodies and quantifying phosphorylation via phosphotyrosine ELISA (Sadick MD, *Dev Biol Stand* (1999) 97:121-133). Another example of antibody based assays for protein kinase

activity is TRF (time-resolved fluorometry). This method utilizes europium chelate-labeled anti-phosphotyrosine antibodies to detect phosphate transfer to a polymeric substrate coated onto microtiter plate wells. The amount of phosphorylation is then detected using time-resolved, dissociation-enhanced fluorescence (Braunwalder AF, et al., *Anal Biochem* 1996 Jul 1;238(2):159-64).

Transporter proteins carry a range of substrates, including nutrients, ions, amino acids, and drugs, across cell membranes. Assays for modulators of transporters may use labeled substrates. For instance, exemplary high throughput screens to identify compounds that interact with different peptide and anion transporters both use fluorescently labeled substrates; the assay for peptide transport additionally uses multiscreen filtration plates (Blevitt JM et al., *J Biomol Screen* 1999, 4:87-91; Cihlar T and Ho ES, *Anal Biochem* 2000, 283:49-55).

Ion channels mediate essential physiological functions, including fluid secretion, electrolyte balance, bioenergetics, and membrane excitability. Assays for channel activity can incorporate ion-sensitive dyes or proteins or voltage-sensitive dyes or proteins, as reviewed in Gonzalez JE *et al.* (*Drug Discovery Today* (1999) 4:431-439). Alternative methods measure the displacement of known ligands, which may be radio-labeled or fluorescently labeled (e.g., Schmid EL *et al.*, *Anal Chem* (1998) 70:1331-1338).

Transcription factors control gene transcription. Electrophoretic mobility shift assay (EMSA) or gel shift assay is one of the most powerful methods for studying protein-DNA interactions. High throughput gel shift assays for transcription factors may involve fluorescence (Cyano dye Cy5) labeled oligodeoxynucleotide duplexes as specific probes and an automatic DNA sequencer for analysis (Ruscher K, et al., (2000) *J Biotechnol* 78:163-70). Alternatively high throughput methods involve colorimetric assays (Renard P, et al. (2001) *Nucleic Acids Res* 29(4):E21), or homogeneous fluorescence assays for the detection and quantification of sequence-specific DNA-binding proteins (Heyduk T, and Heyduk E (2001) *Nat Biotechnol* 20:171-6.)

High throughput assays based on photometric analysis of the activity of decarboxylase enzymes have been described (Breuer M et al (2002) *Anal Bioanal Chem* 374:1069-73).

High-throughput photometric assays for peroxidases have been described (Smith AD et al (2001) Int J Vitam Nutr Res 71:87-92; Smith AD and Levander OA (2002) Methods Enzymol 347:113-21).

High throughput adenylyl cyclase assays are known in the art, and are also commercially available (NEN® Adenylyl Cyclase Activation FlashPlate® Assay, available from Perkin Elmer Life Sciences, Boston, MA). Examples include homogeneous cellular assays that allow direct measurement of receptor-mediated adenylyl cyclase activation/inhibition.

Apoptosis assays. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara *et al.*, 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., *et al.*, 1998, Blood 15:4730-41). Other cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay. The caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell death in many apoptotic pathways. In the caspase 3/7 assay (commercially available Apo-ONE™ Homogeneous Caspase-3/7 assay from Promega, cat# 67790), lysis buffer and caspase substrate are mixed and added to cells. The caspase substrate becomes fluorescent when cleaved by active caspase 3/7. The nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat# 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane breaks down, allowing for accumulation in the cytoplasm. Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis. An apoptosis assay system may comprise a cell that expresses an MBCAT,

and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether MBCAT function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express MBCAT relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the MBCAT plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

Cell proliferation and cell cycle assays. Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, Int. J. Cancer 38, 369; Campana *et al.*, 1988, J. Immunol. Meth. 107, 79), or by other means.

Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specific to the phosphorylated form of the serine 10 residue of histone H3. (Chadlee,D.N. 1995, J. Biol. Chem 270:20098-105). Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an

indirect measurement of cell number (Voytik-Harbin SL et al., 1998, *In Vitro Cell Dev Biol Anim* 34:239-46). Yet another proliferation assay, the MTS assay, is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS. MTS assays are commercially available, for example, the Promega CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Cat.# G5421).

Cell proliferation may also be assayed by colony formation in soft agar (Sambrook et al., *Molecular Cloning*, Cold Spring Harbor (1989)). For example, cells transformed with MBCAT are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

Cell proliferation may also be assayed by measuring ATP levels as indicator of metabolically active cells. Such assays are commercially available, for example Cell Titer-Glo™, which is a luminescent homogeneous assay available from Promega.

Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) *Int J Radiat Biol Relat Stud Phys Chem Med* 49:237-55). Cells transfected with an MBCAT may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.

Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses an MBCAT, and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test whether MBCAT function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express MBCAT relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the MBCAT plays a direct role in cell proliferation or cell cycle.

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses an MBCAT, and that optionally has defective beta-catenin function (e.g. beta-catenin is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether MBCAT function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express MBCAT relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the MBCAT plays a direct role in angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among others, describe various angiogenesis assays.

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glyolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with MBCAT in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and balance N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses an MBCAT, and that optionally has defective beta-catenin function (e.g. beta-catenin is

over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate beta-catenin modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate beta-catenin modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether MBCAT function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express MBCAT relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the MBCAT plays a direct role in hypoxic induction.

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques *in situ* on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).

Tubulogenesis. Tubulogenesis assays monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix. Exemplary substrates include Matrigel™ (Becton Dickinson), an extract of basement membrane proteins containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4° C and forms a solid gel at 37° C. Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, Nature Medicine 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors. In a preferred embodiment, the assay is performed with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates. Moreover, we have found that different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory angiogenic factors such as TNF-alpha. Thus, in a further preferred embodiment, a tubulogenesis assay system comprises testing an MBCAT's response to a variety of factors, such as FGF, VEGF, phorbol myristate acetate (PMA), TNF-alpha, ephrin, etc.

Cell Migration. An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic

signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, *J Biol Chem* 276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hematoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As described above, a preferred assay system for migration/invasion assays comprises testing an MBCAT's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.

Sprouting assay. A sprouting assay is a three-dimensional *in vitro* angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, *J Cell Sci* 112:3249-58). In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: *J Cell Biol* 143: 1341-52, 1998). Spheroids are harvested and seeded in 900 μ l of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents

are added after 30 min by pipetting 100 μ l of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

Primary assays for antibody modulators

For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the MBCAT protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting MBCAT-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators.

Primary assays for nucleic acid modulators

For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance MBCAT gene expression, preferably mRNA expression. In general, expression analysis comprises comparing MBCAT expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express MBCAT) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that MBCAT mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either

the MBCAT protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve MBCAT mRNA expression, may also be used to test nucleic acid modulators.

Secondary Assays

Secondary assays may be used to further assess the activity of MBCAT-modulating agent identified by any of the above methods to confirm that the modulating agent affects MBCAT in a manner relevant to the beta-catenin pathway. As used herein, MBCAT-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with MBCAT.

Secondary assays generally compare like populations of cells or animals (e.g., two pools of cells or animals that endogenously or recombinantly express MBCAT) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate MBCAT-modulating agent results in changes in the beta-catenin pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the beta-catenin or interacting pathways.

Cell-based assays

Cell based assays may detect endogenous beta-catenin pathway activity or may rely on recombinant expression of beta-catenin pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

Animal Assays

A variety of non-human animal models of normal or defective beta-catenin pathway may be used to test candidate MBCAT modulators. Models for defective beta-catenin pathway typically use genetically modified animals that have been engineered to mis-express (e.g., over-express or lack expression in) genes involved in the beta-catenin pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

In a preferred embodiment, beta-catenin pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal beta-catenin are used to test the candidate modulator's affect on MBCAT in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4°C, but rapidly forms a solid gel at 37°C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the MBCAT. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

In another preferred embodiment, the effect of the candidate modulator on MBCAT is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, e.g., Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the MBCAT endogenously are injected in the flank, 1×10^5 to 1×10^7 cells per mouse in a volume of 100 µL using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is

assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

In another preferred embodiment, tumorogenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, and evaluating the target cells for reaction to the candidate modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator.

Tumorogenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.

In another preferred embodiment, a tumorogenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays. In a preferred application, tumor development in the transgenic model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2" transgene, comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812). An "angiogenic switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14 weeks. Candidate modulators may be administered

at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression). Tumorigenicity and modulator efficacy can be evaluated life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.

Diagnostic and therapeutic uses

Specific MBCAT-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the beta-catenin pathway, such as angiogenic, apoptotic, or cell proliferation disorders. Accordingly, the invention also provides methods for modulating the beta-catenin pathway in a cell, preferably a cell pre-determined to have defective or impaired beta-catenin function (e.g. due to overexpression, underexpression, or misexpression of beta-catenin, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates MBCAT activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the beta-catenin function is restored. The phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored beta-catenin function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for treating disorders or disease associated with impaired beta-catenin function by administering a therapeutically effective amount of an MBCAT -modulating agent that modulates the beta-catenin pathway. The invention further provides methods for modulating MBCAT function in a cell, preferably a cell pre-determined to have defective or impaired MBCAT function, by administering an MBCAT -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired MBCAT function by administering a therapeutically effective amount of an MBCAT -modulating agent.

The discovery that MBCAT is implicated in beta-catenin pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of

diseases and disorders involving defects in the beta-catenin pathway and for the identification of subjects having a predisposition to such diseases and disorders.

Various expression analysis methods can be used to diagnose whether MBCAT expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppe-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective beta-catenin signaling that express an MBCAT, are identified as amenable to treatment with an MBCAT modulating agent. In a preferred application, the beta-catenin defective tissue overexpresses an MBCAT relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial MBCAT cDNA sequences as probes, can determine whether particular tumors express or overexpress MBCAT. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of MBCAT expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

Various other diagnostic methods may be performed, for example, utilizing reagents such as the MBCAT oligonucleotides, and antibodies directed against an MBCAT, as described above for: (1) the detection of the presence of MBCAT gene mutations, or the detection of either over- or under-expression of MBCAT mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of MBCAT gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by MBCAT.

Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in MBCAT expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for MBCAT expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer. The probe may be either DNA or protein, including an antibody.

EXAMPLES

The following experimental section and examples are offered by way of illustration and not by way of limitation.

I. Drosophila beta-catenin screen

Two dominant loss of function screens were carried out in *Drosophila* to identify genes that interact with the Wg cell signaling molecule, beta -catenin (Riggleman et al. (1990) Cell 63:549-560; Peifer et al. (1991) Development 111:1029-1043). Late stage activation of the pathway in the developing *Drosophila* eye leads to apoptosis (Freeman and Bienz (2001) EMBO reports 2: 157-162), whereas early stage activation leads to an overgrowth phenotype. We discovered that ectopic expression of the activated protein in the wing results in changes of cell fate into ectopic bristles and wing veins.

Each transgene was carried in a separate fly stock:

Stocks and genotypes were as follows:

eye overgrowth transgene: isow; P{3.5 eyeless-Gal4}; P{arm(S56F)-pExp-UAS})/TM6b;

eye apoptosis transgene: y w; P{arm(S56F)-pExp-GMR}/CyO; and

wing transgene: P{arm(ΔN)-pExp-VgMQ}/FM7c

In the first dominant loss of function screen, females of each of these three transgenes were crossed to a collection of males containing genomic deficiencies. Resulting progeny containing the transgene and the deficiency were then scored for the effect of the deficiency on the eye apoptosis, eye overgrowth, and wing phenotypes, i.e., whether the deficiency enhanced, suppressed, or had no effect on their respective phenotypes. All data was recorded and all modifiers were retested with a repeat of the original cross. Modifying deficiencies of the phenotypes were then prioritized according to how they modified each of the three phenotypes.

Transposons contained within the prioritized deficiencies were then screened as described. Females of each of the three transgenes were crossed to a collection of 4 types of transposons (3 piggyBac-based and 1 P-element-based). The resulting progeny containing the transgene and the transposon were scored for the effect of the transposon.

on their respective phenotypes. All data was recorded and all modifiers were retested with a repeat of the original cross. Modifiers of the phenotypes were identified as either members of the Wg pathway, components of apoptotic related pathways, components of cell cycle related pathways, or cell adhesion related proteins.

In the second dominant loss of function screen, females of the eye overgrowth transgene were crossed to males from a collection of 3 types of piggyBac-based transposons. The resulting progeny containing the transgene and the transposon were scored for the effect of the transposon on the eye overgrowth phenotype. All data was recorded and all modifiers were retested with a repeat of the original cross. Modifiers of the phenotypes were identified as either members of the Wg pathway, components of cell cycle related pathways, or cell adhesion related proteins.

II. Analysis of Table 1

BLAST analysis (Altschul et al., *supra*) was employed to identify orthologs of *Drosophila* modifiers. The columns "MBCAT symbol", and "MBCAT name aliases" provide a symbol and the known name abbreviations for the Targets, where available, from Genbank. "MBCAT RefSeq_NA or GI_NA", "MBCAT GI_AA", "MBCAT NAME", and "MBCAT Description" provide the reference DNA sequences for the MBCATs as available from National Center for Biology Information (NCBI), MBCAT protein Genbank identifier number (GI#), MBCAT name, and MBCAT description, all available from Genbank, respectively. The length of each amino acid is in the "MBCAT Protein Length" column.

Names and Protein sequences of *Drosophila* modifiers of beta-catenin from screen (Example I), are represented in the "Modifier Name" and "Modifier GI_AA" column by GI#, respectively.

Table 1

MBCAT symbol	MBCAT name aliases	MBCAT RefSeq_NA or GI_NA	MBCAT T GI_AA	MBCAT name	MBCAT description	MBCAT protein length	Modifier name	Modifier gi_aa

EX03-053P

ADCY5	ADCY5 adenylyl cyclase 5 adenylyl cyclase type V adenylyl cyclase type 5	XM_171048	22212711	adenylate cyclase 5	response to hypoxia	894	CG32158	24665354
ADCY6	KIAA0422 adenylyl cyclase 6 ADCY6 adenylyl cyclase type VI	NM_015270 NM_02960983	101810	adenylate cyclase 6	regulation of smooth muscle contraction; cAMP biosynthesis	1168	CG32158	24665354
ADCY8	ADCY8 ADCY3 HBAC1 Adenylyl cyclase-8, brain adenylyl cyclase 8 (brain) adenylyl cyclase type VIII	NM_001115	4557257	adenylate cyclase 8 (brain)	learning and/or memory; response to drug; signal transduction	1251	CG32158	24665354
CENTG1	CENTG1 PIKE AGAP2 GGAP2 KIAA0167 centaurin gamma 1 phosphoinositide 3-kinase enhancer GTP-binding and GTPase activating protein 2 Arf GAP with GTP-binding protein-like, ANK repeat and PH domains 2 centaurin, gamma 1	NM_014770 NM_023017	766196	centaurin, gamma 1	na	836	cenG1A	24584217
CENTG2	CENTG2 AGAP1 GGAP1 KIAA1099 GTP-binding and GTPase-activating protein 1 Arf GAP with GTP-binding protein-like, ANK repeat and PH domains 1 centaurin, gamma 2	NM_014914	7662484	centaurin, gamma 2	vesicle-mediated transport; actin cytoskeleton organization and biogenesis	804	cenG1A	24584217
CENTG3	CENTG3 MRIP-1 MRIP-1 protein centaurin, gamma 3	NM_031946	16799069	centaurin, gamma 3	cell growth and/or maintenance; signal transduction; signal transduction	875	cenG1A	24584217

EX03-053P

DDX17	DDX17 P72 RH70 probable RNA-dependent helicase p72 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 17 (72kD) DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 17, 72kDa DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	NM_006386 NM_030881	545384	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	regulation of transcription from Pol II promoter; RNA processing	650	Rm62	24644481	
DDX5	DDX5 P68 HLR1 G17P1 HUMP68 RNA-dependent ATPase DEAD/H box-5 (RNA helicase, 68kD) DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase, 68kD) DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase, 68kD) p68 DEAD box-5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5	NM_004396	4758138	DEAD (Asp-Glu-Ala-Asp) box polypeptide 5	mRNA splicing	614	Rm62	24644481	
FLJ10665	FLJ10665 hypothetical protein FLJ10665	NM_018173	8922581	hypothetical protein FLJ10665	Rho protein signal transduction; cell growth and/or maintenance	790	CG7323	7293694	
KIAA0720	KIAA0720 KIAA0720 protein	XM_030970	29728516	KIAA0720 protein	Rho protein signal transduction; cell growth and/or maintenance	1083	CG7323	7293694	
FLJ20530	FLJ20530 hypothetical protein FLJ20530	NM_017864	8923496	hypothetical protein FLJ20530	na	557	EG:EG003.5	18484916	

EX03-053P

GABRA2	GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2	NM_000807	455760	gamma-aminobutyric acid (GABA) A receptor, alpha 2	gamma-amino butyric acid signaling pathway; gamma-amino butyric acid signaling pathway; chloride transport; regulation of neurotransmitter levels	451	GluClap ha	24648249	
GABRA5	GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5	NM_000810	450386	gamma-aminobutyric acid (GABA) A receptor, alpha 5	gamma-amino butyric acid signaling pathway; chloride transport; synaptic transmission; signal transduction	462	GluClap ha	24648249	
GLRA1	GLRA1 STHE glycine receptor, alpha 1 (startle disease/hyperekplexia, stiff man syndrome)	NM_000171	4504019	glycine receptor, alpha 1 (startle disease/hyperekplexia, stiff man syndrome)	cell surface receptor linked signal transduction; neurogenesis; chloride transport; chloride transport; synaptic transmission; synaptic transmission; synaptic transmission	449	GluClap ha	24648249	
GYG	GYG glycogenin	NM_004130	20127457	glycogenin	glycogen biosynthesis; glycogen biosynthesis; glycogen biosynthesis	350	Glycogen in	24656813	
GYG2	GYG2 GN2 GN-2 glycogenin 2	NM_003918	5453674	glycogenin 2	glycogen biosynthesis; glycogen biosynthesis	501	Glycogen in	24656813	
LOC350705	LOC350705 similar to Glycogenin-1	XM_301113	30147855	similar to Glycogenin-1	na	233	Glycogen in	24656813	

EX03-053P

MLLT10	MLLT10 AF10 ALL1 fused gene from chromosome 10 myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 10 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10	NM_004641	4757726	myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10		1027	Alhambra	24644741	
MLLT6	MLLT6 AF17 Myeloid/lymphoid or mixed-lineage leukemia, translocated to, 6 myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 6 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6	NM_005937	5174577	myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6	cell growth and/or maintenance; regulation of transcription, DNA-dependent	1093	Alhambra	24644741	
POU2F1	POU2F1 OCT1 OTF1 Octamer-binding transcription factor-1 POU domain, class 2, transcription factor 1	NM_002697	4505957	POU domain, class 2, transcription factor 1	transcription from Pol II promoter; regulation of transcription from Pol II promoter; negative regulation of transcription; regulation of transcription from Pol III promoter	743	pdm2	24583942	
POU2F2	POU2F2 OCT2 OTF2 POU domain, class 2, transcription factor 2	NM_002698	4505959	POU domain, class 2, transcription factor 2	transcription from Pol II promoter; regulation of transcription, DNA-dependent; humoral immune response; membrane fusion; pathogenesis; development	463	pdm2	24583942	

EX03-053P

POU2F3	POU2F3 OCT111 PLA-1 Epoch-1 Skn-1a POU transcription factor likely ortholog of mouse POU domain, class 2, transcription factor 3 POU domain, class 2, transcription factor 3	NM_014352	7657409	POU domain, class 2, transcription factor 3	keratinocyte differentiation; epidermal differentiation; regulation of transcription from Pol II promoter	436	pdm2	24583942	
PRKCI	PKCI DDX1179E protein kinase C, iota PRKCI PKCi	NM_002740	4506071	protein kinase C, iota	anti-apoptosis; signal transduction; signal transduction; protein amino acid phosphorylation	587	aPKC	24653760	

EX03-053P

PRKCZ	protein kinase C, zeta PRKCZ PKC2 PKCz zeta protein kinase C protein kinase C zeta PKC zeta	44	NM_002750	108646	protein kinase C, zeta	insulin receptor signaling pathway; cytokinesis; glucose transport; antibacterial humoral response (sensu Vertebrata); activation of MAP/ERK kinase kinase; positive regulation of transcription from Pol II promoter; actin cytoskeleton organization and biogenesis; T-cell activation; protein kinase cascade; anti-apoptosis; chemotaxis; positive regulation of cell proliferation; monocyte activation; cytokine biosynthesis; cytokine and chemokine mediated signaling pathway; cell cycle arrest; signal transduction; signal transduction; signal transduction; inflammatory response; protein amino acid phosphorylation; protein amino acid phosphorylation; protein amino acid phosphorylation; protein amino acid phosphorylation	592	aPKC	24653760	
-------	--	----	-----------	--------	------------------------	---	-----	------	----------	--

EX03-053P

SLC1A2	SLC1A2 EAAT2 GLT-1 glutamate/aspartate transporter II excitatory amino acid transporter 2 H.sapiens mRNA for glutamate transporter glial high affinity glutamate transporter solute carrier family 1 (glial high affinity glutamate transporter), member 2	NM_004171	4759124	solute carrier family 1 (glial high affinity glutamate transporter), member 2	neurotransmitter uptake; synaptic transmission; glutamate transport; glutamate transport	574	Eaat2	17137666	
SLC1A3	SLC1A3 EAAT1 GLAST GLAST1 solute carrier family 1 (glial high affinity glutamate transporter), member 3	NM_004172	4759126	solute carrier family 1 (glial high affinity glutamate transporter), member 3	neurotransmitter uptake; neurotransmitter uptake; neurotransmitter uptake; synaptic transmission; glutamate transport; glutamate transport	542	Eaat2	17137666	
SLC1A7	SLC1A7 AAAT EAAT5 excitatory amino acid transporter 5 (retinal glutamate transporter) solute carrier family 1 (glutamate transporter), member 7	NM_006671	20070239	solute carrier family 1 (glutamate transporter), member 7	vision; glutamate transport	560	Eaat2	17137666	
SLC1A4	SLC1A4 SATT ASCT1 glutamate/neutral amino acid transporter alanine-serine/cysteine/threonine transporter solute carrier family 1 (glutamate/neutral amino acid transporter), member 4	NM_003038	21314632	solute carrier family 1 (glutamate/neutral amino acid transporter), member 4	neutral amino acid transport; neutral amino acid transport	532	Eaat2	17137666	

EX03-053P

SLC1A6	SLC1A6 EAAT4 excitatory amino acid transporter 4 solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6	NM_005071	4827012	solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6	aspartate transport; chloride transport; synaptic transmission; glutamate transport; glutamate transport; glutamate transport	564	Eaat2	17137666
SLC1A1	SLC1A1 EAAC1 EAAT3 excitatory amino acid carrier 1 excitatory amino acid transporter-3 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	NM_004170	18252049	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	synaptic transmission; glutamate transport	524	Eaat2	17137666
SLC1A5	SLC1A5 R16 AAAT ATBO M7V1 RDRC ASCT2 M7VS1 RD114 virus receptor baboon M7 virus receptor neutral amino acid transporter B solute carrier family 1 (neutral amino acid transporter), member 5	NM_005628	5032093	solute carrier family 1 (neutral amino acid transporter), member 5	neutral amino acid transport; neutral amino acid transport; EGF receptor signaling pathway	541	Eaat2	17137666
SLC7A1	SLC7A1 ERR ATRC1 CAT-1 HCAT1 RECIL ecotropic retroviral receptor amino acid transporter, cationic 1 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1	NM_003045	4507047	solute carrier family 7 (cationic amino acid transporter, y+ system), member 1	basic amino acid transport; amino acid transport; arginine transport; amino acid metabolism	629	CG11128	7296600

EX03-053P

SLC7A2	SLC7A2 ATRC2 CAT-2 HCAT2 amino acid transporter, cationic 2 solute carrier family 7 (cationic amino acid transporter, y ⁺ system), member 2	NM_003046	4507049	solute carrier family 7 (cationic amino acid transporter, y ⁺ system), member 2	basic amino acid transport; amino acid metabolism	657	CG11128	7296600
SLC7A3	SLC7A3 ATRC3 CAT-3 FLJ14541 solute carrier family 7 (cationic amino acid transporter, y ⁺ system), member 3	NM_032803	17939406	solute carrier family 7 (cationic amino acid transporter, y ⁺ system), member 3	amino acid transport; amino acid transport; amino acid metabolism; L-amino acid transport; L-amino acid transport	619	CG11128	7296600
SULF2	SULF2 SULF-2 HSULF-2 KIAA1247 sulfatase 2 similar to glucosamine-6-sulfatases	NM_018837 XM_030036	29789100	similar to glucosamine-6-sulfatases	metabolism	870	Sulf1	18487383
SULF1	SULF1 SULF-1 HSULF-1 KIAA1077 sulfatase FP sulfatase 1	NM_015170	29789064	sulfatase 1	metabolism	871	Sulf1	18487383
LOC151531	LOC151531 liver-specific uridine phosphorylase	NM_173355	27597096	liver-specific uridine phosphorylase	na	317	CG6330	23172399
UP	UP uridine phosphorylase	NM_003364 NM_181597	4507839	uridine phosphorylase	nucleobase, nucleoside, nucleotide and nucleic acid metabolism; response to drug; response to drug; response to drug; response to drug	310	CG6330	23172399

EX03-053P

RAB32	RAB32 RAB32, member RAS oncogene family	NM_006834	580313	RAB32, member RAS oncogene family	small GTPase mediated signal transduction; organelle organization and biogenesis; protein-vacuolar targeting; exocytosis; endocytosis; mitochondrial membrane organization and biogenesis; membrane fusion	225	Rab-RP1	6561893	
RAB38	RAB38 NY-MEL-1 Rab-related GTP-binding protein RAB38, member RAS oncogene family	NM_022337	11641237	RAB38, member RAS oncogene family	small GTPase mediated signal transduction; vesicle-mediated transport	211	Rab-RP1	6561893	
RAB7L1	RAB7L1 RAB7, member RAS oncogene family-like 1	NM_003929	4506375	RAB7, member RAS oncogene family-like 1	na	203	Rab-RP1	6561893	
C6orf37	C6orf37 FLJ20037 retinal expressed gene C6orf37 chromosome 6 open reading frame 37	NM_017633	8923042	chromosome 6 open reading frame 37	na	447	CG30497	24586361	
FLJ20202	FLJ20202 hypothetical protein FLJ20202	NM_017709	8923192	hypothetical protein FLJ20202	na	391	CG30497	24586361	
MGC16491	MGC16491 MGC20845 hypothetical protein MGC16491	NM_052943	16418427	hypothetical protein MGC16491	na	424	CG30497	24586361	
MGC26999	MGC26999 hypothetical protein MGC26999	NM_152630	22749287	hypothetical protein MGC26999	na	389	CG30497	24586361	

III. High-Throughput In Vitro Fluorescence Polarization Assay

Fluorescently-labeled MBCAT peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of MBCAT activity.

IV. High-Throughput In Vitro Binding Assay.

^{33}P -labeled MBCAT peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS, and counted in a scintillation counter. Test agents that cause a difference in activity relative to control without test agent are identified as candidate beta-catenin modulating agents.

V. Immunoprecipitations and Immunoblotting

For coprecipitation of transfected proteins, 3×10^6 appropriate recombinant cells containing the MBCAT proteins are plated on 10-cm dishes and transfected on the following day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at 15,000 $\times g$ for 15 min. The cell lysate is incubated with 25 μl of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).

VI. Kinase assay

A purified or partially purified MBCAT is diluted in a suitable reaction buffer, e.g., 50 mM Hepes, pH 7.5, containing magnesium chloride or manganese chloride (1-20 mM) and a peptide or polypeptide substrate, such as myelin basic protein or casein (1-10 µg/ml). The final concentration of the kinase is 1-20 nM. The enzyme reaction is conducted in microtiter plates to facilitate optimization of reaction conditions by increasing assay throughput. A 96-well microtiter plate is employed using a final volume 30-100 µl. The reaction is initiated by the addition of ^{33}P -gamma-ATP (0.5 µCi/ml) and incubated for 0.5 to 3 hours at room temperature. Negative controls are provided by the addition of EDTA, which chelates the divalent cation (Mg^{2+} or Mn^{2+}) required for enzymatic activity. Following the incubation, the enzyme reaction is quenched using EDTA. Samples of the reaction are transferred to a 96-well glass fiber filter plate (MultiScreen, Millipore). The filters are subsequently washed with phosphate-buffered saline, dilute phosphoric acid (0.5%) or other suitable medium to remove excess radiolabeled ATP. Scintillation cocktail is added to the filter plate and the incorporated radioactivity is quantitated by scintillation counting (Wallac/Perkin Elmer). Activity is defined by the amount of radioactivity detected following subtraction of the negative control reaction value (EDTA quench).

VII. Expression analysis

All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues are obtained from Impath, UC Davis, Clontech, Stratagene, Ardais, Genome Collaborative, and Ambion.

TaqMan analysis is used to assess expression levels of the disclosed genes in various samples.

RNA is extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/ μ l. Single stranded cDNA is then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).

Primers for expression analysis using TaqMan assay (Applied Biosystems, Foster City, CA) are prepared according to the TaqMan protocols, and the following criteria: a) primer pairs are designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product. Expression analysis is performed using a 7900HT instrument.

Taqman reactions are carried out following manufacturer's protocols, in 25 μ l total volume for 96-well plates and 10 μ l total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis is prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good. The raw data are normalized using 18S rRNA (universally expressed in all tissues and cells).

For each expression analysis, tumor tissue samples are compared with matched normal tissues from the same patient. A gene is considered overexpressed in a tumor when the level of expression of the gene is 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue is not available, a universal pool of cDNA samples is used instead. In these cases, a gene is considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type is greater than 2 times the standard deviation of all normal samples (i.e., Tumor – average(all normal samples) > 2 x STDEV(all normal samples)).

A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating

EX03-053P

a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

WHAT IS CLAIMED IS:

1. A method of identifying a candidate beta-catenin pathway modulating agent, said method comprising the steps of:
 - (a) providing an assay system comprising a MBCAT polypeptide or nucleic acid;
 - (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
 - (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate beta-catenin pathway modulating agent.
2. The method of Claim 1 wherein the assay system comprises cultured cells that express the MBCAT polypeptide.
3. The method of Claim 2 wherein the cultured cells additionally have defective beta-catenin function.
4. The method of Claim 1 wherein the assay system includes a screening assay comprising a MBCAT polypeptide, and the candidate test agent is a small molecule modulator.
5. The method of Claim 4 wherein the assay is a binding assay.
6. The method of Claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.
7. The method of Claim 1 wherein the assay system includes a binding assay comprising a MBCAT polypeptide and the candidate test agent is an antibody.

8. The method of Claim 1 wherein the assay system includes an expression assay comprising a MBCAT nucleic acid and the candidate test agent is a nucleic acid modulator.

9. The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.

10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.

11. The method of Claim 1 additionally comprising:

(d) administering the candidate beta-catenin pathway modulating agent identified in (c) to a model system comprising cells defective in beta-catenin function and, detecting a phenotypic change in the model system that indicates that the beta-catenin function is restored.

12. The method of Claim 11 wherein the model system is a mouse model with defective beta-catenin function.

13. A method for modulating a beta-catenin pathway of a cell comprising contacting a cell defective in beta-catenin function with a candidate modulator that specifically binds to a MBCAT polypeptide, whereby beta-catenin function is restored.

14. The method of claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in beta-catenin function.

15. The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

16. The method of Claim 1, comprising the additional steps of:

(d) providing a secondary assay system comprising cultured cells or a non-human animal expressing MBCAT ,

(e) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and

(f) detecting an agent-biased activity of the second assay system,
wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate beta-catenin pathway modulating agent,

and wherein the second assay detects an agent-biased change in the beta-catenin pathway.

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-human animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses a beta-catenin pathway gene.

20. A method of modulating beta-catenin pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a MBCAT polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the beta-catenin pathway.

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising:

- (a) obtaining a biological sample from the patient;
- (b) contacting the sample with a probe for MBCAT expression;
- (c) comparing results from step (b) with a control;
- (d) determining whether step (c) indicates a likelihood of disease.

24. The method of claim 23 wherein said disease is cancer.

ABSTRACT OF THE DISCLOSURE

Human MBCAT genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of MBCAT are provided.

Nucleic Acid and Polypeptide sequences

>gi|27480832|ref|XM_171048.2| Homo sapiens adenylate cyclase 5 (ADCY5), mRNA
 ACATCGTGGGTGCTGCACCCACTATCCGGCTGAGGTCTCCAGAGACAGGTTCCAGGAGACCCGAGA
 GTGCATCCAGGCGCGGCTCACTCGCAGCGGGAGAACAGCAGCAGGAACGGCTCTGCTGTCTGCCTT
 CCCCGTCATGTTGCCATGGAGATGAAAGCAGACATCAACGCCAAGCAGGAGGATATGATGTTCCATAAGA
 TTTACATCCAGAAACATGACAACGTGAGCATCCTGTTGCTGACATCGAGGGCTGAGGGGCCCTCGACTC
 AGCTGGGGTAGACGGGCTCGAATGTGGCCTGGGAGAGCTAGGGGGCCCAGGGCTGCTTTCTATG
 TGAGGCCTTAAACTCAGACAGGCCACCCTGCACCTGCAGGGCTTGGCACAGGAGTGCCTGGCTTT
 GGAGGGACTGTGGCCTTCATCGTGGCTCTGCCCACACCTCACGCACACAGACAGTGCCTAGGAGG
 AAACAGAACTAATTACGAGGGGGAGGCAAGAGGACGCCAGCAAGGAGTGGTGTAGTCTGAGAAAAATATT
 TATTAATAAAAACAAAACAAGTTCTCGTGCCTTCTTAACTATGCTAGTTGATGCGTGTAAAGAGAC
 ACACAAGCAAACGAGGACGCCACTCGGGGGAGGGGGATCCCCACTGTCTTTTGATTTTGTATTTTTAT
 TTTGTATTATGAAAGCCTTGGAGATCTCACAGATAGATATGCCAAATTCTATATTGTAATTCTCTA
 TATTAGAAAACAGCTGTGCACAGCAGGGCGGGTGTCTCATTTGACTGTGTATGTCGGTGTAC
 TGGTGTATATGTTGTGTGTTCATGCTGTGAACTGGTCTCACACAGATGTGTTCCCTCATTCAGAT
 TTGGCAGTTGGTTTCCAAGGTACCAAGCAGAGCAGTGGGTGTGCTTTGGGTACCATATGCTCA
 GATTAAGTAGGAGGATGCATGGACACACTGCCCATCTTCTGACACACGCCACACGTATGACACACAT
 GCACACACCCCTTCCCCTAAGCAAACGCCAGATGGAATAAGAAAACAAAAGCTGCTTCCATCCCA
 GGCGCAGCTGGAACCAAGGGAGCAATCTCATCTGCACAGGCAAGTGTGGTGCCTCCACACCTGAGA
 TTTCAGACGTTGGCCTTACAGAGGCAGGCCACAGATTCCAGAGTGTCTACAGAAGGCCAGGTGCTT
 TGCAGGGCTGGGACGAGGAAGCCAAGCCTCCCTGGCTACTCAGTTGGCAAGGTGCAAGGTGGCTTCC
 GGAGATGTTCACTCAGACTGGGGATGCAATGTGAGCCTTCAGGTTGCGGAAAGGGAGTGGCTTGAC
 CTCCACCGGAAACCAAGGCAGAGGAATGGTAGAGGCCAGCTTGTAGAGTCCACAGGGAAAGCTAGCAGGA
 ATTTGTTTAGTGGAGGGGGCAAGTAAACATACCAAGAAAAAAATACTATTTTATAACCTATGAGGA
 AGACATTTGAAATGATACTCTAGCACAGAATTCACTGGAATCTTAGGGCCATGCCAAATCTTCC
 ATTGCTTCAGGTTAGAATGATCTCACCTCAACATGAGCTTGGAGGTATGAGGCAGTGGCTCTGTG
 CCAGCTGCCACAATGTGACTTTGATGTCACCTGTACCCACCTCTCACTGGCTCTAGCACCACCTCC
 TCCCCGCACACCAACTGAAACACAGCTCTGAGAACGAAAGTGTGTTGGACCCAAACTGCCAAGCCTGAGTC
 TGTCCCGTGTCTGCTGCCATCCTTGAGTTCTGCAATTGCCATCTGACGTCGGCCACAGGAGGCCT
 GCTTCTCCAGCTGTTCTCAAGTTCCCTGCCACATGCCGCCAGTGGTGTGGTTTCC
 TTCTGCTCCAACCTGAGTAAAGTGTGTCGTTGAGTTCATCCCTAGTTCTCCATGGTCACTGGCTTCCC
 GGCCCCATGGGACCCCTCTCCATCCAGCTGACTGGTGACAGTGTGCAAGGTGCAAGTGTCTTT
 CGTTCCCTCTAAAGGGTGTGCACTTTTATTCCACTCTGCAAAAACAGATACGATTATGATTCCC
 ATGGAAATTGAAAAGCTATTAAATAATTAAACTATTAAACACTTTCACTGGT

>gi|10947059|ref|NM_015270.2| Homo sapiens adenylate cyclase 6 (ADCY6), transcript variant 1, mRNA
 CCGGTCTATAGGTGCATACCACCAACACCAGGCTAATTTCAGGGATCTCAGTCTGTCAC
 CCAGGCTGGAGTGCAATGGCGGATCTTGTCACTGCAACCTCTGCCACCCGGGTTCAAGCAATTCTCC
 TGCCTCAGCTCTGAGTAGCTGGGATTACAGGCCGCCACCACGCCGGCTAATTGGTATTTTAA
 TAGAGACGAGGTTTACACAGGTGAAAGCCACTGTGCTGGCTTGGCTCTGAGCTACCTGACCTTGTGAT
 CCTTCCAAAGTGTGCTGGGATTACGGACGTGAGCCACCACGCCCTGGCCAGGCTAATTGGTAAATTAA
 TAGAGGCAGGGTCTGCTGTTGCTCACTGGCTCTCACATTCTAGCTTAAGCCATCTCTATCTC
 GGCTCACAAGTGTGCTGGGATTACAGGTGAAAGCCACTGTGCTGGCTTGGCTCTGAGCTACCTG
 CTGTCCTGGGTTCTCACCTGTTGATTGGGATACCCCTGTTGCTCACCTCAAGTAAATTGAGGA
 TGAAAATCATAGCTGTGCACTGGGAGTGCTTGGGAAAGTGTGCTTGGGAAAGCTACTAGTGGTGGCAGTGGCTGTGATGG
 TGGTATTAAATACCACTCTACTGGATGGTCTCTAATACTATCTCCCTCCCTACCAAGCAACATGTCA
 TGGTTAGTGGCCTCTGGCTCTAAAGTGGATGAAAGGAAACAGCCTGGGCAACGCAATGGCAGA
 AGCGTTGCGGGCGCGTGGCACTCGGGCAGGTGGCTCTGCAAGGCCCGCTATATGAGCTGCCCTCCGG
 TGCAGAGCCACCCAGCCCCACCCCTGCCGGCCCCCTGGCAGGATGACGCCCTCATCCGG
 AGGGGCGGCCAGGCAAGGGCAAGGAGCTGGGGCTGCCAGGGTGGCCAGGAGTGGGCAATCCGAGG
 TGACAAACGACAGCGGGCGGGACGGCTGAGGTGGCGCCAGCGGGTGGCCAGGAGTGGGCAATCCGCTG
 GCGCCGCTGGTGCAGGTGTTCAAGTCAAGCAGTTCGTTGCGCAAGCTGGAGCGCTGTACCGAGG
 TACTTCTCCAGATGAACCAGAGCAGCCGTGACGCTGCTGATGGCGGTGCTGGTGTGCTCACAGCGGTGC
 TGCTGGCTTCCACGCCGCACCCGCCCTCAGCTGCCTATGTTGGCACTGTTGGCCTGTGCCGCC

EX03-053P

CCTGTTCGTGGGGCTATGGTGGTGTAAACCGGCATAGCTTCGCCAGGACTCCATGTGGGTGGTGGC
TACGTGGTGTGGCATCTGGCGCAGTCAGGTGGGGCGCTCTCGCAGCAGACCCGCGCAGCCCC
CTGGCGGGCCCTCTGGTGCCCTGTGTCTTGTACATCGCCTACACGCCTCCCTCCCATCCGATGCGGG
TGCGCGTCCCTAGCGGGCTGGGCTCTCCACCTTGCAATTGATCTTGGCTGGCAACTTAACCGTGGTGT
GCCTTCTCTGGAAAGCAGCTCGGTGCCAATGTGCTGCTGTCTCTGCACCAACGTCAATTGGCATCTGCA
CACACTATCCAGCAGGGTGTCTCAGGCCAGGCCCTTCAGGAGACCCGGTTACATCCAGGGCCGGCT
CCACCTGCAGCATGAGAATCGGCAGCAGGGCTGCTGCTGGTATTGCCCCAGCACGTGCGCATG
GAGATGAAAGAACATCAACACAAAAAAAGAACATGATGATGTTCCACAAGATCTACACAGAACATG
ACAATGTCAAGCATCTGTGAGACATTGAGGGCTTCACAGCCTGGCATCCCAGTCAGTGCAGG
GCTGGTATGACCCCTGAATGAGCTTTGCCCGGTTGACAAGCTGGTGGAGAACATGCGCTGAGG
ATCAAGATCTGGGGACTGTTACTACTGTGTCAGGGCTGCCAGGGCCGGGGGACCATGCCACT
GCTGTGGAGATGGGGTAGACATGATTGAGGCCATCTCGCTGGTACGTGAGGTGACAGGTGTAATGT
GAACATGCCGTGGCATCCACAGCGGGCGCTGCAGTCAGGCCGCTTGGTCTGGGAAATGGCAGTTC
GATGTGTGGTCCAATGATGTGACCTGGCAACCACATGGAGGAGGCCAGGGCTGGCCGATCCACA
TCACTCGGGCAACACTGCAGTACCTGAACGGGACTACGAGGTGGAGGCCAGGGCTGGTGGCAGCGAA
CGCGTACCTCAAGGAGCAGCACATTGAGACTTCTCTCATCCCTGGGCCAGCCAGAACGAAAGAGGAG
AAGGCCATGCTGCCAAGCTGCAGCGACTGGGCCACTCCATGGAAGGGCTGATGCCGCTGGGTT
CTGATCGTGCCTCTCCGGACCAAGGACTCCAAGGCCATGGCAGATGGCATGATGATTCCAGCAA
AGACAACCGGGGACCCAAAGATGCCCTGAACCCCTGAGGATGAGGTGGATGAGITCTGAGCCGTGCCATC
GATGCCCGAGCATTGATCAGCTGCCAGGACCATGTGCCGGTTCTGTCACCTTCAGAGAGG
ATCTTGAGAAGAAGTACTCCCGGAAGGGTGGATCCCCGCTCGGAGCCTACGTTGCTGTGCCCTGTTGG
CTTCTGCTCATCTGCTTCATCCAGCTCTCATCTTCCCACACTCCACCCCTGATGCTGGATCTATGCC
AGCATCTTCTGCTGCTGCTAATCACCCTGCTGATCTGCTGTGTACTCCTGTGTTCTGTTCTGTTCTA
AGGCCCTGCAACGCTGTCGCCAGCATTGTCGCCACATGTCACCTGTAACCACACCCCATACGGAGCT
CGTCCCTGCTTGTGTTACTTCTGCCATTGCCAACATGTTACCTGTAACCACACCCCATACGGAGCT
GCAGCCGGATGCTGAATTAAACACCTGCTGACATCACTGCCCTGCCACCTGCAAGCTCAATTACTCTC
TGGGCTGGATGCTCCCTGTTGAGGGCACCATGCCACCTGCAAGCTTCTGAGTACTTCTATGGGAA
CATGCTGCTGAGTCTTGGCCAGCTCTGCTCTTGCACTGCAACATCAGCAGCATCGGGAAAGTGGCATGATC
TTTGTCTGGGCTCATCTATTGGTGTGCTCTGCTGGGCCCCAGCCACCATTTGACAACATATG
ACCTACTGCTTGGGCTCCATGCCATTGGCTTCTTCAATGAGACCTTGATGGCTGGACTGTCAGCTGC
AGGGAGGGTGGCCCTAAATATGACCCCTGATCTGCTGGTGTGAGTGTGGCTGACTCTGCA
GCTCAGCAGGTGGAGTCAGGCATACAACCGGAGGCTGCTGATAACATCTGCCAAGGACGTGGCGGCC
AGATGGAGGAGCTACAGGCATACAACCGGAGGCTGCTGATAACTCTACTATCAGTCGTTGAGTGTGGCTGTTATGTT
CTTCTGCCCGGGAGGGCCATGAGTAACTCTGAGTTCTATGTTGAGCTGGAGGCAAAACATGAGGGTGTGAGTGC
GCCTCCATTGCAACTCTGAGTTCTATGTTGAGCTGGAGGCAAAACATGAGGGTGTGAGTGC
GGCTGCTCAACGAGATCATGCTGACTCTGAGATTATCAGCAGGGAGCTGCCAGCAGCTACGATCAGGTGGGC
GATCAAGACGATTGGTAGCACCTACATGGCTGCCAGGCTGCTGATAACATGAGGGAGCTGGAA
CGCTCCACATCACTGCCCTGGCTGACTACGCCATGCCCTGCTGAGGAGATGAGTGTGGCTGTTATGTT
ACTCCTCAACAATTCCAGATGAGAAGATTGGGCTGAACATGGGCCAGCTGTCAGGTGTCACTGGG
TCGGAAGCCACAGTATGACATCTGGGGAAACACAGTGAATGTCCTCTAGCTGCAAGGGCTACCAGCTGGAGTGT
CCCGACCGAATCCAGGTGACCAACGGGACCTGTGCTGGGCTGAGGAGGCTACCTACGGAGAGGATATGCAAGTG
GAGGGGTGGTCAAGGTGAAGGGCAAGGGGAGATGACCAACACTTCTCAATGGGGCCCCAGCAGTAA
ACAGGGCCCAGCCACAATTCAAGCTGAAGGGACCAAGGTGGCATTGAGTGGACTCTGTCCTACTGGG
GGAGCTGTCGGCAGGGGCACTGAGCCTCCAGGCCCTGCTAACCACAAAAGGGAAACATCCCAGCAGGCTGT
GCTTGGATCATGCTGCTGCCCTCAAGTGGAAAACAAGGGCTACCTACGGAGAGGATATGCAAGTG
ACTTTCTTCTTACTTGGGTAGGGCTGTTCCCTCTCAATCTTCCAGCCTTGGGAGCAGGGAGGGGT
CAGTAGCAGAACAGGGAGGCTCTGCTGAGGGATTAAATGGCAGCTGCCATGCTACCCCTC
CTGTCGCTCTGGCAGGGTTCAGGGCTGAGGCCCTCTTCCCTCTTTCTGGGAAATATTTGTA
CAATATTGTACAAAGACAGGCATGAGGAGTGCCTATCCATGCTGCTTGCCTTGCACATACCTGCATCCCC
AGCACTGGTCTGGCACTTCCCACCCAGCCAGGTGCTCCCTCTATGCACAGGAGCACAGGGAGGGAGAA
GCTCTGGGAGGCCAGCTTGGCATATTCAAGGAGAATGTTCCATGCAACAACTTGTCCCATGATC
TGTCCCCAAAGGGAAACAAAGGGACCTCTGACAGCTTAGATTTAGCCCCAGTCCCTGCACGCTCCAGGG
ACGGGGTGTCTGGCTCACTGGTACTGTGAAAAATGCTCAGAGAGCAAGCCTGTCAGGGAGTGT
TCAGGAGCTGGAAGTTCACCTGCAGGTGCCAAGAGCAGGCCAGGGCTGGGAGTGCAGACTCT
GATCTGAGGACCCCGTCGGGTCAGATCAGGTCACTCTGCCCAAGTGCCTCTTGTCTGTCAG
GGGGCATGGAGCATCTCTTCTCTGTCAGGAAATAGAAAAGGGTCAAGGGCATGGAGAAAGGTGACC
CTGATCCAAACCTGCCCTCCCAAGTCTCTGGTGTGGGAGGGCCGTGTTGTAACTGTGTG

EX03-053P

CATGTTGGTCTTGTGTGCATATCTGTTTCCAGGTATGTGAGTCCTGTGCTCTGCTCCTCAGCTC
TCCACCCCCAGGTTGCCCTCTCTCGTGGGCCTCTGCTCTCGGAATAAGCAGGGTTCTACTTCAGG
GGATGTAGAGAGATGCCAGGTTGCACAGGAGTGGGATGGGTGTGGTAGCAAAGGAGGGAGAGGAGTC
CTTTTGTCGCAAATCCCTAAGTGCCGTTCGGGGCCATGTGTCAGCATGACTCTCCCTGTCTGTGGCA
GGGACCAAGCGCTTGCTTAAGCCCAGTGCTCCATGCCAGCACTTGAACGTGCTGGGACATGGTATGCTTGGGCTGGGTAGC
GAGGCTGAGGAATTCTGGCTCCAGATAGTGCCTGGACATGGTATGCTTGGGCTGGGTAGC
ATGGAATCCCTCTGAGGACCTGGATACTGGTACTACGGGTGGGAAGAGGAACCTAAACTGGCTTC
CCCAGCCTCAGCCTGAGTCTAGCATGTTCTAGCTCCCAGTCCCTGTGAAGCCTGAGGGCTGGCAG
AAGGTTAGGAGGTGAACCTAGATTCCCTCTGCTTGCCTCCCTTACCCCTTCCCTGCAACC
TCCTGACTCTGGCTGAATTGTGGTGCCTCAGTTCTGTCTGTACCTATTAAAGCAAAGGACT
AGCCTGAATTGTGCTGAAGATCATTGCTTGGAAATGACTAGAGAGCAGAGGAGAAGGGTTCCAG
AGTTGCTAGGTTGGGAGTGGAAAGGGCAGGCAGTGCACTTGCCCCCTCATGCCCTCTGACACCAG
CTCCCTGGAGGCCTGGTTCTGGTAATGCCCTGGCATCTCATGCATCAACAAATGGGCA
TCAGGTACTTCATTAGTCATGGCAGAAGGAGGGAAAAGACTTGTCTTGCCCTCCCTGGGCTACCAATTGTCCC
TGTCCCCAGCCATATCCCTGGATAGGAAGGGATAGGAAGAGACTACTGGTGCATGGGTAGGGTAG
GGTATAAGTAGATCAGGTGGGAAGACCTCAGCCTGGGTGCTCTGCTCTTGCCAGACAGAAAATCTACTCCCC
GGCCTGTCCACACCCCTGGATCCCGTACCACTGGCAGGCTGGGCTTGGTTATAATGTAACCAC
TTCCCTACCCAGTTGGTAGAGGGAGTCAGGAGGTGGGAGGCCGTGGGCTTGGTTATAATGTAACCAC
TGTGGGGGTGGGGAGGATGGTGAACCATGTATTCAAGTAAATATTAAATATCAATAAAA
ATCAAACCTTTGT

>gi|4557256|ref|NM_001115.1| Homo sapiens adenylate cyclase 8 (brain)
(ADCY8), mRNA
GACTGGCTGCAGCCGAGTCTTGGTGGAGGAGGTGGTACCAACCACCGCTCCTCACCTGCATCCGGCTG
CGGGACTGCGCGGCCGCGTGTGCCCTGCAGACCCCTGCACCCCGGGACCGCGCTCATCTGTCATTAGCAC
CGGCACTAAGCTCCACCGCTAGCGACTTGGTCCGCCGAAGCTCCGCCAGGGCTTGTCCGCTAGCG
CTCGGCTAGTCTGGCGGGCGGGAAACCTGGCTAGGGCAGGGGGCCCTGGACATGCCTTCTCC
ACGTCCGCCCTCTGACCCCTATTGTAAAGCGGAGAAACTTAGTGTGCGAGGCAAGGGAGCTCCCAT
TTTGTATGTCCTGACCCCTCCACCCCTTCGGATCGAGGTAGTAAAGAGGCTCTGTAGGAAACTGACTGC
CTCTATGATTGGCGCTTGGGGATTGGCTTGGCCGAAAGTTGGCTTGCCTAAAGACGCACGG
GTAGGAAGGGCAGAAAGGAAACCTGTATTCCGTGCGCTGGCTCTCGAGTCCGTGCGCAAGCGGCC
TACGAGTCTGGCTCCGACCTGCAGAGGACAAGAGCCAATGCCCTAAAAGAACAGCGGAGGAACCGGC
TGGCGGCCAGCTGGAACGCTGGATCGAGTGCAGCCAGGGAAAGGCCGGGGCGCCGGCCCTAGC
CCTCAGTGGCTCTCCACGCCGGCGCGTGCCTGCCTACAAGACCTGGGCGTCTGGCCAGA
TCTGGATGGCAGGTCCCTCGCCACCCCCGGCCGTTCCGGGGCGTGGCTTGGCGCGGGGGCGGGTT
AAAGTCACCGCGGGTGTGACCAACTCTGACAGGTCTCCAAATTCTCCAGTCGCTGGCGCCCGCGGTG
CGTTTCAGAGCTCCAGGGTGGCACCGCGCGCTCCCTAGATCCAGAGGCCTCTGTGCACTTCCAC
GCGGCCCTGGGCTCCCTCTCGGAGCTCCCTCCAAACCTCGCCCTATCCGCCAGCTTCGGTTCTAGCCTCAGAT
ATCCGCACCGGGCGGCTCTCTCGGAGCTCCCTCCAGCTCCCTCCAAACCTCGCCCTAGGAGCTCC
CCGCTCTCCCTGATCCCTCTAGCTCCGAGCCAATGGACTCCAAAGAACGAAATAAGGGATGAGAACT
GTGTGCTGCAACCCCTTCGAAAGACACAGCTGAAAGCGTTGACCTCGTCTATAGATCAGGCTGGGACCTG
GGCGAGAGTCCCCACACCCCTCCGGAGGGATGCTTCTGGCCAGAGCCAGCGCTGCGCTGAGTCCT
TGCTCCGAACTAGGAAAGAGCTAGGAGGGAGCCTAGCAGCATACCCCTCTCCAAATTAAACTATTGGT
GAATTGTTAGCGCCAGGCTACACCTCTCCAACCTCTGAGGAGCCAAGGGCTGCACTTCC
CTCTCCCTCCCTTGTGCCACGCCAGCTCCGCCCTGCTCCCTAGATCCGGCGCAATGGAGTTCTC
CGAAGGGCAGTATCCAGGCCACATCTGCTAACCTCGCACCCATCGCTGCCGCGGTACCGCTGACCC
GCCCTGAGCCGCGAGCAGTGGCGTCAAAAGGCCAGTGCAGCAGGCCAGGACCCGCCAGCGCAG
CAGAACCGGCCAGGCCAGCGCTTGGAGAGCAAAGGCTGCGCAGAACGCTGAGCCTAG
AATCAACCAAGGAGCCTGAGCCAGGAAGGGCTGCGTGGCTCACAGCGCTGGCTCCGTAGGACAAAT
AGCCACTGCCGCTGCGTACCCAGCTGCCGGCTGGGGAGAGCAGGCCAGAACGACGCCAGGTC
CCGGCATCTCCAGGTGCCCTTGCCCTGGGACAGTATGACCCGACCTACAGGGAGCCCTAGCGCAGG
GCTCTGCAACGGGTCAAGGATAAAAAGGATCCTGCAAGCTCTACAGGGAGCCCTTGGAGTCT
TTAGGAACCCCTCCCGCTGCCCTCCAGGTCTGGGCTCCCTTGCCCTGGGAGGCTGGGCAAGCCTGG
CTCTCCGATGTGCGCTGCCCTAACGGAGGAACTCTACACCATCCACCCAGGCCAGGCCAGG
ACGGCAGGAGCGCCCTCCGGCCAGCGCTGCTGTGGCAGACGGGGTGCACACATCACGGAGCAGCG
CTTCATTCAAGGGCACGGGGAGGCGAGCGCAGCGAGGGAGTGGAGGCTGGGCAAGCCTGGACCCCTGCG
GGCGCGGCCAACCAACCAACCGGCCAGCTGCAAGCGACTCGCGCTGCCCTACTCGCTGGGCC

EX03-053P

CGGGAGAGCGAGCGCACAGCACCTGGGCACCAAAGTCTTCCCGAACGCAGCGGGAGCGGCAGTGCCAG
CGGCAGCGAGGCGGGCGACCTGGCTTCCTGCACCTTGACTGTGCCCTAGCAACTCGGATTTCTT
CTTAATGGGGCTATACTACCGAGGGGTCATTTCACCCCTGCACACTCCTCAAATCTCGGATT
TGGAACGCCCTACCGCCTATTCTGGGCAAAGGCACATGGAAGTGGTATGAACGTGCTGGA
CGTGCCTGACCAAACACTCCTCTGGCTCACACTTGAGCCTGGCTCGGCCCTGGGCCCCATGGACCCGCTCAAG
GGCATCTGCTGGCTCTTCACCGGATTAGGCTAGTGATCTGGCTCGGCCCTGGTGGTCAGGAAGGACA
CCACCTCCCACACGTACCTGCAGTACAGCGGCTGGTACCTGGCTGCCATGACCACCCAGATCCCTGGC
AGCAGGCCCTGGCTACGGCTCCCTGGCGACGGCATAGGCTACGTCTTCACGCTTCCGCCACCTAC
AGTATGCTGCCGCTGCCCTACCTGGGCCATCTGGCCCTGGCACCTCGCTGCTGAGGTATCC
TCCAAGTGGTCATACCCCGCTGGCGTCAATTCCATCAACCAAGGTTGGCCACGGCAGTGTATTGAT
GTGTATGAACACAGCTGAATCTCATCAGTACCTGTCAAGACCGGGGCAAGGCCAAGCTTCCGGAG
ACTCGGAGGTGTGGAGGCCAGGCTGGCCTGGAGACAGAGAACAAAGACAGGAGCGGCTCGTCTT
CTGTGCTCCCCGGTTGTGCTCTGGAAATGATCAACGACATGACCAATGTGGAAGATGAGCACCTGCA
GCACCAGTCCATCGGATCTACATCCATCGCTATGAGAACGTCAGTATTCTTTGAGATGTTAAAGGA
TTTACCAACCTCTCCACGACCTGCTGCTAGGAGCTGGTCAGGATGCTCAACGAGCTTCCAGGAG
TTGATGCACTGGCCATGAGCATCACTGCTCTCGTATTAAAATCTGGGGACTGCTACTACTGCGTGT
TGGACTCTGAGCCCCGCCAGGACCATGCCACTGCTGTTGAAATGGGCTCAGCATGATCAAAC
ATCAGGTATGTGCGGTCAGGACAAAACACGATGTTGACATGAGGATTGGAATCCACTCCGGCTGGTGC
TGTGCGGTGTTGGACTACGGAAGTGGCAGTTGATGTCCTGGTCTGGGATGTTGATATTGCAAACAA
ACTCGAACATCTGGAGGAATCCCCGGAGGATTACACATTCTCAAAGCCACGCTGGACTGCTCAACGGTAC
TATAACGTGGAAGAGGGCATGGTAAAGAGAGGAATGAATTCTGAGGAAGCATAATATCGAAACTTACT
TAATTAAAGCAGCCTGAGGACAGTCTGCTGCTTGCCTGAAGATATCGTCAAGGAGTCAGTGA
AGACCGGAAACAGTGGGGCACATTCACTGAAGGATCTGGAGGCCCTGAACTGCCCTTGATAATATC
GTGGGGAAACAGAAATACTCTGGCTGCCCTAACAGGAAATTCAATAAAATCTGCTTCCAAACCATCTGCA
AAGCTTGCACTGTCAGTCTGGGCTGAGGAATTAAACAAGAGAAATAGAACATACCATGACTTGGAG
TGGCGATAAATTGAGAAGAGAGCATATCAAGCATTCTCACTGATGTTAAAGACTCCAGGCTGGAGC
AAGTATTCTCAAATGAGGATGAAGTGGTCAAGTCAAACTGTCCTGCAATTGATGTTCTTCTGAT
TCACGGCAATACAAAGTTGCTTCTTCTCAAGAGTGTGCAATGACCATCCAGTTCTCATTCTGAT
TATGCTGCACTGGCTCTGGCTCATCACACAGCAGGATTATAAAATGTTGCCCCTCATCCTCCGG
AAAAACTTGGTGTGTTAATGAGACCTATTGGCCCGAACGTCATCATTTGAGAT
ATTCCTGGGTGCCATCTTAAATATCTGTTGATGACAAGTCGATACCCAGAGTACTTGTCTTCACGGGGTGTG
TTCAATTCTCAGCTGTGTTACAGATATCTGCTCTACCCAGAGTACTTGTCTTCACGGGGTGTG
GCCATGGTGACCTGTCAGTTCTCCGGCTGAACCTCGCTCTGAAGCTGGCAGTGTGCTGATCATGA
TTGCCATCTATGCCCTGCTCACTGAGACGCTACGCAAGGCTCTTCTGCGTTATGACAACCTCAACCA
CAGTGGAGAAGATTCCTGGGGACCAAGGAGGTATCACTGACTGTGATGGCATGTTCTCCCTGGCTGTG
TTCTACCATGGACAGCAGCTGGAGTACACAGCCGCTGGACTTCCTTGGCAGTACAGGCAAGAG
AGATCAATGAGATGAAGGAGCTGAGGAACACAATGAGAACATGCTCCGGAATATCTTACCCAGCCATGT
GGCCCGCATTCTAGAGAAGGACGGAGACAATGAGGAGCTGATTCCTCAATCCTATGATGCTGTTGG
GTGATGTTGCTCCATCCCAGGATTGCGACTTTACTCTCAGACTGAAATGATAACCAAGGGAGTGG
AATGCCCTGCGCTTGCTCAATGAGATCATTGCTGACTTCGATGAGTTGCTTGGTGAAGACCGATTCAAGA
CATTGAAAGATTAAGACCATGGCAGCACCTACATGGCGTGTCAAGGCTGTACCTGAAAAACAGCAA
TGTGAAGACAAGTGGGGACATTGTTGCTCTGGCTGACTCTCAGACTGAAATGATAACCAAGGGAGTGG
AGATCAACAAGCATTCAACAAATTGAACTCCGGATTGGCATCAGCCACGGCTCAGTGGTAGCTGG
CGTTATCGCGCTAAGAAACACAGTATGACATTGGGGACAAACTGTGAACCTGGCAAGCCGAATGGAC
AGCACGGGGTTAGTGGCCGGATCCAAGTCCCAGAGGAGACCTATCTCATCTGAGGACAGGGCTTTG
CCTTGTGATTACGAGGGAGATCTATGTGAAGGGTATCACTGAAACAGGAAAGAAAATCAAACGTACTT
TCTTCTGGGAAGGTCAACCAACCCATTCACTTGGCCCTAACAGAAGACTGCTGGCAGTACTCCCTG
GCCGCGTTGCTGGACTTGCTCAGTCCCTCAATAGGCAAAGGAGAACAGCAGCTACTCAATGAGAAC
ACAACACAGGAATCATCAAGGTCAATTACAACCGGGGACTTTGTTGTCACCCAGGCGCACAGGCTGG
AGCCCAGGCTGAAGGCACCGACAAATCTGATTGCTAAAGCAATTCTTCTGTTTTTTTTTT
TGTATTCTTTATATAAAATATAACTAATAAAAGGTTAATTGTTAGAACAAAAAA
AAAAAAAAAAAAAAAAAAAAACCCAAAAAA

>gi|7661961|ref|NM_014770.1| Homo sapiens centaurin, gamma 1 (CENTG1), mRNA
AAGGGGCCCTCTGAGGTTGGGGCTGTAGGGCATGGCCTCAGGGCAGAGGTGGTGTAGCCTGGC
AAGACAGGTCTGGCAACATGCACTGCCAGAGGCACTGCTGAGTGCAGTGCAGAGCAGAACAGTCA

GACATGAGGTGGCCAAGCAGGCTCTAACCGCCTCAGGAAGCTGGCAGAGAGGGTGGACGACCCGAAC
 CCAGGACAGCATCCAGGCCTCATGGACAGCATTGAGAGGCTGTGATCAATAGCAGGAATGGACTTTG
 AGCCGCTCATTCTGAACCTGCGCTGGGTGCTGGGCGATGCCAGGAGTGGGAAGTCATCGCTCATCC
 ACCGATTCCCTGACTGGCTCATACCAGGTGCTGGAGAAGACAGAGACTGAGCAGTACAAGAAAGAAATGTT
 GGTGGATGGACAGACACATCTGGTCTAATCCAGAGGAAGCTGGGGCACCTGATGCCAAGTTCAGGC
 TGGGAGATGCTGTGATCTTCGTCCTCAGCCTGGAGGATGAGAACAGTTCCAGGCTGTGAGCCGTCTCC
 ATGGGCAGCTGAGITCCCCCTGGGGGGAGGGACGAGGAGGCTGGCCTTGGCACTGGTGAGGACACAAGA
 CAGGATCAGTGCCTCCCTCCCCTCGGGTGGGGAGATGCTGTGCCAGAGCTCTGTGCGCGGACATGAAA
 CGCTGCAGCTACTATGAGACTTGTGCAACCTATGGCTCAATGTGGATCGGGTCTCCAGGAGGTGGCCC
 AGAAGGTGGTACCTTGCAGCAGCAGAACAGCTTGGCTGCAAGTCCCTGCCAGCTCCCCAAG
 CCACTCAGCTGCATCCACTCCGGTAGCTGGCAGGCTAGTAACGGGCCACACTAGCAGTACTCTTCT
 TCCCTCCCGTCTCACCAGTGTGGTACCCGGAGCTCCGAGGCCAGGCTTTTGGCAATCGTGGGGTACTGTA
 GCACCCCCAGGGTCCCTGCACCGGGCAGCCAAGCCAGGACAGGCCATCCCAGCTCAAAACAG
 CTCCGAGAAACGAAGCTGGATAGTCGGGGAGAGACAACAGGAGTGGCGAGGCCATCCCAGCTCAAAACAG
 AGCTTCTACTAAAAGAAGTGGCAATTCTTGAACAAAGAATGGAAGAAGAAATATGTAACCCGTCCA
 GTAATGGCTTCTACTTACCAACCCAGTATTACGATTACATCCACAGTACCCACGGCAAGGAGATGGA
 CTTGCTGCAACAACAGTCAAAGTCCGGCAAGCGGCCCCAGGGGCAATCTGCTTGTGCCCCCTCA
 GCCAGCATTAAACGGGCTGTCAGGACATGAGCAGTGTCCAGATGGGTGAAGGCCACTGCA
 CCATGCCAAGCCCCTAGCCCCAGCCCCAGTCCCTGCAGCACCACAGATCAGACATCCAAACACCTGCT
 GAAGCCAGACCGGAATTGGCCCGAGCCCTCAGCACGGACTGTACCCATCTGGAGACATCCAGGAC
 AGTCGGGAACCCCCCTCTTCTCCATGGTGAAGAAGCAGAGGAGGAAAAATGACAACACCATCCAAGA
 CTGAAGGCTGGCTGGCAGGCTGAAGAGGAAACTTGAAGTCTCTGATCGTGTCCAGCACGGTCAGAC
 GTGGCACTTGAGGCCAGTTGAGGAGCGGGATGCTGGTCAAGGCCATCGAGAGTCAGATCCTA
 GCCAGTCTGCAATGCTGTGAGAGCAGCAAGGTCAAGCTGCGCACAGACAGCCAAGCGAGGCCGTGGCA
 TCCAGGGATCCGGAACGCCAAGGGGAATTCAATCTGCTGGACTGCCGGCCCCAACCCCACGTGGC
 CACCTTGAACCTGGGCCCTCATCTGCATCGAGTGTCTGGCATCCACCGCAACCTGGCACACACCTG
 TCCCGCGTCGCTCGTGGACTTGGACACTGGCACGGAGCTGGCACCCCTGGTGTGACGGCTATTGGCA
 ACGACACGGCCAACCCCGTGTGGAAAGCGACACCGCAGGGCGTCCAAGCCCTCGCGGACTCTCGCG
 GGAGGAGCGCAGTCGTGATTGCGCCAAGTACGAGCAGCTACTGTTCTGGCGCCGCTGAGCACCTCG
 GAGGAGCCGCTGGCCCGCCAGCTGTGGCCCGCTGCAAGGCCAGGACGTGGTACCGTTCTCTGCTT
 TGGCCCATGCGCACACGGCCGCTCGACACCAGCGTAGAGGACCCACAGCTGCGCTCCCCACTCCACCT
 GGCGGCCAGGGCCGACGGCGCTGTTCTACGCCCGCCAGGCTGGAAGGCCAGCTGTGCGCCGACATCCTTC
 GACGCCAGGGCCGACGGCGCTGTTCTACGCCCGCCAGGCTGGAAGGCCAGCTGTGCGCCGACATCCTTC
 TCCAGCACGGCTGCCCGGGTGAGGGCGCAGCGCGGCCACACGCCAGCGCGGCCACACGCCAGCAT
 CACCGCCACGCCAGCCCCCGCCGGAGCAGGCCGCTAGCGTGGCCGCGGCCACGCCGGTTGCG
 CTGGTATAGTTGCCAGCGGGAGAGACACCCCATCCCCACGCGGGCGGGCACGACCACACCGGGCGGA
 CCGCTGGACAGACGCCACCACTCACCTCTCCGATCCGACCCCGCCCCACGGGAGCACTTCTACCCCA
 CGAGGGCACGCCAGCCCCCGCCCTCCAGAACAGACACAAACTCACCTCCCTCTCCCCAACGAGGATGGAGAC
 CCCAGCTAACACGCCCTCTCCATTGTTCCACACTCGGATTGCTCTGGGTCTACCCGCTGGGGTTC
 GCGGAAGGGGAGGTCCCCAGCGGTACGGGCTCTAGGGCTTGGACATGCCGTTGTGCCCCCTAGGGG
 CGGAAAGAAGACCCGGTCTCTGCCAGCTAACAAATCCAGGGGGAGCCATACCCAGGCTGGCTCT
 GGGCGAGGCCACGCCAGAGGGAGGGTTAGTACATGGGAGGGCTAGCCCGGACTTGGGGCCAATACG
 GAAACCTTACCCCTCCATGCTCATCTCACTGCCAGTGAAGGGGCAAGGGCAGCGAGGGCAGGCC
 CTGCTGCTCATGGGGTGGGGTCCCCAACCTTCTCGTGAAGGGAGCCGTGAGTAGTGGAAACCAGGAC
 GTCCCCTACACCTACCCATGGTGGAGCTAACAGTCTGGGGAGGAAACCAAGAGCCTGGGTCCCTCCAC
 TACTATCTGGGAGGGAGAGGGATGGAGCAGGAGGCCATAAGAGGGCTGCCGGGGCTTGTAAATTAT
 TGCTTGTCCCCAACATGGGATGGGGCGGGCAGGGCGTGGGGAGGGCTTTGGGGTAGGGGAAGC
 CCAGGGTGGGCAGGGGGTGGGTGGGGTGGGGTCTCGGGTTGTCTGTGACCGTGACTCGTAC
 TGTGACTGTGCAGGCCCGTGGTGTCTGGGTAGGGGAGCCCTACAGTGGGACCCCTCCCCATTAT
 TCTTCTGTCCAGCCCTCCCTCCACTGGAGCAGCTCCAGGCCATTCTCACCCCCGTGACCTCTCC
 AGCCAGGGCTGAGAGGATTGAGGTGGCTGGAGGGTTCCAGGCCCTGCCCTCAGCCAACCCAGGCC
 GTGATAGGGCGGACTTACCTGGCCAGGCCCTGCCCTCAGCCAACCCAGGCCCTGGGCTGTCTGTGTC
 AGTGGTTCCGGTCTTTTTTTTTCTGGCTAAAATAGTTGCAAGAGGACCAAGGTAATTGGG
 GAGGGGAGAGGGAGGTGGGGCAAGGGGAAATGCCCTGGAGGGAGTGGTGTGAATCTCT
 TCAACAGCAATTAAAGAGGAAGTGATTG

EX03-053P

>gi|7662483|ref|NM_014914.1| Homo sapiens centaurin, gamma 2 (CENTG2), mRNA
CAAGGGCCTGCGACTCGTCCCAGGTGGCGGGCGCGCGGGCTCGCGGGGGCCCCGGCGCG
CCGGGCGGCCAGTCAGCAGCGCGGACCCACGCCACGCCAGGAGCCCAGAGCAGCGGCCACACTG
CCCAGGGGCTGGCCCTCGGCCCCGGCGCTGGAGCGCGGGCTGCCTGGGTTAATGGCTGCTCCCG
GAGCAGCGCCTAGGGCTGGAAGGGCGCTGCGCTCAGGAAGTCACCCAGCAAGCCTCCTCGGGCG
CCGCACCCCGCGGGCGCTCCATGGGGCGCTCCCCCGGGCGGCCGCTGACCCGGACGCCGG
GCCCCTCGCTCGCCGGCGCGTCCCGGCCATGAAGTCAGGCCAGGGCCAGCCCCGGCGCTGCTCCG
CCCGCGCCCTTCTCGCGCCCTCCCGCCGCCGGCGGGCTCCCCGGGGCTGCCGGCG
CCGGGCTCGCGGCCGCCGGGGCGGGGGCGGGCGGGCGGGCGGCCGGCTCCGGCG
GCGCTGACCATGAACATACCAGCAGCTGGCAACTCGGCTGCCATCCGGCGAGATCCAGCGCTT
CGAGTCGGTCCACCCAAACATCTACTCCATCTACGAGCTGGAGCGCTGGAGGAGCCGGTGCAG
AACCAAGATCCGGAGCACGTATCGCCATCGAAGATGCCCTCGTAACAGCCAGGAATGGACGCTGAGTC
GATCTGTCCGGAGCTAAAGTGGAAATTGGGTAACTGGCCAGGGCAAGTCGCCCCGGTGCACCG
GTACCTGACGGGCACATATGTCAGGAGGAGCTCCGGAGGTGGCAGGTTCAAGAAAAGAGATTGTCGTT
GATGGACAGAGCTATGCTGCTGATCAGAGATGAAGGGGCCCCCGAGGCGCAGTTGCCATGTCGG
TGGACGCTGTTATTTGCTTCAGCTGGAGGATGAAATAAGTTCCAGACCGTTTACCAACTACAG
TCGAATGGCCAATATCGAACACGAGCGAGATTCCCTGGTCTGGGGAAACCAGGATGCCATAAGT
TCTGCTAACCCGAGGGTATCGATGACGCCAGGGCGAGGAAGCTCTCCAACGACCTGAAACGGTGCACGT
ACTACGACAGCTGCTGCTACATACGGGCTGAATGTGGAGAGGGTCTCCAGGACGTTGCCAGAAGATTGT
TGCCACAAGGAAGAACGAGCTGTCATAGGACCCCTGCAAGTCGCTACCTAATTCTCCAGCCATTCC
TCGCTCTTCCCGCGAGGTGTCGCCGTGACATGCCAGACAAGTAATGGAGGTGGGAGTTAACG
ACTATTCCCTCCCGTCCATCGACTCCCAGCATGCCAGAACAGGAACCTCGGATCGATGTTCCCTCCAC
TGCCAACACGCCAACGCCGTTGCAAGCAGCTAAGGCCGGTCAACCTGTTACCTCTCGGAAAGGG
AGCGACCCAGACAAAGAGAAGAAAGGCTGGAGAGCTGTCGGAGCACGATTGGAGCGGCCAGCCATCC
CAATTAAACAGGGATGCTGTTGAAGCGAAGTGGAAATCGTTGAATAAGAGTGGAAAAGAAATATGT
CACCCCTGTTGACAATGGCGTGTGACCTATCATCCAGTTACATGATTACATGAGAATGTTATGGT
AAGGAGATTGACCTTCTGAGAACACTGTGAAAGTCCCAGGGAAAGAGGCCACCCGAGCCACGTCAGCCT
GCCGACCCATCTCCAGCCCTAAACCAATGCCATGCCAACAGGACATGAGCAGTTACACATCTCACCCAA
TTCAGACACAGGGCTGGGTACTCGTATGCTCCAGCCCCAGTATCTCCAGCACACCAGCCCCAACGCTC
GACCCGCCCTCCCTCACGCAACAGAACAGAACAGGAAAGAAAAGCACTAGCAACTTCAAAG
CCGACGGGCTGTCGGCACTGCTGAGAACAGAACAGAACAGGAAAGGAGCTGGTCCACTGG
CCAAACATGGCACTTGAAGGCCAGACGTATGAGGAGGGAGCCTGGGTCAGGCCATCGAGAGGCCAG
ATCCCTGGCAGCCTCGACTCGTGTGAGAGCAGCAAGAACAGTCCCCGCTGACGAGCCAGAGCGAGGCCA
TGGCCCTGCACTCGATCCGGAAACATGCGGAAACTCCACTGTGGACTGCGAGACCCAGAACATCCAA
CTGGGCCAGTTGAACATTGGGACCCCTCATGTCATCGAATGCTCAGGGATCCACCGGAATCTGGCACC
CACCTTCCCGAGTCCGATCTGGACCTGAGACTGCCATCGAGCTCATCAAGGTGATGTCATCCA
TCGGGAAACGAGCTAACCAACAGCGTCTGGGAGAGAGCAGCCAGGGCGAGAACACCACCGTAGACTC
CACAAGGGAAAGAGAACAGGGGAACTGGGATCCGTGCCAGTACGAGCAGAACAGCTTCTGGCCCCGCTGCC
TGCACGGAGCTGTCCTGGGCCAGCACCTGCTGCCGGCACCCGCCAGGACCTGCCAGGGAGACGCCAG
TGCTGCTGGCACACGGCTCCGGGACGGGTGAACGAGAACCTGCCAGGGAGAGACGCCAG
GCATCTGGCTGCCAGGGGAATGTGGTCTGGGCCAGCTCTGATCTGGTACGGAGTGGACGTCAC
GCCGAGATGCCACGGGAACACAGCTCTGGCTACGCCGGCAGGCCAGGACCTGCCAGGGAGACGCCAG
TGCTGCTGAGTACGGCTGCCGGACGGCGCTTGCTGTCATGGCACCCCTAACCTGTCAGGAGAAA
CAATAACCGAACACAGCAGTGGGAGGGTGGCCACCATCATGAGGAACAGCCGTGCCAG
CCGCACCTGGGACGCCAGCTCGCCGATTCTCGTCAGAACGTCGCCAGCTGAGTCCCGTCAC
CCCTCCCTTCTGGGCCACCTCCCTCCGCCACCCACTCTCACCCCCAACAAAATCACAAAACCT
GGACATCCCTCAAGGGGCGAACAGGGCGGGGGAGACTGCAAGAAGTGGCTCTTTCATAAACTCCCC
AACACACACAGGAGAGAGCAGGGCTCGGCCCTTGTGATGATGACACATGGCGAGGCCCTG
GGTGGCACAAGGGATGGGGACGCCAGGGGGAGGGAGGGAGGAACAGGAGAACAGGGCAACTTCT
ACTGGCAGTTGAGCACATAGTACATTTCCTCTACCAACGGAACACTTGGATTCCATCTCT
GGAGCTGACGGCATAAATCAGAACAGCACAGAGTTGTCAGGTTGAAGGCCCTATGATGGTGTG
TCAAATCAGTTGAGCTAATCTGTCAGGGAGAACACTGGCTTACCTACACTTGTCAGGCCAG
CCGCATTACTGCTGTTAATAGAACGAGTGTGATTAGTCATGCCAGGAGTGTGATTGCA
GTCACGCCAGGCCAGGCCGGTGAATTGCCACCGATGTGATTGCAAACTCTAGAACGAC
ACATGTTCTTCAAGGCCCTGGAGGCCCTCTAAATTCACTGTCATCATTAGTATCTGTTAATT
AGTCCAAAGAGAGGAAATCAGTCGCTGAGTATTGACTCCGGTCTCCTGGTCAAAAACAAAATGG

EX03-053P

AAAAAAATAAAGAATAACTCAGAACTCAAAGGAAACCACAAATTCAAGCTAATAATAGCATTCGAG
TATATTTCTGAACTAAGGAAATACACAAAAGGCTGTTTTCCGACTGTAAAGAGATATTGTATGTCCT
TTGCCGAGGTGGATGTGTTAGTCAGGCCCTCGAACGTTGCCAAGTCACACAGGCTCTGT
TTATGTATTTAGATAAGATGTGTAAAAATATTTGAATAAAGAAGTTCAT

>gi|32307157|ref|NM_031946.3| Homo sapiens centaurin, gamma 3 (CENTG3),

mRNA

GCCATGAACCTCCAGGGGGGGGGGGGGGGAGAGCCCGCAGCAGCAGCAGCAGCTGGCCGGGGCCCCCCC
AGCAGTTCGCGCTCTCCAACCTCCCGGGCATCCGGCGAGATCCAGCGCTCGAGTCCGTGCATCCAA
TATCTACGCCATCTACGACCTGATCGAGCGCATCGAGGATTGGCGCTGCAGAACAGATCCGGGAGCAC
GTCATCTCCATCGAGGACTCGTTTGAAACGCCAGGAGTGGACGCTGAGCCGCTCCGTACCGGAGCTTA
AAGTGGGCATAGTGGGAAACCTGCTAGCGGAAGTCAGCCCTGGTGACCGCTATCTGACGGGACCTA
TGTCCAGGAGGAGTCCCTGAAGGGGGGGGGTTAAGAAGGAGATTGGTGGATGCCAGAGTTACCTG
CTGCTGATCCGAGATGAAGGAGGCCCCCTGAGCTCCAGTTGCTGCCCTGGTGGATGCAGTGGTGTGG
TGTCAGCCTGGAGGATGAAATCAGTTCCAGACGGTGTACAACACTACCTCTGCCGTCTGCAGCTCCG
CAACGCCAGCAGGTGCCATGGTGTGGCAGCGAGGATGCCATCAGCGCTGCAGATCCCCGGGTT
ATCGACGACAGCAGAGCCGCAAGCTCTCCACAGATCTGAAGCGGTGCACCTACTATGAGACGTGCGGA
CCTACGGGCTCAATGTGGAGCGTCTTCCAGGACGTGGCCAGAAGGTAGTGGCCTTGCAGAAGAAGCA
GCAACTGGCATGGCCCTGCAAGTCAGTCCCCAACTCGCCAGCCACTCGGGCCATCGGCGCTTCAGCGACT
ATCCCGGCCGTGACATCAACCAGGCCACGAATGGCGGGCAGCGCCCTCAGCGACTACTCGTCCTCAG
TCCCCCTCCACCCCAAGCATCAGCAGCGGGAGCTGCGCATCGAGACCATCGCTGCCCTCCACCCCCAC
ACCCATCCGAAGCATGCTCAAGGGCGCTCCACATCTCACGTCTCGGAAGGGTGTGACCTGGACCGG
GAGAAGAAGGCTGCCAGTGCAGGTCAGCAGCAGCATCGGGAGCCGCGCATCCCCATCAAGCAGGGGA
TCCTGCTAAAGCGGAGCGGCAAGTCCCTGAACAAGGAGTGGAGAAGAAGTATGTGACGCTCTGTGACAA
CGGGCTGTCACCTATCACCCCAAGCTGCATGATTACATGCAGAACATCCACGCCAGGAGATTGACCTG
CTGCGGACAACGGTGAAGTGCCAGGGAAAGGCCCTGCCCCAGGCCACACCTGCCACAGCCCCGGCACCA
GCCCCCGTGCACAGGGCTGTCCTGGAGGGAGTAACACACAGCTGGTGGGGCACAGGTGGGGGG
CTCGGCCAGCGCATCCCTGCACTCTGAGCGCCCCCTCAGCAGCTGCCCTGGCTGGCCCGGCC
GAGGGGCTGCACCAGCGCTCTGCTCCGTTCCAGGCCGACCAGTGGAGTGAGGCCACCTCCCTGC
CCCCAGGCATGCAGCACCCCTGCCAGTGGCCAGCTGAGGTACTCAGTTCCAGCCCCAACGCTGGATCTCC
CCCCATCTCCCACTCCAACCGGAGAACGACCGGAGGAAAGAGCACCGGACCCCCCGACAGACGGC
CCCAGCAGTGTACTGAAGAGGAGAGGAGTCGTTGAATTGTGGTGGTGTCCCTACTGGCAGACGT
GGCACTTCGAGGCTCAACGGGGAGGAGCGGGAGCTGTGGGTTAGGTGTGCAAGGCCAGATCTTG
CAGGCTGCAAGGCTGCCAGTGCAGGACAAGACTCGACTGGGAACCAAGAACGCAAGCTCTGGCTGT
CAGGCCGTCGGCAGCCCTGCGCAACAGCTTGTATCGACTGCAGTGCACCCAACTCCAGACTGGCCA
GCCTGAAACCTGGGTGCCCTGATGTGATTGAGTGCAGGATCCACCGACACCTGGGGCTCACCTGTC
CGGGGTGCGCTCCCTGACCTCGATGACTGCCGCTGAGCTGCTGTGTCATGACTGCCATGGCAAT
GCCCTGCCAACAGCTCTGGGAGGGGGCTTGGTGGTACTCCAAGCCAGGGCTGATGCCCTGCAGAG
AGGAGAAGGAACGCTGGATACGGGCAAGTATGAACAGAACGCTCTCCCTGGCCCCACTGCCAACGCT
TGTGCCACTGGGAGCGCAGCTGCCGGGGCGTGGTGGAGATGACCTGCCGCTGTTGGTGTGCTCTG
GCACATGGCTCCAAAGAGGAGGGTGAATGAGACCTATGGGAGGGGAGGGCTGAGCTGAGGAGGCC
CCAGTGCATGGCAACGTTGCTTCAGCAGCTGCTCATCTGGTACGGGTTGAGCTGAGACATCTGATC
CGGGGGGGCTGACTCCACTGGCATATGCTGCCGGGGCGCAGGCCAGGAGTGTGAGACATCTGAC
CAGCATGGCTGCCCTGGGAGGGCTGTGGCTTAGGCCCTACCCCCAACAGAGAGCCTGCCAATGGCACCA
ACCCCTGCTGAGCTGCACCGTAGTCCCTAGCCTCTATAAGGCCAACAGAACACAGAGATGGAGAAC
GGACTCCATGGCCCAAAGACCCCTCCCTGCCAGGCCAGTGGGAACAGAACACAGAGATGGAGAAC
GACATGCTGAGAGGAGCAAGGAAATTAGGGAGGAGACTCAAAGGGATCAAGGAGAGTTGGGATT
TGAGCTGAGAGGAGGGATGAGGATTAGCCCTCTGCCCTAAGGTGCCATTGAAAGGGACAGGACC
CTTCGGAGGTGCCCTGTGAGGAGAGGGAGGCCAGGACCTCCCTCCAGATCCCTGCCCTAGTGC
GCCCTCACACGCCCTCATCCTGAAACAGGAAGAGGCCACCAAGTTGGGGTGCTGGATGAAAGAGA
CGAGGGGTGATCTGTGAGTCCCAGTGTAAACTTTGTACATTGGAAATTTATGTGTTGTACATATTGAT
GTGTGTGTATGAGCAATAAACAGACTGTGTGCGTGGAAAAAAAAAAAAAA
AA

>gi|13787202|ref|NM_006386.2| Homo sapiens DEAD (Asp-Glu-Ala-Asp) box
polypeptide 17 (DDX17), transcript variant 1, mRNA
ATTTGTGCAGTCGCTGGGAAGGAAGGAGACGCCCTAACCGCGGACTGCCCGGTTGAGCGTAGCCAAA

EX03-053P

CCTGCCAACGGCTTGTAGCCCCGATTCTCTGTGTTTGCTCCGTCCTCGACGAGAGAGGCCGACG
GTGGCGTCTGCACGGAGACAGCGCTCGAGCGAGAGAGCGCTGCCCTGCCGCCAAACAGCGG
AGGCGCCGCCCATCGTCACCAGCCGAGCCGAGGCCCTCCGAGGCCATCGTCCCC
GCTCCCAGATCTATCCTTTGGACCATGCAGGGCTTGGGACCGGGACGGGATCGTAC
CGTGGAGGATTGGAGCAAGAGGTGGTGGCTCCCGAAGAAATTGGTAATCCTGGGAGCGTT
TGCCTAAAAAGTGGGATTGAGTGGCTCCCAAGTTGAGAAAATTGGTATGTGGAACATCCGA
AGTAGCAAGGCTGACACCATATGAGGTTGATGAGCTACGCGAAAGAAGGAGATTACAGTGAGGGGGGA
GATGTTGTCTAAACCGTGTGCTCCATCATGTAACCTCCACAATATGTAATGGATGTGTTGA
TGGATCAGCACTTACAGAACCAACTCCAATTAGTCCAGGATTCGGCTGGCTCTAGTGGCCGGGA
TATGGTGGCATTGCTCAGACTGGCTGGGAAGACGTTGGCTATCTCGCTGCAATTGTCATATT
AACCAACAGCCATACTGGAAAGGGAGATGGCCAATCTGCTAGTCTGGCTCTACCAAGAGGCTTG
CCCAGCAAGTACAGCAGGTGGCCGATGACTATGGCAAATGTTCTAGATTGAAGAGTACTTGTATTTATGG
AGGTGCTCTAAAGGTCCTCAGATCGAGACTGGAAAGAGGTGGTGTGAGATCTGCATAGCCACTCTGGA
CGTCTGATAGATTCCTGGAGTCAGGAAAGACAATCTCGCCGATGTACTTACCTGTATTGGACGAAG
CTGACAGAATGCTTGTATGGGTTGAACCCAGATCCGAAATGGTGTGAGGATTCCTCGTGT
GCAGACACTGATGTGGAGTGCACCTGGCAAAGAAGTAAGCACAGCTTGCAGAGGATTCCTCGTGT
TACACCCAGATCAACGTAGGCAATCTGGAGTGTGACTGCCAACACATCTCCAGATGTGGATGTCT
GCATGGAAGTGAAAAGACCAAGTTGATCCAACTAATGGAAGAAATAATGGCTGAAAAGGAAAACAA
AACAAATAATTTGTGGAGACAAAGAGACGCTGTGATGACTCGAAGGATGCCAGAGATGGTTGG
CCAGCTATGTGTATCCATGGAGACAAGGTCAACCAGAAAGAGATTGGTACTTATGAGTTCCGTTCTG
GAAAGGCACCCATCCTTATTGCTACAGATGTAGCCTCCCGTGGCTAGATGTGGAGATGTCAAGTTGT
GATCAACTATGACTATCCAAACAGCTCAGAGGATTATGTGACCGTATTGGCGAACAGCCCCTAGCACC
AACAAAGGTACCGCCTATACCTTCACCCAGGGAACTAAACAGGCCAGAGAGCTTATCAAAGTGC
TGGAAAGAGGCAATCAGGCTATCAATCCAAAATGATGCTGAGCTGTGGACCCACAGAGGAGGGGGAGG
CGGGGGTGGCTCGTTCTCGTACCGGACACTCTCAGCCAACAACTCCAACTGTGATGTATCAGGATGAG
TGTGACCGAAGGCTCGAGGAGTCAGGATGGTGGCCGGAGAGACTCTGCAAGCTATGGGATCGTAGTG
AAACCGATAGAGCTGTTATGCTAATGGCAGTGGCTATGGAAGTCCAAATTCTGCCCTTGGAGCACAAGC
AGGCCAATACACCTATGGTCAAGGCACCTATGGGCAGCTGCTTATGGCACCAGTAGCTATAAGCTCAA
GAATATGGTGTGGCACTTATGGAGCTAGTAGCACCACCTCACTGGAGAAGTCACAGAGCTAGCC
AGCAGTTAGTGGGATAGGCCGCTGGCAGCAGCCACAGCCACTGATGTCAACACAGTTGCACAGCC
TCCGGGAGCTACCAATATGATAGTTACATGGGCAGACTGCCTACCAATACCCCTCCTCTCCCCCT
CCTCCTCCTCACGTAATGAAACCACTCAAGTGGTAGTGTGACTCCAGCAGACTTAATTACATTAAAGGA
ACACTGTCTTCTTTTCTCTTCGCTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
AATTTTCCCCCAACATCGTATTGCTTTCTCATGAGATTAGTTAGAATTCACTGCCAGGTTCT
CTGCCAACAAATGATCCAGTGGATAAACATTGTAAAAAAAAAAAAAA
CTGCCAACAAATGATCCAGTGGATAAACATTGTAAAAAAAAAAAAAA

>gi|13514826|ref|NM_004396.2| Homo sapiens DEAD (Asp-Glu-Ala-Asp) box
polypeptide 5 (DDX5), mRNA
ACCTCATTCATTCTACCGTCTCTAGTAGTGCAGCTTCGGCTGGTGTATCGGTGCTTCCGCTG
CCGCCCCCGCAAGGCTCGCGTATCGAGGCCATTCCAGCGACTGTGCGACGCTTCTATATAACTT
CGTCCCCGCCAACCGCAACCAATTGACGCCATGTGGTTATTGAGTGCACGGAGACCGCGCCGGGACC
GAGGGTTGGTGCACCTCGATTGGAGGAAGTAGGGCAGGGCCCTATCTGAAAGAAGTTGGAAACCC
TGGGGAGAAATTAGTTAAAAGAAGTGAATCTTGATGAGCTGCCAAATTGAGAAGAATTTTATCAA
GAGCACCCCTGATTTGGCTAGGCCACAGCACAAGAGGTGGAAACATACAGAAGAAGCAAGGAAATTACAG
TTAGAGGTCACAACCTGCCGAAGCCAGTTCTAAATTGAGGCAATTCCCTGCAATGTGATGG
TGTTATTGCAAGACAGAAATTCACTGAACCAACTGCTATTCAAGCTCAGGGATGCCAGTTGCTCTAAGT
GGATTGGATATGGTGGAGTGGCACAGACTGGATCTGGAAAACATTGCTTATTGCTTCTGCCATTG
TCCACATCAATCATGCCATTCTAGAGAGAGGCCATGGCTTATTGTTGGCTGGCACCAACTCG
GGAACCTGGCCCAACAGGTGCAGCAAGTAGCTGCTGAATTGAGGCACTGCTGAAGTCTACTTGT
ATCTACGGTGGCTCTAACGGACCACAAATACGTGATTGGAGAGAGGTGGAAATCTGTATTGCAA
CACCTGGAAAGACTGATTGACTTTAGAGTGTGGAAAACCAATTGAGAAGAACACCTACCTGTCT
TGATGAAGCAGATAGAATGCTTGTATGGCTTGTGAAACCCAAATAAGGAAGGATGTGGATCAAATAAGA
CCTGATAGGCAAACCTCAATGTGGAGTGGCACTTGGCAAAAGAAGTAAGACAGCTTGTGAAGGATTTCC
TGAAAGACTATATTCAATAAACATTGGTCACTTGAAGTGAACCTGGCAAACCAACATTCTCAGATTGT
GGATGTGTGATGACGTAGAAAAGGATGAAAACCTTATCGTCTAATGGAAGAGATCATGAGTGAGAAG
GAGAATAAAACATTGTTTGTGGAAACAAAAGAAGATGTGATGAGCTTACAGAAAAATGAGGAGAG
ATGGGTGGCTGCCATGGTATCCATGGTACAAGAGTCACAGAGCTGACTGGGTCTAAATGAATT

EX03-053P

CAAACATGGAAAAGCTCCTATTCTGATTGCTACAGATGTGGCCTCCAGAGGGCTAGATGTGGAAGATGTG
AAATTGTCAATTATGACTACCCCTAECTCCTCAGAGGATTATATTATCATCGAATTGGAAGAACTGCTC
GCAGTACCAAAACAGGCACAGCATAACACTTTCTTACACCTAATAAACATAAAAGCAAGTGAGCAGCTTAT
CTCTGTGCTTCGTGAAGCTAATCAAGCAATTAAATCCCAAGTTGCTTCAGTTGGTCCAAGACAGAGGTTCA
GGTCGTTCCAGGGTAGAGGAGGCATGAAGGATGACCGTCGGGACAGATACTCTGCGGGAAAAGGGGTG
GATTTAATACCTTAGAGACAGGGAAAATTATGACAGAGGTTACTCTAGCCTGCTAAAAGAGATTTGG
GGCAAAAACCTCAGAATGGTGTTCAGTGCTGAAATTACACCAATGGGAGCTTGGAGTAATTGAAAGTAA
TCTGCTGTTACAGACAGCTTCTAGGACTGGTAAATCCAAACAGGGACTTACCAAGGAAATGGTTATGATAGCA
CTCAGCAATACGGAAAGTAATGTTCAAATATGCACAATGGTATGACCAACAGGCATATGCATATCCTGC
TACTGCAGCTGCACCTATGATTGGTATCCAAATGCCAACAGGATACTCCAAATAAGACTTTAGAAGTATA
TGTAAATGTCTGTTTCATAATTGCTCTTATATTGTGTTATCTGACAAGATAGTTATTAAGAAAC
ATGGGAATTGCAAGAAATGACTGCAGTGCAGCAGTAATTATGGTGCACCTTTTCGCTATTTAAGTTGGATA
TTTCTCTACATTCCCTGAAACAATTTTAGGTTTTTTGACTAGAAAATGCAAGGCACTGTTTCACAAA
AGTAAATGTACAGTGATTGAAATACAATAATGAAGGCAATGCATGGCCTTCCAATAAAAAATATTGAA
GACTGAAAAAA

>gi|8922580|ref|NM_018173.1| Homo sapiens hypothetical protein FLJ10665
(FLJ10665), mRNA
AAGCGCCTCGGGGGCTGGCCCGGAGTGGAGGGCGCGCGGTCCCAGGCCCTCCCCCTGGCCGGCGGGT
GTCGAGTTCAAGCCCTAGGGGACCTCTTCTCTGGACATTGAAGATATGGCCCTTGGAGGTGACCCAGG
AGAGAAGGGATGAAGGCCCTTGGCCTCCACATGAGGGCCCCCTCCAAGGACTCGTGGCCTCCGCATTG
AGACTTATGGGGGCCGGCATCGAGCCTCTGCTCAGAGCACTACTGGCAGACTCTATCCCCGAGGATAACCC
TGTGCTGGATCCCAGTCGCCGACGCCCTCAGCAGTATGTCCTTIGCCAGGGTTCTGGCCAGGCCGA
GGCCTGTCACCCATGAGACTGCGAGATCCAGAGGCCGAGAAGAGGCCAGGGGGCATGTGGGGCTGGCC
TGCTTCACTCCCCAAACTCAAGGAACTCACCAAGGCCATGAGCTGGAGGTGAGGCTGCACACTTCAG
CATGTTTGGATGCCCGGCTGCCCTGAGGACCGGGCACTGGAGATAGGAGAGGGTGGCAGACT
GGCCTGACCATCGAGAAGTCTGGAGGGAGCTGGCTGGGACAAGGAGATGAGCCAGGAGCTCTGCC
ACCAACAGGAGGCCCTGAGGAGCTCTGACCACCGAGCTACGTGAGAAAGCTCAAGATCATGAC
TGATCTGCTAGCCGCCCTGCTGAAACCTGCAAGCGAGTGGACTGCTGATGGAAGTGTCACTGAGACC
CTGTTGAAATGTCCCCAGGCTGATTGAAACCCACCGAGCTTTGGATGAGGTGCTGGGGCCACCC
TGGAGGAGACTCGGGCTCGGGCCAGGCCCTGGACCCATTGGCTGCAAAGTGGCTTCTGACGTTG
CCAGCGGTTCCACCCCTATGTCAGTACTGCTCCGAGTGAAGCAGACATGGCTTACGCCAGAGAACAG
CAAGAAACTAACCCCTCTTCCATGCCCTCGTCAAGGAGCACAAGCGCTCTGGAGGCAGA
TGCTCTGACTTGGTTATCAAGCCCCACCGCGCATACCAAGTACCCACTGCTGCTCCATGCTGTGCT
CAAGAGGAGCCCGAGGCACGCCAAGAGGCCCTGAATGCCATGATTGAAGCCGTGGAGTCATTCTG
CGACATATCAATGGCAGGTGGAGCCACCCAGTGAATGAGGTGAGAAGAACCTGCGCCATTCTCACCG
GCCCTACGAGGTGGCTGGAGGCCACCCACTGCTGAGTGGCTTACGAGACAGCTGCTGCTGGAGGGGCTGTGCGA
CCTGACGTCCCCATGCTGGGGGTGGATCTGAGGACACCCAGACAGCTGCTGCTGGAGGGGCTGTGCGA
GTGAAGGAGGGACGAGAAGGGAGCTGGACGTGACCTGTTCTCTCTGATGTGCTCTGTGACCA
AGCCCCAGCGAAGCGGACAAGCCAAGGTCACTGCCACCTCACTGAATTCCAGTGTGCTCCAGCGCCCTC
ACCCCTGCGAGACCCCAACAGCTCCCTGCTGATCCACCTCACTGAATTCCAGTGTGCTCCAGCGCCCTC
CTTGTGACTGTCCCTACAGACCGTGGCCAGTGGCTGGAGAAGACCCAGCAGGCCAGGCCGCC
TACAGAAGCTGAAGGAGAGTATGTTCAACAGAAGAGGGAGCTCTGACCCCTATCGGGACAGGA
CAGGGAGTCCCCCAGCACCAGGCCCTCCACGCCCTGGAGGGCTCTAGAGCAGCGCAGAGGGGAGG
ACTCCTGAGTTCTGACCATTATCCCCCACCTGGTGGAGAAGAACAGATGAAGATGCTCCCTTG
TGCCAGATGATACCTCAGACTCTGGCTACGGCACTTTGATCCAGGCCACCCACGGGTCCCGCTCCCC
ACTGAGGCCGTACGCCAAAGAGGCCCTGGGGACCCCTGCCCTACCTTCTCCACCCCTGGAACCTCGGG
GACATCCCTCTGCGTCCCCACCCCTCCGACCCCAAGCTCCCAACGCCGAAGGCCAGGCCAACTGCC
AAGGAATCTAAAGGAGGCAGTCTCCAGGAAGACCCACCAACCTGGCTGAGGAAGAAGATGGGG
CTCCGAGCGAGGGAAATGTGGTGGAAACACTCCACAGGGCCGGCTTGGGGCCAGCTCCCTC
CCAACCCATGCTGACTCTGGGGGGAAAGGCCCTGGAGTCTCAGGGAGGGAGAAGAAGAGGGGCTC
TGTTCCTGAAAGCTGGCCACACATCCCTGCGCCAAATGCCCTGGAGGACATGCTCAGAGAGATCGGG
GGAGCTGGCCAGCCAAAGGATTGAGGGGGCGAGGAGCCCGGGACAGCAGGCCACGGAAAGCTGACTCG
GCCAGCTGCAGAGGATGCGGGGGCCACATCATTGAGCTGGACACCCCTGTCGGCATCAGAGGTAT
GAGGAATGCAAGGAGCCTTGGCATGCATCTCTCCAGGAGATCTCTCCAGTAGTGTGCTGGTCACCC
TCCGGCATCTGTGACTCTACCTCAAGGACACATTCCCAAAGGAAGCCTGGGCCAGGCACCCCTGCC
TGCTCTGTTGGGATCAAGAATGTAATTATGATCATAGGTGCACCTGAGCCCCACAGAAAGTGT

EX03-053P

GCATAAAAATGACTGCCCTGGCTGGCATGGCTGCCTGTAAATCCCAGCACTTGGGAGGCTGAGGTGGGA
GGATCCCTGAGCCCAGGAGTTCCAGACCAGCCTGGCAATATAGGAAACCTGTCTTACAAAAAAA
ATTTTAAAAATT

>gi|29728515|ref|XM_030970.9| Homo sapiens KIAA0720 protein (KIAA0720).mRNA
AAACTAAGGCCCTCCCTGGTAGCCAAGGAGGCCAGCAGAGGGGCTGCTGCTGGCTGGGATTGCAGAGG
CCGGGGTCTCTGTGGTTGTTCTCTGGAAAGGAGGGACGGCACCTCCAGGGCAGCCAGCAGTGTGGGA
GCCCATTCAGGGCCAAATGGCACTCAGGAATGGAAATCCAAGAAGGAACCAACCACCAAAAGGAA
ATGCAGTGTGAGCGGGCTGCGAAGTCTGTGCTTCAAAATACAGCGCCCAGGGGACCTGTGTTGGAC
GGGGAGCAAATTGGCAGGGCTGAGAGCGCTTGGTTCTGTGAGACAGGTCCAGCTGCAGAAATTAAAG
ACTGGGCTGAGTCGGGAGAACGCTCCATGTTGAGATGGCAACTGGGAAAGCAGGACGGAGACCTGT
GTGCTGATTAGAGAGGCCTGGCATGGCATGTGGCTGGAGGTCAGGCAGGGTGCCACCCAGCAGA
GGTCAAGCATGAATTCACTGCTGACAAAACATGGGCTCACCTCGAAGCTGGCTCAGCCTTGTTCAGG
AACCGACGACCAGAGCCCCGCTGAAAAGAAGGGACTGCGCTGTCAGAACCCGCCATGGACAAGGGG
CGGGCGCCAAGGTATGTCACCACGCGACTGCCAGCAGCTGCCAGCGCCGGGGCCCTCACCTCTGG
AGGCCTGTGACAGCAAGTCCACAGCACCATGCTTATGATGGCATGTCCCTCGACCTTCCCCACAA
AGGCTCTGTGCTGGCCCGAACGTGTCACCCGGTATGCCCGCCGCACCAGCCCCGAGTGGACTTG
GAGGAGGAGGAGGAGGAGAGCTGTGGATGGCAAAGGGGACCGGAAGAGCACAGGCTGAAACTCTCCA
AGAAGAAAGCAAGGAGGAGACACGGATGCCAAGCAAGGAATGCTTCACTCTGAAATTGACCTGAA
TGTGGACATTGAGACAGAGATGTCACCCAGGCATGAAGAAGAAGTCACGGGGAGGTGCTGCTGCTGTA
TTTGAAAGGAAGGGCATTGCGCTGGCAAAGTGGACATCTACCTGGACCAGTCCAACACACCCCTGTCCC
TCACCTCGAGGCCATCAGGTGCGGAGGAGACTACCTCGTGTCAAAGCCCCAGCCAAGCCTGGAGATGA
GGGCAAGGTGGAGCAGGGCATGAGGACTTCAAGTCCCTGAGTTGCGGATTGCGGCCAGCTGGGACC
GGGCCCCCGCCCTGGAGCGTGTGGACGCCAGAGCCCGGGAGAGCTGGACATCTGGCCCTGGCC
GCCGCCGAAGAACATGCGGAGTTCCTGGGGAGGGCAGCATCCCCGGCAGGAGCCCCCACGCCCTC
CAGCTGCTCTGCCAGCGCAGCAGTGGCAGCACCAACTGGCAGCAGCTGGAGAACCCGGCGGCC
AGTCGCTTCAGCGGCTTTTCAGCTCCGGCCAGCACCGGCCCTTGCGGGAGGTAGACAAGATGG
AGCAGCTGGAGGGCAAGCTGACACCTACAGCCTCTCAGGGCTGGACGCCAGAGCCGGGAGGCTGGAG
CGACCATGACTCTGGAGGAGGAGTACGATGAAGACGAGGATGAGGACAATGCCCTGGCTGAGGCTGGAG
GACAGCTGGGGAGCTCATTGATGGCATGAGAACGCTGACCCGGGGAGCTGGCTGGGAGGCTGGAG
TGTGGAGCTGTCACACGGAGGCTCTACATCAGGAAACTGCGGGTGATCATCAACCTGTTCTGTG
CTGCCCTCTGAACCTGCAAGAGTCAGGGCTGCTGTGAGGTGGAGGCGGAGGCCCTGTTAGCAACATC
CCGGAGATCGCGCAGCTGACCGCAGGCTGTGGGCTAGCGTGTGGCGCCGGTGTGGAGAACGGCG
GCACCGAGCGCTGCTACAGCCGGGACTTCTCAAAGGCTCAAGATGTTGGCTCGCTCTTCAAC
CTACATCCGCTACTGCATGGAGGAGGGCTGATGGAGTACATGCGCGGCTGCTGCCAGAACGAC
CTCTCCGGGCCTACATCACGTGGCGGAGAACACCACAGTGCCAGGGCTGAAGCTGAGCGACATGC
TGGCAAACCCCCACCAGCGGCTCACCAAGTACCCGCTGCTGCTCAAGTCGGTGTGAGGAAGACCGAGGA
GCCCGCGCCAAGGAGGCCAGTCGCCATGATCGGCTCCGTGGAGCGCTTACATCCACCACTGAAACCG
TGCATCGGGCAGCGGAGCGCAGCGGCTGGCGCCGTGGTGGAGGCCGATCGACGCTACAGGTTGG
TGGAAAGCAGCAGCAGCAAGTGGACAAGCTCTGAGGAATTCTGCAACCTGGACTTGACAGCGCCCAT
CCCTGGCCCTCCCCGGAGGAGACCGGAGCTGCTGTGGAGGGGAGCTGAGGATGAAGGAGGGGAAG
GACAGCAAGATGGATGTTACTGCTTCCCTTCAGGGATCTGCTGTTGGTGACCAAGGAGCTACGGGACCC
CAGAGAGGACCAGGGTCACTACCTGAATGAGTTTACAGTGTGTGGAGGGCTACAGTCCAGGCCAGT
TGGGTCTTCCCTTATCTACCTGAATGAGTTTACAGTGTGTGGAGGGCTACAGTCCAGGCCAGT
GGCCAGGCCCTGTGCCGTGGCTGGTGACACCATTACAATGCCAGAACCCAGCTGCAACAGCTGCGT
CACAGGAGCCCCCAGGCAGTCAGCAGGCCCTGCGAGGAGGAGGAGCTGGAGGAGGAGGAGGAGGAG
AGAG
ATGCGAAAAGCAGCGCAGCCCCGACTCTCAGACTGTGCTGAGATGGCTCCACGGAGACCCCTGGCCA
TGGTTGTGGTAGAGCCTGGGACACGCTCTCAGCACCCTGCTCACGGATCTGCTGTTGGTGACCAAG
TGATGAGACCTCTCAGCACCCTGCTCACGGACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
GTGGACGGCCGCTCTGCTCATGGACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
TGGCCCCAGGCCAATGGCAGAGCTAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
CTCGCCCCGCTCCGCCGCCACCCCTGCTCAGCTGCTGCTGCTGCTGCTGCTGCTGCT
TCCGAGGCCAGGCCCTCCAGCTGCTGCCAGGGCTGGCACCCATGGGACACCCCTGCTGCTGCT
GCCCTGCTAGAGCTGCTGCCGTGGTCAAGCCCCAGGTATTAGGACTCAGGGCTCCCTCAGGAAGCTGG
GCCCAAGCTGGGATTGCCAGGGGCCCTAGCCCTGGCAGCGGCTCTGGGCTAGTCGGCTGCTGGCCGG

EX03-053P

GAACCTGCAGGCTCCACAGGAAGAGGTGGAGACCTGCCCTCGGGGGCCTCTCCAGGGTCCAGCCCTG
AGCCCCCACCGGGGTCTCTGCCACAGCACAGGAAGCTGACCTGGCCAGCTCTACCGAATCAGGACCAC
CCTGCTGTTAACCTCACGCTCACTGCCCTGGAGGTCTGAGCAGAGGGAGGGCCCAAGAGTGCCATTGA
CCAAGAGACAGCAGACAGCCTGCCCTGGGGCTGCCGGACCTGCTTCAGCTACTGCCCTGTATGC
ATGAGCCGGATGCTGGCAGGATCCCTGCCCTACGCCGGGGCGATTGCGTTGCCGGACTGGATGGA
GTGGAGGAGGCCAGGCCACAGTACCAACCCCACCTGCCAGGCAGCCCTGTCACCTACTCCCCGAAGT
TACCAAGCTCAGCTCAGTCTCAGGGCTGGGCTCTAGGGCTGCCCATCCTACTTCTACCCCTACTGGCCT
CCAGTGGGATTCACTCTGCCCTGCCCAACCTTCCCAGTCCCACAGGCCACCCCTGGCTGGGCTGGGT
TCTGTGAAGTTACGTATTGAGCTTTGGTCTTTATAAAAGACTTGTCTAGACTCC

>gi|8923495|ref|NM_017864.1| Homo sapiens hypothetical protein FLJ20530
(FLJ20530), mRNA
GAAAGGAAACATGGCTGCTTCTAAAGAATGTGTCTGGGGTTGGAAGATCTGCAGTATGTTCATG
ATTTCTCACATGAGCTTCATTACATTGTTGAAAGATGAAGAACGAAAGCTACTTGTGATCAGATGA
GGAAGAGATCCCTAGAGTAATCTGTGCTTAAACCTGTAACTTCATTATGATATCCCAGCTTCAGC
AAGTGTCAACATTGGTCAGTTAGAGCATCAACTTATATTGTCACTGGATCCTGGAGGATTAGACAATT
TTAATTGAATTACATGGTATGACTTCAGAGGCCAGTCTGGACAGTGTCTAATAAGTGGAAAGTACCTT
CTGTCTATAGTGGTGTATCTGGGAATTAAAGACAATTAAACAAGAGATTGGTTATATCTTATGGC
CAAAGGTTGCACTGCAGTACTGTTAAGGACTTTCCCATGCTAAACAGCTTGTGCTGTTGGAG
TTGGTAACAGAGTTCTCACCGAAGCTCGTCAGGTCACTGTAATGAGATGTTGCTTTGGATATTCA
CACACGAAGCTGGGACAGGGCAGGGCAGGAGAGACCGCCATCGACCTTATAAGTAGAGTACGAGGCTA
TCTGGAATGAGGCTCCTGATATTCCCTCTCGTCAAGTTAGCTGAGGAATGTTGCTTATGTTA
AACTGGAGAGAAAATGAATACCTTACACTCCAAGTCTGCTTCAAGTCAATCCTATGTA
AGCTTGGACAGCTTTAGCAGCTACATGCAAGAACTTCCAGGCCCTAAAGAAGTAGACGGACTGCCA
AGACCTTGGGAAGTTGTTGTCAAATCTGTAGTGTCCAGTCAGCACAAACGAGGAATGATGGCAGA
GTTAGTTAATAAAACAGAGGGAACTACGTTAGGTATCATGTATCGGAGTGAACGTGTTCTTTATCA
AAAAATTACGAGAACCACTCGTTGACTATTATTTATCACTTGTGCAAACCTCACAATGTTGGGA
GGACATTGTGAATGATATTACAGCTGAACACATTCTATTGGCATCTCCATTCCAACTCCAGTCT
GTGGACTTTGAAGCTGTGGCAATCACAGTGAAGAGCTAGTTGATATACACTCAGTATAAATCCA
ACCATTCTGGTTAATTATCCAGGCAGATAATTACTTGTGCAACGAATCAGTATCTAGCAGCTTCA
TTACCTCCAGGCAGGAGCTGTGTTCTGACTTCTTAAACAAGGCTGTGCCCCCTGATGTTTATACAGAC
CAGGTAAATAAAACGAATGATAAAATGTTGTTCTTGCTGAATTGCAACACACAGGTGGCATTATGTC
AGTTCTCAGAGAAATTGACTACAAAACAGCGTTAAATCTGCAAGAACAAAACAGTCATGATGCTT
GGACTCTACTACGACTACATGGGATGTTACCATTTGGAATACTGACTTATCTTCATCATAAAAGA
GGAGAAACAGATAAAAGACAAATTGCAATCAAAGCCATCGGCCAGACAGAGTTGAATGCAAGCAATCCAG
AAGAAGTGTACAGCTGGCAGCGCAGAGAAGGAAAAAAAGTTCTCCAAGCAATGGCAAACCTTACTT
TTAACAGTTAAATTGTTACTTTTAAACAATGGCTAAAAATAAACAGTATTAAAGGTT
AAGTTTATATAAAAAAAAAAAAAAA

EX03-053P

CTCTCCCCAAAGTGGCTTATGCAACTGCCATGGACTGGTTATTGCTGTTATGCATTTGTGTC
TGCCCTAATTGAATTGCAACTGTTAATTACTCACCAGGAGATGGACTGGATGGGAAGAGTGTA
GTAATGACAGAAAAAGAAAAGGCTTCGTTATGATAACAGAACAGCTTATGCACTGGCTGTTGCCA
ATTATGCCCGAATCTTCAAAGATCCAGTTCTCCACCATCTCCAAGAGTGCAACCACGCAGAAC
CAACAAGAAGCCAGAAAACAAGCCAGCTGAAGCAAAGAAAACCTTCACAGTGTTAGCAAATTGACAGA
ATGTCAGAATAGTTTCCAGTTGTTGATCCTTAAATTAGTTACTGGGCTACATATTAAACA
GAGAACCTGTTAGGGGTCACTGCTGAATTGAGACCCATGTTATCTTGGGATGTATAGCACATTAA
ATTGGTTGTTGCTATGTAAGTCTGACTAATAACTGCTAATTGATCCAAACATGTACAGTATGT
ATATAGTGCACATAGCTTACCACTGAGACCTTAAATGGAGACATGCACTGTAACATGGAACTGCAGAC
AGAAAGCACTCCATGCAAAACAGCCATTGCCCTTTAAAGATTTACCCCTAGGACCTGATTAAAGTGA
ATTTCAGTGACCTGATTAATTCTATTCTCAAATGAGATGAAAATGGGATCCTGTACAAACCTT
GTGGACCCCTGGTAGCTCTTAAAGTAGGGTATTCTACTGTTGCTTAATTATGATGGAAAGATAAC
ATTGTCATCCTAGATGAATCCTTGAAGTAACAAACATTGATCTGACATCAGCTGTTCATGAGTC
TCAGAGTCCTGCTAATGTAATTGGAAGCTGGTACACATAAGAAAACTAGAGATTGAAATCTAGCTA
TGAATTACTCTATATAGTATGCCATGTACATATTACAGCATGACAAGCTCGAAATAATTATGAGT
CAGCCCAGAAGATGTTAAT

>gi|6031207|ref|NM_000810.2| Homo sapiens gamma-aminobutyric acid
(GABA) A receptor, alpha 5 (GABRA5), mRNA
GAAGATGCTGTTGAGGGCCCTGGAGAAACTTCAGCAGAACAGGGCCTCTCCCTTGCAAGGCCAGGCC
GCCCTGCCCTCCCCCTCCGCCAGCTCGGCCAGGGCGCATTGCTGAGCGCTGGCGCTCGGGCAGTGCT
GAGCACCTCTGCAGAGGCCGATCTCCAGGCCAGAGACATGTGGCGCTCGGGCAGTGCT
AGAGAGGAGTAGCTGCTGGCTTGAACGCGTGGCGTGGCAGATATTCAAGAAAGCTTCAAGAACAGCT
GGAGAAGGAAAGAGTTATTCTCCATATTCACTGCTTCAACTACTATTCTATTGGAATGGACAATGG
AATGTTCTGGTTTATCATGTCAAAACCTCTCTCTTTGTATTCCATGAACTTATCCAGTCAC
TTGGCTTCAACAGATGCCAACAGTCAGTGAAAGATGAGACCAATGACAACATCAGTATTACCA
GGATCTGGATGGCCTTGGATGGCTACGACAACAGACTTCGGCCGGCTGGAGAGCGCATCACTCA
GGTGGAGGACCGACATCTACGTACCAGCTCGGCCGGTGTCCGACCGGAAATGGAGTACACCATAGAC
GTGTTTCCGACAAGCTGGAAAGATGAAAGGCTCGGTTAAGGGGCCATGAGCGCTCCCTCTCA
ACAACCTCTGGCAGCAAGATCTGGACCCCCAGACACGTTCTCCACAACGGAAAGAAGTCCATGCTCA
CAACATGACCACGCCAACAGCTGCTGGCGTGGAGGACGGCACCCCTGCTTACACCATGCGTTG
ACCATCTGCAAGATGCCCATGCACTTGAGGACTTCCGATGGATGGCAGCGCTTGGCTCTGAAAT
TTGGCAGCTATGCTTACCCATTGAGTCGTTACGCTTGACCAACGGCTCCACCAAGTCGGTGGT
GGTGGCGAAGATGGCTCCAGACTGAAACAGTACCACTGATGGGAGACGGTGGGACTGAGAACATC
AGCACCAGCACAGGGAATACAATCATGACAGCTACTTCCACCTGAAAAGGAAGATTGGCTACTTTG
TCATCCAGACCTACCTCCCTGCTAATGACCGTGTCTTACAGGTGTCTGGACCAACGGCTCCACCAAGTCGGTGGT
ATCAGTCCCAGCCAGGACAGTTGGGGTCAACCACGGTGTGACCATGACGACCCCTGACATCAGCGCC
AGGAACCTCTGCCAAAGTGGCTACGCCACCGCATGGACTGGTCAAGTGTGTGCTATGCCCT
TCTTCTGGCGTGTAGAGTTGCCACGGTCAATTACTTACCAAGAGAGGCTGGGCTGGATGGCAA
AAAAGCTTGGAAAGCAGCAAGATCAAGAAAAGCGTGAAGTCATACTAAATAAGTCAACAAACGTTTT
ACAACGGAAAGATGTCACCCCTGAAAGAGAGACTTCTGAAAGCAAAAGACTTACAACAGTATCAGCAA
CCTCAGTCTCAGTAAACCCCTGAAAGAGAGACTTCTGAAAGCAAAAGACTTACAATTTGCTTGTGATGTTCTATATG
AATTGACAAAATGTCCTGAAAGATCTGTTCCGACTTCCGACTTCAACTTGTGTTACTGGCAACG
TATTGAAATAGGGAGCCGGTGTAAAGGAGCCGCTCTCCAAAATAACCGGCCACACTCCAAACTCCA
AGACAGCCATACTTCCAGCGAAATGGTACCAAGGAGAGGTTTGCTCACAGGACTCTCCATATGTGAGC
ACTATCTTCAGGAAATTGGTCAATTGATAAAATATGACAAATAATTGCTTGTGATGTTCTATATG
TAACCTCAGATGTTCCAAGATGTCCTGCTGCAAAACTTCTGGAAAACAGGATACG
ATGACTGACACTCAGATGCCAGTATCATACGTTGATAGTTCAACAAAGATACGTTATTTAACTG
CTTCAAGTGTACCTAACATGTTTATACTTCAATTGCTTACACAATTTCAGTGAATAA
ATATTTAGGAAACTCTCCATGATTAGAAGACCAACTATAATTGGGAGAAAAGAGATCATAAGAGC
ACGTTTCCATTAGGGAAACTGGACATTGTCACAAATGAAATTGCCCTTGATAATTCTTACTGTT
CTGAAATTAGGAAAGTACTTGCATGATCTTACACGAAGAAATAGAATAGGCAAACCTTTATGTAGGCAGA
TTAATAACAGAAATACATCATATGTTAGATAACACAAAATATT

>gi|4504018|ref|NM_000171.1| Homo sapiens glycine receptor, alpha 1
(startle disease/hyperekplexia, stiff man syndrome) (GLRA1), mRNA
CGGGAGGCAACAGACACGCTGGAGTTAACAAACAGCAATACTCTCGCGCTCCTGAAAAGCAGGTCTGG

EX03-053P

ACGCTCTCCGTGGTGTGAAACGCCCGCAGCCGCCGCTGTCCGTGGTATCTACGACCCCCTCGCTCCAA
TTTCCCCCTGGGGCTCTCCCTCCGCCCTGTCCCCGCCCTCCCTTAACATCTGGATTATTTTGCAA
TAGCGCTTCTGGTTTGTAAAGTCCAATTGAAACATTTTGCCCTAATCTCGTGGACTACAAAGC
ACAAAGGACCTGAAAAATGTACAGCTCAATACTCTCGACTCTACCTTCGGGAGCCATTGTATTCTC
AGCCTTGTGCTTAAGGAGGCTGAAGCTGCTCGCTCCGCAACCAAGCCTATGTCAACCTCGGATTCC
TGGATAAGCTAATGGGAGAACCTCCGGATATGATGCCAGGATCAGGCCAATTAAAGGTCCCCAGT
GAACGTGAGCTGCAACATTTCATCAACAGCTTGGTCCATTGCTGAGACAACCATGGACTATAGGGTC
AACATCTTCTGGCGAGCAATGAAACGACCCCGCCTGGCTATAATGAATACCTGACGACTCTCTGG
ACCTGGGACCCATCCATGCTGGACTCCATCTGGAAACCTGACCTGTTCTTGCCAACGAGAAGGGGGCCA
CTTCCATGAGATCACCAACAGACAACAAATTGCTAAGGATCTCCGGAAATGGGAATGTCTCTACAGC
AGAATCACCTGACACTGGCTGCCCATGGACTTGAAGAATTCCCATGGATGTCCAGACATGTATCA
TGCAACTGAAAGCTTGGATATACGATGAATGACCTCATCTTGAGTGGCAGGAACAGGGAGCCGTG
GGTAGCAGATGGACTAATCTGCCCAAGTCTGTTATCTGAAGGAAGAGAAGGACTTGAGATACTGC
CACTACAACACAGGTAATTCAACCTGCATTGAGGCCGGTCCACCTGGAGCGCAGATGGTTACTACC
TGATTCAAGATGTATATTCCCAGCTGCTCATGGTCACTCTCATGGATCTCTCTGGATCAACATGG
TGCTGCACCTGCTCGTGTGGGCTTAGGCATCACCCTGCTCACCATGACCACCCAGAGCTCCGGCT
CGAGCATCTCTGCCCAAGGTGCTCTATGTAAAGCCATTGACATTGGATGGCAGTTGCCTGCTCTTG
TGTCTCAGCCCTATTAGAATATGCTGCCGTTAACTTGTGTCTGCCAACATAAGGAGCTGCTCCGATT
CAGGAGGAAGCGGAGACATCACAAGGAGGATGAAGCTGGAGAAGGCCCTTAACTTCTCTGCCATGG
ATGGGCCAGGCTGTACAGGCCAAGGATGGCATCTCAGTCAGGGCGCAACAAACAGTAACACCACCA
ACCCCCCTCTGCACCATCTAACGCTCCAGAGGAGATGCCAAAATCTCATCCAGAGGCCAAGAAGAT
CGACAAAATATCCCGATTGGCTCCCCATGCCCTCCTATTCAACATGTTACTGGATCATCTAC
AAGATTGTCGTAGAGAGGACGCCAACCAAGTGAAGGGTCTGAAAGGTTGGGGAGGCTGGAGAGGG
GAACGTGGGAATAGCACAGGAATCTGAGAGACGGT

>gi|20127456|ref|NM_004130.2| Homo sapiens glycogenin (GYG), mRNA
CTCTGAGTCACCAACCTGAGGCTGCCCGGCCCTGCGCACCCGGCAGCACCATGACAGATCAGGCC
TGTGACACTAACCAACAAACGATGCCATGCCAAAGGTGCCCTGGCTCTGGGATCATCTGAAACAGCAC
AGGACCACCCAGGAGGCTGGTGTGCTGCCACCCCTCAGGCTCAGACTCCATGAGAAAAGTTAGAGA
CAGCTTGTATGAAAGTCATCATGGTAGATGCTTGGACAGTGGCATTCTGCTCATCTAACCTTAATGAA
GAGGCCAGAGTTGGGTGTACGCTGACAAAGCTCCACTGCTGGCTACACAGTATTCAAATGTGTA
TTCATGGATGCAGATACTCTGGCTCTAGCAAAATATTGATGATCTTTGACAGAGAAGAATTGTCAGCAG
CACCAAGACCCAGGGTGGCCTGACTGCTCAATTCCGGAGTCTCGTTATCAGCCTCAGTTGAAACATA
CAATCAGCTGTTGCATCTGCTCTGAGCAAGTAGTTGATGGGGGACCAAGGCATACTGAACACA
TTTTTAGCAGCTGGCAACAAACAGATATCAGAAAACACCTGCCCTTATTATAACCTAACGAGCATCT
CTATATACTCCTACCTCCGGCATTAAAGTGTGCAAGTGCCTAGTTGCAAGTGTGCTATTCCGG
AGTCAAACCATGAAATTACTTATGATCCAAAACAAAAGTGTCAAAAGTGTGAGGGCCATGATCCAAAC
ATGACTCATCCAGAGTTCTCATCTGTTGGGAACATCTTACCAACGTTTACCTCTGCTTCAAC
AATTGGCCTGTCAAAGACACCTGCTCATATGTAATGTCTTCTGACTTGGCTATACACTGGCTT
CTCTTGCGCTCTGTAGAAAGGAAGATGCTCAGGAGCCATATCACATCTGCCCTGGGAGATCCCA
GCTATGGCACAGCCGTTGTATCTCGGAAGAACGGAGGAACGATGGGACAGGGCCAGGCTGATTATA
TGGGAGCAGATTCTTGTACAACATCAAGAGGAAACTTGACACTTACCTCCAGTAGAAACACTGCA
TCTGTGAACACATCCACTTACAAGCTTGTGTTCTGATACTTAGTATCTAGAGCTGGTTGAGAAAAGTC
TGTACAGTTGCTAGAGGTTCTATTAAACATTATCAGATGAGAGGCTTTTTAGGATAAGAGGTGAGAA
CTGGGCAAAAGTGTGAAGCAGCAATTCTGTTATGAGACTGTTCTGCTTAACTCTATTAGCTT
GTTTCAGAAATTCTCACTTTGTGACTGCCAACATACAAAGTAAGGGAAACTCAAGATATAAGATGGC
TGTATCAGTTCTAAATCTGAGAGCCTGGTCAAAATCAGTCACCTCCCTCAGAAGCAGACATGGCAT
CTGTTCTTGTGTTGGTGTACTTTCACGAGACCTGAATTTTAGAATTGCCAGTGTGATTCTAA
AGAGTGTGAGTGTAAATTCTCTTCAAGTAAAGATAGGCTATCTAACACTGCTGAGTGTGATTCT
CATATCAACCAATAGCATTAAACCAATTTCCTGCTTCAAGTGTGCTGAAGATGCTCACCAAGTT
GTGTACAGTAAGGCAGCATGCTAAATGCTTGTGACTTCTGGATATTGAAAATAGCAGTGTGTTCT
CTGATGGTTACCTGCACTGGCACCCGTACAAAAAATAGACTTATTGGTGTAAA

>gi|5453673|ref|NM_003918.1| Homo sapiens glycogenin 2 (GYG2), mRNA
CGCGGGCTTGCGGGCAGGGGCTGCAGGGAGGGAGAGGGACCCGCCGCCGCGGGGCTGGGCGGAGGCG
GGCGGGCTTCCGGACAGAGGCCAATCGCTGCCCTGGGCCCTCAGCGCCGGCTGGGCCGAGGCAGC
CAGAGCGGAAAGAGGCCCTGGAAATCCACCGGGATTCCGGAGACGGCGCCTCTGCTCTGCGGGTTCTG

EX03-053P

GGGAGGAAGTCCACCCACTGCTCCGGCGCAGGTCTGCAGGTCCGCCACTGCCGCCGGGCCACTG
ACCATGTCGGAGACAGAGTTCACCATGGTCCCAGGCTGGTCTGAACCTCTGAGGTCAAGCAATTCA
CCACCTCAGCCTCCAAAGTGTGAATGACAGTGAATGACTGAGGCTTTGTACACTAGCCACCAATGA
CATCTACTGCCAGGGGCCCTGGTCTGGGGCAGTCAGTGAGGAGACACAGGCTGACGAGGAAGCTGGT
GTGTTGATCCTCAGGTGTCCAGCCTGCTAGGGTACCTCTCGAAGGTGTCGATGAAGTCATTG
AAGTGAATCTAACGATAGTGCCTACATCACCTGGCCTTCTGAAGAGAGACCTGAGCTCAGGCTCAC
CCTCAGCCAAGCTTCACTGTTGGACTCTCACTACAGCAAGTGTGTTCTGATGCAGACACTCTG
GTGCTGTCATGTCAGTGGACTCTCACTACAGCAAGTGTGTTCTGAGGCCCCGGACCCGGATGGCCGG
ATTGCTTCAATAGCGGGGTGTTGCTTCCAGCCTCTCCACACGATAAAACTCTGCTACAGCACGC
CATGGAACACGGCAGCTTGACGGGGCAGACCAAGGCTTAAGTGAATAGTTCTCAGGAACGGTGCACC
ACAGACATCCACAAGCACCTGCCATCTATAACTTGAGTAGTAAACAGATGTAACACTACAGCCCTG
CCTTCAAGCAATTGGTCCAGTGCAGGCTCCACTTTGGGTCATGAAACCTTGGAAACTACAA
GTACAATCCACAGAGTGGCTGGTGTGGAGCAAGGCTCAGTGTCCAGCAGCCAGCAGGGGGCATTC
CTTCATCTCTGGTGGACGGTCTACAGAACACAGTGTGCCCTTATAAAAGCTCCAAGGGGGGAAG
CACGGCGTCTCTGGTACACACTTGCCACAGTGTGTTGGGGGGCGTGTGGGATTCTAGGCTCTGG
TGTGAGAGAGCCGTGAAAATTCAACACCCAGTGCAGGGCGTGTGCAAATTCAACACTGGGTTCT
AACCAGCCTGTCAGGGCCTTCCGGAGCGACCCAGATAGTGGATGAGACCCCTGTCCTACCTGAAGGAC
GCCGTTCAAGAGATATGATAGCTGTCTGAAACTGAGACTCCTGCCGTGATAACGTGTGACCCACTGTC
CCAGCCTTCCCCCTCAGCCTGCAGACTCACAGAGACTGAAACCATCTGCAGCCAGCAAATAAGTCGA
AGTGTCTCATCCAGGAAACCTCGAACCAAGCCAGGAACCTCCCTGCTGAGGCTCTCAGGGACCCAGTC
TGCAGGATGCACTGGAGGTCGACCTGGCGTCTGTGTTCCAGATCTCCATCGAACAGAGAAGGTGAAGGA
ATTGAGCCCCAGGAAGAGAGGGAGGAAGTGGAGGAAGGGCGTATCGACTACATGGGAAGGGACGGT
GCTCGCATCCAGGAGAACCTGGACCGGTTCTGCAGTAATCCGGCAGCTGGTGGCTCCGCTCTTG
GACAATGTCCTGTTGGTGGTCTGTTGCGTGGAGATCCTCTGGTCTTCAAGGGAAACGCTGTTG
AACCTTGTGCTCTATTATGCTTAATCCATTGAGTGCCTCACACAAAAAACGTAGAGTATAGAAATCC
ACCTTAAAGCCCCCTGCCCAACTCTCCACCAACGCCCTCTGGGCTTCTCAGAGGTCACTTCTACCC
TTGAAGCTGCGAAAAGCGAGCAGTAATAACATTCTAGTAGACTCTCGATGGTGGCTCCGCTCTTG
CCGAAGGACCTCTGAAGTACGCTGGATCTGTGTTGACAGGTGCTGTGAGACCTACCCATTCA
AACCTCACTGCAAATTCCCTCCCATCGAACGCTAACACACTAATATACGTATTAGCACCTCTGAGG
TTGCCATGGAGACCAATTCTGTAGGGCTAAGGAAACATTAGACGTGGTACTGACTTTCACTTGGACT
TGGCAAGTGTATCTGAGAAACACCTCGGCTGTGGCTCTCTGCTTTAAATCTAACAGGACTTCTAGA
GCGTTGACAGAAATTCTACTCGTGGACGTTGGAGAAAGAAGTGTAGGTGGCTGGGAATGTGGTGG
TTAGAGGATCTAAACCGATTCACTTCTGGTGGAGAACGAGGCTTGCTCAAATCGTTAGAGGA
TAACAGGATCTAGAGATGCTCTGCTTGACAACAAAAGTCAGGGTGCAGTCGGTCCACCTTGACTGCT
CTTGGCTGGCTCACCCCTCACTACCTCAGTTCTCAATAACTTAGTGAATCACTGCCCTCTCAAAGCC
ATTTCCACTCAGCTCTTCCAGAGAACCTCTAGTTTATGAGACGGAAACTTATTTCACGAGAAAGCC
TCATTGTCAGAAGTATCTCATTCAATGGGACAATATGCTGTATCTCACCAAGGTAGCTGTCAGGGG
CACCGAGAGTGTGTTAAAATGGGATCTGTTGTAATAAAGGAGGAAGTGCAGCTTTGAAATGTTGG
AAGGTTTATTCTCATGCACATTCCAGGGAAAAGCAGAGACTAAATTAGAGACGGGATAGGAAGGGCGTG
GGAGAACCTGATCCTAGCCTGTCAGCTGGATGTGTTACGTGGAGAGGCGTGGCCACTTTTAGGTCA
CCTGAAGCAGTTAGCCTTGGGATAGAGGAACCTGCCGTAATTATGGCATTAGTGGTGGCATTTTTG
TGTACAAGATGTGGGTGATGGAGGGCTGTTCTTTCCGTGTTGAGGTTAAATACGTCACTCGG
AGGGCGATGCTCGTAGGATATTCAAGGTGAGTCAGGGTGGATGGTCATGGCTTCAAGGGAGACCAC
GGGAATGTTCAAGGAAACAATGTCAGCTCTGAGGACCAATT

>gi|30147854|ref|XM_301113.1| Homo sapiens similar to Glycogenin-1
(LOC350705), mRNA
ATGACAGATCAGGTCTTGTGACACTGACCACAAATGATGCCCTACACCAAGGTGCCCTGGTCTGGGCT
CATCTCTGAAACAGCACAGGACACCAGAACAGACTAGTCATGCTGCCACCCCGAGGTCTCAGACTCCAT
GAGAAAAGTTTAGAGACAGTCTTGATGAAATCATCGTGGTAGATGTCCTGGACAGTGGTATTCTGCT
CATCTAACCTTAATGAAGAGGCAGAGTTGGCATTAAAGTGTGTTGGTGCAGTGCCTAAAGTTGTGATT
TCCCTGGACAAGTCACCCATGGAATTATACCTATGATCCAAAAGTGTCAAAATGAGTCCCA
CCATCCCAACGTGACTCATCCAGAGTTCTCATCCTATGGTGAACATCTTACCAACCGTTTACCT
CTGCTTCAACAATTGGCTTGTCAAAGACACCTCTCATACGTAATGTGGAAAATGTCTCAGGAGCCA
TATCACATCTGCTCTGGGGGATCCCAGCTATGGCACAGTCTGTGTTACCTCAGAAGAACATCAAGAGGAAGGAG
CGGTGGAACAGGGCTAGACCGATTATATGGGAGCAGATTCCCTTGACAACATCAAGAGGAAGCTTGACA
CTTACCTCCAGTAGAAACACTGCAATTCTGTGGACACATCCACTTCACAAGCCTGTTCTGATACTT

EX03-053P

AG

>gi|4757725|ref|NM_004641.1| Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10 (MLLT10), mRNA
GCCCTCTTGTATTATGTTGCGCCCTCTCCGGGCCCCGCGTTAGCGGCCGGTGGAGGTGGGGAGGGAAAGAC
GCTGAG
TGACTCCTGTGCGGAACGTGAGTGACTGAGCGGCAAAGCCCATAATGGTCTCTAGGCACCGGCCGTGTCA
CTGGAGGACGAGGTCTCCCATAGTATGAAGGGAGATGATTGGAGGCTGTCAGCGTCGCGGTGCATCAAGCTTGCTA
GCTGGGCCGAGAACCCGCTGGTTATTGCGACGGCACGGCTGCAAGCTGCGGTGCATCAAGCTTGCTA
TGGCATTGTCAGTACCCACTGGACCGTGGTTTGCAAGGAAATGTGAATCTCAGGAGAGAGCAGCCAGA
GTGAGATGTGAACCTTGTCCCCATAAGGATGGACTTAAAGAACAGATAATGGGGTTGGGCCATG
TGGTTTGTGCCCTGTATATTCCAGAGGTACAATTGCAATGTTCCACAATGGAACCAATTGTTTACA
GTCTGTTCCGATGATCGTTATAAAAGACTGCTACATTGATGAACAAAGGAAGAGAACAGCA
GCCACTGGTGTGATGACATGTAATAAACATGGATGTCGACAGGCTTCCATGTAACATGCGCTCAGT
TTGCCGGACTGCTTGTGAAGAACAGGTAATGGTGCATAATGTCATAACTGTGGCTACTGTAAATA
CCATTAGTAAGCTGAAAAAGAGCAAACGGGATCTAATAGGTATGATCAAAGTTAAGTGAATTCT
TCCCTCACTCTCAGGATAAAACATCATGAGAAAGAGAAAAAAATATAAAGAGAACAGGAAACACAAAC
AGAAACACAAGAACAGCCAGAACATCACCTGCATTGGTCCATCCTGACTGTTACTACAGAAAAAC
TTATACAAGCACTAGAACAAACTCTATATCTGGATCATGAAAGCGCTGGAAAGATACTACTGCACGATT
ACAAATGCAAATTTCAGGAAGTCTGCACACACCTCTAGTGGAAAAGATGTTCAAGAGACTAGAGGGT
CAGAGGGCAAAGGGAAAGAAATCTCAGCTCACAGCTCAGTCAAAGGGAAAGAACGCTGGTGGTGGAAAG
AAATCCAGGAACAACGTGTCAGCAGCTAGCCCTTTCTCAAGGCAGTTTCAGGAACCTCAGGCAGT
GTAAAGTCATCTCTGGAAAGTTCACTGCAGTCTCCCAAGGATTTCTGAGCTTACAGACTCAGATCTGC
GTAATGACAGTTACTCTCACTCCAACAGTCATCAGCAACCAAAGATGTACATAAAGGAGAGTCTGGAAAG
CCAGGAAGGGGGGTTAAATAGTTAGTACCTTAATTGGCTCCCTCAACCTCAGCTGTTACTCACAG
CCTAAAGCTTGTAAAATTCACTGGAGATTGGGTAATTCCAGCCTCTACAGCAGGATAAAAGCGGG
CTCAAACCTCTGGCATAGAAGAACAGTGTAAAGGAAAAGAAAAGGAAATAACAAAGTAAGCA
TGGGCTGGCAGACCCAAGGAAACAAAAATCAAGAGAAATGTTCTATCTCTCAGTTCTGCTTCA
CCAACATCATCTGTAGCATCAGCTGCAGGAAGCATAACAAGCTCTAGTCTCAGAAATCTCTACATTGC
TCAGGAATGGAAGTTACAGAGCCTCAGTGTGGCTCATCTCCAGTGGTTCAAGAAATTCCATGCAGTA
TCGGCATGATGGAGCTTGGCCAAACAAACTACGTTCTCAGAGTTGCTGAATGCAATACACAACGACAGAGGT
GACAGTTCTACACTAACAAAGCAAGAACCTAAATCATAGGTATTATAACAGCAATGATGTAGCAGTAT
CGTTTCAAATGTAGTATCTGGCTGGGATCTAGTACTCTGTCTCCAGCTCTCACTTACCTCAGCAGTC
TTCTGGGATTGCAACAAAGTAGGAGCGCTCTCCCTCAGCTGTGTCATCTGAGCCCTGCTGTTGCT
ACAACCTCAGGCAAATACTCTATCTGGATCTCTCAGTCAGCAGGACATCTCATATGATGGCAATAGAT
CAAATTCAATGGCAGCTTATAGCTCAGTCTGAAAACAATCAAACAGATCAAGATCTGGAGACAA
TAGCCGAAACCTAGTGGCAGAGGAAGCTCACCCGAGGAAGTCTCGCCACGATCCCTGTAAGCAGC
TTACAGATTGCTATGATCAACCCAGGAAACAGCAGTTGGAAAATCTGCCCTCAGTAGCAGCCACCATAG
AACAGCTTGGAGAGGCACTGGAGTGAAGGACAGCAATTTTACTAGAACAGGGTACTCCTAGTGACAT
TTAGGAATGCTGAAGTCATTACACCAACTCAAGTTGAAAACCGAAGATTAGAGGAACAAATTAAAAAC
TTGACTGCCAAAAGGAACGGCTTCAGTTGAATGCAACAGCTTCAAGTGCCTTCAACAAATAACAG
CAAACCTAGCCGCTCATCAAATACACACATTTCAGCACAGACTGCTCTACTACTGATTCTTGAA
CAGCAGTAAGAGGCCCTCATATAGGAAACAGCTTAAACTGATAATTCTCTCTGTTAAATCAGGAC
TTAACCTCAGTGGACAAAGTACCGCAGCTCATCAGCTCTTCTCACCCACCTCTGCTGGCAGAGTC
CGGCTCAACAAAGGCTCAGGAGTGAAGTGGAGTTCAAGCAGGTCATGGCTGACAGTGGGGCACTAGCTAG
TGGAAATGCGCTGTAACCTCCACCATTCCTGCGCTGTCAGTGGGTGGAAATAATTGGAGCTTGTGCA
GGTAACCAACTGGCAATTAAATGGCATTGTAAGGAGTTAAATGGGGTATGCAAGACTCCTGTCACAATGT
CCCAGAACCTACCCCTCTCACCCACACAACCGTACCCACCTAATGCAACACATCCAATGCCAGCTACACT
GACTAACAGTGCCTCAGGACTAGGATTACTTCTGACCAGCAACGACAACAAACTTATTCTACACAGCAG
TTTCAGCAGTTGTTAAATTCTCAACAGCTCACACCAGTACACAGGCAACCCCCACTTCACACAGCTAC
CAACCCATTCTCACCATCCATGGAGATAATGCAAGTCAGAAAGTAGCAAGACTTAGTGAATTTGGG
CCTGTAGCTCAAGAGAAAAGTGAACACCTGAGAAACATCTAGAAATTGCTATCTGCTGTTAGC
TCATCTGGCTGCCATTGCAAGTCTTTACTACAGCTATGAAAGAACGCAACAAGAAACTCAATGCCACA
AAAGGATTAATTGCTGCAAGGACATTCTGTAAGGCTTGTGATTAGTTCTGCTTGTGCACTGA
AATGGAATTCCCAGGCCCTACCCCTACCCCTAGTTTGTGAAACATGGAAAGAAAATTAAACTTTT
AAAGTGAACATAATTACATGCAATATGTTATCAACTCAAGAATTAAATAGTTGTACACAACAGTT

EX03-053P

TTGTTTATAAATTGGAGATGCAAATAGCAAAACTAAATACCTGCTCCATTACAAACTACTTGATTTAT
TGTACAAGTTGAAATATGCTTTGTTGGGTTACAGTATGCTGCTTAAGTCAAATTCCAAGGAAC
AATTCTCTCCTGGAGTTGCATTGATTCAAGTATTACAAATATAGCACATCACCTGGGAC

>gi|5174576|ref|NM_005937.1| Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6 (MLLT6), mRNA
ATGAAGGAGATGGTAGGGAGCTGCTCGTATGTTGGACAGAGGGGCTGGGCCAGAACCCGCTGGTCT
ACTGCGATGGGCACCGTGCAGCGTGGCCACCAGCTGCTATGGCATCGTCAGGTGCCAACGGG
ACCCCTGGTCTGCCGGAAATGTGAATCTCAGGAGCAGCAGGGTGGAGGTGTGAGCTGTC
AAAGACGGGGCATTTGAAGAGGACTGATAATGGAGGCTGGCACACGTGGTGTGTC
AGGTCAATTGCAACGTGCTCACCAGGAGCCCACCGTGCAGTACGTGCCATGATCGCTCAA
CAAGACCTGTTACATCTGCGAGGAGACGGGCGGGAGAGCAAGGGCCCTCGGGAGGCTGCATGACCTGT
AACGCCATGGATGTCGACAAGCTTCCACGTGACCTGCCCCAAATGGCAGGCTGCTGTGAGGAAG
AAGTGTGGAGGTGGACAACGTCAAGTACTGGGCTACTGCAAATACCACTTCAGCAAGATGAAGACATC
CCGGCACAGCAGGGGAGGCGAGGAGGAGGCGCTGGAGGAGGAGGCTGCAGCATGGGGGAGGTGGCAGT
GGTTCATCTCTGGGAGGAGAACGGCGTCAGCCTCACCATCCACGCAGCAGGAGAACACCCACCCACC
ACAGAGGGGCCAGAAGAAGACTGCAAAGAACGCCCTAACGGAGAACAGACAAGAACAGGGCCTGA
GTGCCCCCCAGCATCTCACCCGCCGTGTCCTTACGTGACAAAGGCTCTCTCTGGCTTCT
TCCTCCACACGAGGCCAGCAGCAGGAGACCTCTGAGAGCAGCAGGGAGTCAAAGGGAAAAAGTCTT
CCAGCCATAGCCTGAGTCATAAAGGGAAAGAAACTGAGCAGTGGGAAAGGTGTGAGCAGTTACCTCCGC
CT
AGCTCCCCCTGACTCTCTGCAATTCCCCAAGCTGGAGCAGCCAGGGAGAACAGTACTCAAAGCCCACAG
CCCCCGCCCCCTCAGCCCCCT
GGTGGTCTCTCTGGCTTTGGGCCATCATGCGCTTCTCACCACCTCAGCTCAGGCCGGGGGGGG
GGCCTCTCTGGGACTATAAGTCTCCCCACGTCAACGGGTCTGGGCCCTGGCAGGCCACCAAAAC
GGATGCCGCAGTGAACGCCACCCCTGTGCTGATGAGACCCCTGAGACAGGCTGAAGGAGAACAA
GCACAAAGCCAGCAAGAGGAGGCCATGGCCAGGCCCTCCAAAGGGCAGGCCAGAACAGGAGGGCACT
GGGGGCCAGCTGCCCATCTTGCCAGTGGCCAGCTGGCTGGCTTACCGCACTGCTGCCCTCACCT
TCTCTGGAGGTTCTCTGGTCACTCCGGCTGGAGCTGGGAGGCTGTCTCTCCGAACCTTGGCCTCTGGGAG
CTTGGCCAGCTTGAGCTGGAGTCCCCCTTACTAGGGCAGGCATCTACACAGTAATAAGGACCCATC
TCCCACAGTGGCGGGATGTCGGGCTGTCTGCAACCCCTCTCTCTCCAGCCTCTGGGCCCCAG
GGACCTGGGCCCCCTGCCCTGCCCTAGCCGCTCCCGTTACCGCACCCCTCCCCCTCTCTGCTTCTAT
CTCCACCAACTCAGGTGTTCTGGCTGGCTTACCTTACGCTCCCTTACCCACATCTTGGAAC
CCCAGGGTGCCTTAATCCCCCTCTCCAAAGCTGAGAGCAGCCACACAGAGCAGACCTGGAGGACT
GCAGCTCCGGTGTGGGGGACCTCCCCCTCAGGAGAGTCTGCTTACGCCCCCATCAGCAGCCTCCC
CGCACTCTCGACCAAGACAGCCTCTGCAACCTGTGGGGCGGCCAGTAGACCCGGGGGGGGAGGACG
ACTAACATGGACCAAGCTCTGGAGAACAGAGGGGAGCAGGGGAGGCCGGTCAACATCGTGGAGATGCTGA
AGGCCTGCACGCCGTGCAAGAGGAGAACAGCGCTGCAAGAGCAGATCTGAGCCTGACGGCAAAA
GGAGCGCTGCAGATTCTCAACGTGCACTCTGTGCTCTCCACAGCACGCCCCCAGCCTGCCCTGCC
GCCAACGGCCCTGCCCCCTGGCCCTATGGCTGCCCTCCCCAAGCGGGAGCAGCAGCTCCTTGAGCACCA
GCAAGAGCCCTCCGGGAAAGAGCAGGCCCTGGACACTCGCTGTCCACTCTGAGGGACCCACA
CTCAGGTGCCAGGCCGAGCAGCTGCTGCTGTCTCCACAGCACGCCCCCAGCCTGCCCTGCC
CAGCAGAGCCCTGCCACTCTGCCCTGGCCCTGCCCTGGGGGAGCAGCAGCTCAGCAACTCCAGCAG
ACGGGTTGGGCCGGCACCGGGGAGCAGGGGCTGGGGGGCTGGGAGCTGGGAGGAGGAC
GCTGGCAGGCAGTGGGGCCTGCCCTCAATGGCTCTCTGGGGGGCTGGGAGCTGGGAGGAGGAG
CCCCGAAGCTTGAGCCAGGCTGGCGGGGCCCCACGCTGAGCTGCCAGGCTGTCTCAACAGCCTTACAG
AGCAGCAGAGACATCTCTCAGCAGCAAGAGCAGCAGCTCAGCAACTCCAGCAGCTCCTGGGCTCCCC
GCAGCTGACCCCGAACACCAGACTGTTGCTACCGAGATGATCCAGCAGATCCAGCAGAACAGGAGCTG
CAGCGCTGCAGATGGCTGGGGCTCCAGCTGCCATGGCCAGCCTGCTGGCAGGAAGCTCCACCCCG
TGCTGCTGCCTGGGGTACCCCTGGCTGCTGCCACAGCGCTGTCTGCCACCCCTGCTGCCCTGGAGGCC
AGTGGCTCCCTCGCTGGCAACAACACAAGTCTCATGCCGCAGCAGCTGCACTGCAAGCTAGCAGCA
GCAGGGGGACCTCACTGCCAGACCAACCCCTTCCCTAGCCTGTCAGGCCGGAGCAGAGGGCAGTG
GCGGTGGCCCCAAAGGAGGGACCGCTGACAAAGGAGCCTCAGCCAACCAGGAAAAGGCTAA

>gi|4505956|ref|NM_002697.1| Homo sapiens POU domain, class 2, transcription factor 1 (POU2F1), mRNA

EX03-053P

GAGGAGCAGCGAGTCAGATGAGAGTTCAGCCGGCGGCAGCAGCAGCAGACTCAAGAATGAACAATCC
GTCAGAAACCAGTAAACCATCTATGGAGAGTGGAGATGGCAACACAGGCACACAAACCAATGGTCTGGAC
TTTCAGAACGAGCCTGTGCTGTAGGAGGAGCAATCTCAACAGCCCAGGGCAGGGCTTCTGGACATC
TCCATCAGGTCAACTCGCTGGAACAAGTTACAGGCTGTGCTCAGTCTTAAATGTACAGTCTAAATC
TAATGAAGAATCGGGGATTGCAAGCAGCCAGCCTCCCAGCAGCCTCAGTGCAGGCAGCCATT
CCCCAGACCCAGCTATGCTAGCTGGAGGACAGATAACTGGGTTACTTGACGCCAGGCCAGCAACAGT
TACTACTCCAGCAGGCACAGGCACAGGCACAGCAGCTGGCTGTGCAGTGCAGCAGCACTCCGCCAGCA
GCAGCACAGTGTGGAGGCCACCATCTGGCTGTGCCAGGCCATGACGCCAGATCCCCCTGTCT
CAGCCCATAACAGATCGCACAGGATCTCAACAACAGTCAACAGCAGTCAACAGCAGAATCTCAACCTGCAAC
AGTTTGTGTTGGTGCATCCAACCACCAATTGCAAGCCAGCAGTTATCATCTCACAGACGCCAGGG
CCAGCAGGGTCTCTGCAAGGCCAAAATCTCAAACGCAACTACCTCAGCAAAGCAGCCAACTCCTA
CAGTCGAGCCAAGCATCACCCCTACCTCCAGCCAGCAACCCAAACAGCACAATAGCAGCAACCCAA
TTCAGACACTCCACAGAGGCCAGTCAACACAAAAGCAGATTGATACTCCAGCTGGAGGAGCCAGTGA
CCTTGAGGAGCTTGAGCAGTTGCCAAGACCTTCAAACAAAGACGAATCAAACCTGGATTCACTCAGGGT
GATGTTGGCTGTTGGGAAACTATATGAAATGACTTCAGCCAAACTACCATCTCTGATTGAAG
CCTTGAACCTCAGCTTAAAGAACATGTGCAAGTGTGAAGCCACTTTAGAGAAGTGGCTAAATGATGAGA
GAACCTCTCATGTTCTGCTCCCTCTCCAGCCAAGTGCCTGAATTCTCCAGGAATTGAGGCTTGAGC
CGTAGGAGGAAGAACGCAACAGCATAGAGACCAACATCCGTGTGGCCTTAGAGAAGAGTTCTTGAGA
ATCAAAAGCCTACCTCGAAGAGATCACTATGCTGATCAGCTCAATATGAAAAAGAGGGTATTG
TGTGTTGGTCTGTAACCGCCGCCAGAAAAGAAAAAGAATCAACCCACCAAGCAGTGGTGGGACCAGCAGC
TCACCTATTAAAGCAATTTCAGCCCAACTCAGTGTGGCAGCACACCAAGCCTTGTACTAGCA
GTGAGCCAACATACCCCTACAGTCAGCCCTGTCCCTCTGACCAGTGTGACGAATCTTCAGT
TACAGGCACCTCAGACACCACCTCAACAACACAGCAACCGTGAATTCCACAGCCCTCCAGCTTCTCA
GCAGTCACGTCCCCCTCTGAGTCCCTCCCCCTCTGCTCAGCCTCCACCTCCAGGCACTCCAGTGC
GTGAGACCAGCACAACACAGACCCACTCCACTCTTGTCTCCCTTGGGACCAAGCCAGGTGATGGT
GACAGCATCAGGTTGCAAACAGCAGCAGTGTGCCCTCAAGGAGCTGCACAGTTGCCAGCAAATGCC
AGTCTTGTGCCATGGCAGTGTGAGGACTAAACCCAGCTGATGGCACCCCTCACAGTTGGCTG
GAGGTGCTTACTCAGTCTGAATCCAGGGACCTGAGGGTGTCTCAGCCAGCTAAATGAGCAACAG
TACACTGGCAACTATTCAAGCTTGTGTTCTGGCTCTTCATAAACATCACTTGATGCAACTGGG
AACCTGGTATTGCAAATGCGGGAGGAGCCCCAACATCTGACTGCCCTCTGTTCTGAACCCCTCAGA
ACCTCTCTGCTCACCAGCAACCTGTTAGCTGGTCTGTGCCCGCAGCATCTGAGGGAACTCTGC
ACCTGTAGCCAGCCTCACGCCACCTCTGCTGACTCCAGAACTCTCTTCACAGTGGCC
CTGCCAGCGGGCTGCGTCCACCAACACCAGCCTCAAGGACAGTGTGGCAGGCTGGGAGACCTGGCTG
CCAGAACCTTTTCACTCTGCACTGTGATTGGACTGCCAGGTTAATAAAACTGAAAAATGTGATTG
GCTTCTCTGCCGTGTTGTGAGGGCAAAGGAGAGAAGGGAGAAAAAAACACACACAC
ATACACAATATACAGAAAAGGAAGGAAGGATGGAGACGGAACTTGCCTAATTGTAATAAAACACTG
TCTTTCAAGGGTTGCTTCATGGGTTGGAGGACTTCTAACAAAAATTAAAAAA

>gi|4505958|ref|NM_002698.1| Homo sapiens POU domain, class 2,
transcription factor 2 (POU2F2), mRNA
CGTCAACATGAGTTGGCCTGGGCAGATGAGGCTGGCTGGCGGGGGAGCAGCATGGTCACTCCAGCA
TGGGGCTCCAGAAAATAAGAATGTCTAAGCCCCCTGGAGGCCAGAACGGTCTGGACTCCCCATCAGA
GCACACAGACCCGAAAGAAATGGACAGACACTAATCATCAGAACCCCAAAATAAGACCTCCCCATTC
TCCGTGCCCCAAGTGGCCCCAGTACAAAGATCAAGGCTGAAGACCCAGTGGCGATTCAAGCCAGCAG
CACCCCTGCCCTCAGCCGGCCAGCCTCATCTGCCCAAGGCCAACTCATGTTGACGGGAGCCAGCT
AGCTGGGACATAAGCAGCTCCAGCTCCAGCAGCTGGCTTGTGCCAGGGCACCACTCCAGCCA
CCTGCTAGTTCTGCTACCGCAGGCCAGCAGAGGCCAGGCTGCTACCGACACCAAAATCTATTCC
AGCTACCTCAGCAAACCCAGGGAGCTTCTGACCTCCAGCCCCGGGGCTTCCCACACAGCCCC
CAAATGTTGGAGCACCATCCACCCCGAGGAGGCCAGTGTATGGAGGAGCTGGAGCAATTGCCGC
ACCTTCAAGCAACGCCCATCAAGCTGGGCTTCAGCAGGGTGTGATGGGCTGGCATGGCAAGCTCT
ACGGCAACGACTTCAGCCAGACGACCATTTCCGCTTCAGGCCCTCAACCTGAGCTTCAAGAACATGTG
CAAACCTCAAGCCCCCTCTGGAGAAGTGGCTCAACGATGCAGAGACTATGTCTGTGGACTCAAGCCTGCC
AGCCCCAACCAGCTGAGCAGGCCAGCCTGGGTTTCAGGCCAGGGCTGGCTGCCAGGAGACGCAAGAAGGAGA
CCAGCATCAGAGACAAACGTCCGCTCGCCTTAGAGAAGAGTTCTAGCGAACAGAAGCCATCTCAGA
GGAGATCTGCTGATGCCGAGCAGCTGCACATGGAGAAGGAAGTGTATCCGCGTCTGGTTCTGCAACC
CGCCAGAAGGAGAAACGCACTAACCCCTGCACTGCGGGCCCCATGTCGCCAGGCCAGGGAGCCGGCCA
GCTACAGCCCCATATGGTCACACCCAAAGGGGGCGGGGACCTTACCGTTGCTCAAGCTTCCAGCAG

EX03-053P

TCTGAGCACAACAGTTACTACCTTATCCTCAGCTGTGGGACGCTCCACCCCAGCCGGACAGCTGGAGGG
GGTGGGGGGCGGGGCGGGCTGCGCCCTCAATTCCATCCCCCTGTCACTCCCCCACCCCCGGCCA
CCACCAACACCACAAACCCCAAGCCCTCAAGGCAGCCACTCGGCTATCGGCTTGTCAGGCTGAACCCCAG
CACGGGCCCCGGCTGGGACCCCTGCCCTTACCGAGCTTGATGCCAGCGGGAAATCTGGTGTGG
GGCAGCCGGTGCAGCCCCGGGGAGCCCTGGCTGGTGCACCTGCCGCTTCTTGAAATCATGCTGGCTG
CCCCCTGCTCAGCACCCCGCTGGGTGTGGCTGGTCTCAGCAGCGGCTGGCTGTGGCAGCCATCT
CCAGCAAGTCTCTGGGCTCTCCCTCATCTCATCTCATCTCATCTCCCTCCACTTGAGCAG
GACGGCAGCACAGACAGCCCCGGGGAGGGCCGAGGCAGGGTCAAACCTGAGTGAGGGCCAGCC
ATGCCCTCCCCCTCCCATCTCTGGTCCCTGCCCTGGCTGGTCTGGGAGAGGGGGAGGAGGCCAGTG
GTGGGGACCCAGAGGGTCTCAGAGCAGGAGTGACAAGGGAGGAAGACCAAAAAAACAACCAACCAAAA
AAAAAAAAAAAAAGGAAAGAAACTAACCAACAAAGAGAAAACCAAAAAATAATCACAAACAGAAACCAGC
TGCCCCAAAGGAACCAGAGGTGAAAAACAAACAAAAACCAAAACCAACCAACCAACCAACCAACCA
TCTACCCCCCTAGAGCC

>gi|7657408|ref|NM_014352.1| Homo sapiens POU domain, class 2,
transcription factor 3 (POU2F3), mRNA
GGGGAGGATGGTGAATCTGGAGTCATGCACACAGATATCAAGATGAGTGGGATGTAGCCGATTCCACG
GATGCTCGCAGCACTCTCAGCCAGGTGGAGCAGGAATGATCGAAAAGGCCCTAGATTCACAGGCAGA
TTAAAACCGAAGATCTCAGTGAATCCCTGCAGCAGACCCCTCCATGCCATGCCACCTGAGTCAG
ACCTGCCATGATGTCCGGAAACCAAAATGTCGGCTAAATGCCAGCCATGTCAGGACATGGCTTCCCTC
CATCCGCTCCAGCAGCTTGCTGCTGGTCCGCCACTTACAGTGTATCCCTGCTATCTCAGA
CCCAGCCTGGCAGCAAGGCTGAGCCAAATCTCCTCCCTTCCACAGCAACAAAGGGTCTCCT
CCCACAGACTGGGCCCCGACTGGCATCCAGCATTGGCACCCCTGGCTGCCAGGATCTCTTTAGAA
CCCCACCTGGAAGCATCCAGCATCTCCAGTGGCAAGACATCTACCCAGCTCTGGAGGGCCGATGAGC
CCAGTGACCTCGAGGAGCTGGAGAAGTTGCAAGACCTCAAGCAGAGGCGCATTAGCTGGCTTCAC
ACAGGGAGATGTGGGCTGGCATGGGAAAGCTGATGGCAACGACTTCAGCCAGACCACATTCACGA
TTTGAGGCCCCCTAACCTGAGCTCAAGAACATGTGCAAGCTAACGCCCCCTGCTGGAGAAGTGGCTGAATG
ATGCAGAGTCTCTCCGTAGACCCCTCAGTGAAGCACGCCAGCTCTAACCCAGCTCAGTGAAGTATT
TGGTAGGAAGAGAAAGAACGGACCAGCATCGAGACCAACATCCGCTGACTCTGGAGAAGAGGTTCAA
GATAACCCAAAACCCAGCTGGAGGAGATCTCATGATTGAGAGCAGTTGTCATGGAGAAGGGAGGTGG
TGAGGGTCTGGTTCTGCAACCGACGCCAAAGGAGAAGCGAATCAACTGCCCTGTCGGCCACACCCATCAA
ACCACCTGTCTACAACTCCCGCTGGTATCTCCCTCAGGGCTCTGGGCCCCCTCTGTCCCTCCTGTC
CACAGTACCATGCCCTGAAAGCTAACGTCACTCTGTTCCCTGGAAACAACAGCAGGCCCTCATCTCCTG
GCTCAGGACTCCACCCAGCAGCCCCACTGCATCTCAAATAACTCCAAGCAGCAGTGAACCTCCGCTC
CAGTTTAACTCTCAGGATCTGGTACCGATGGAATCACTCCACCTACCTCCACTGAGACCAAAAGTT
TCTCCTACTCCAGCTGGCCCTGTATTCCCTGGAGGAAGGAATCATGCCCTCATATACAGACAGATT
GCCCTCAGAAGAGTGGAGAAGAAAATCTCAACTATCAATGAACCCAGACTCTGTCTTCTCAAGAGCAAGG
GCCCTCGAGATCCAAACTGTGATTGAAACAGTGCAGACTCCATACTGCTCTGAAATACACAGCCCTC
CTAGGAGCTTACCATTTCACCTCTTGCTATGCCCTGCCCTAGTCCAAATATTTAGCCAGCT
TCACTGTGGCAATAGTCTTCAAGAAAAGACTCTTGCTGTTATTCTCAACTCATCCGTTGGCTTCTG
GGGACAGCCATTGGCTGGGTGCCAACACCAGAAGGGGAGATAATAGTTGACTCTGAACCTGGCA
CAACCCCTGAACTGATCCAAAATCTGTGAAAAGATTGAAATCTCCACCAAAGCCTTGATGTT
TTCTCTGTACAGCTAAGTTCTGATGGAATCTCATCTCACCCATTTCCTTTAACCTGCCCT
TTCTACAATCAAATCCATTCTATTGCGCCCTCCAGGCTCCCTCTGGAGGTTGCAAGAGGTGAAAAGAGC
TGCCCTTGGTGGGTGCCCTTGAGCATGTTGCAACGCCCTGCTGGTGCCTCTGTCTGCCACGTCTGCC
AGGGCTCAGGAGTGTGTTCTTCCCTGGGCCCTGGGTTCTCTTATCTGTCTCCCTCTCCTTCTC
CTGGCAGCAGAAAAGGAAGAACACAAGAGAAACACACAACATGATGGTGGCAAAGTACCTGTATATAG
CCCTTTCCCATTTTGCAATTGTTCTTAACCTCTTAATGTGGAATTTCAGAAAGTAACTCTG
GTGTGATTGGAAATGTCTGTAAATATTTATCTCTTAAAGGGGGGAAATACAAAGTG
TGAAATACTGTGCTACCTCCAGGTTCCACATGGGCTGGGATTTTTTCTTTTCTTTTCTT
TTTTTGAGACAGTCTGCTCAGGCCAGGCTGGAGTGCAGTGGCATGATCTGGCTCACTGCATGCTC
TGCCACTGGGTTCAAGCGATTCTCTGCCCTAGCCTCTCAAGTAGCGGATTACAGGGGCCACCA
AAATTAGCCCAGCTAATTTGATTTTAGAGAGATGGGTTTACCATGTTGGTCAGGCTGGCTT
AACTCTGACCTCTGATCCACCCACCTCAGCGTCCCGAAGTGCAGGGATTACAGGTGTGAGCCACCGCG
CCTGGCTGGGCTGGGAATCTTGTTGACTCTTGGGAACATTATCTCTAGAGTGCTGCTTTTGAGGG
CCAGTTGTAGAGATGTAACATGAAGCCATTCCAGAAATGGTAACCTAAAAAAAGACTACATGTCT
AGGAAACTGTTGAGATTCAAAGGAATCTCACTGTTCTAAATAATGTGTTAGTGATTGAAAGT

EX03-053P

>gi|31543438|ref|NM_002740.2| Homo sapiens protein kinase C, iota
(PRKCI), mRNA

```
AGCGGTTTGGGCCGGCGCTGTAGAGGCCGGCGCCATCGGCAGTGGGAGGAGCCGCCGGTTCC
GGCTGCTCCGGCAGGCCACCTGGTCGGCGCTGCGGGCAGGTGGCAGGTAGGTGGCGGACGGCC
GCGGTCTCCGGCAAGCGAGGCCGGAGTCCCCACGGCCCGAAGGCCCGCACCCCGCACCCCGGCC
TCCAGCGTTGAGGGGGGGAGTGGAGATGCCGACCCAGGGACAGCAGCACCATGTCCCACACGGTC
GCAGGCCGGCAGCGGGGACCATCCCACAGGTGGTGAAGCTACTACCGGGGGATATCATGA
TAACACATTGAACTTCCATCTCCTTGAGGGCTTCAATGAGGTTGAGACATGTGTTCTTG
CAACGAACAGCTTCACCAGAAATGGATAGATGAGGAAGGAGACCGTGTACAGTATCATCTCAGTIG
GAGTTAGAAGAAGCCTTAGACTTTATGAGCTAACAAAGATTCTGAACCTTGTGTTCCCTT
GTGTACAGAACGTCCTGGGATGCCCTGACAGAGAAGATAATCCATCTACCGTAGAGGTGCACGCC
CTGGAGAAAGCTTATTGTGCCATGGCCACACTTCAAGCCAAGCGTTCAACAGCGTGTCACTGT
GCCATCTGCCACAGACCGAATATGGGACTTGACGCCAGGATATAAGTGCATCACTGCAAACCTTGG
TTCATAAGAAGTGCATAAACTCGTCACAATTGAATGTGGCGGATCTTGCACAGGAACAGTGTGAT
GCCCATGGATCAGTCATCCATGCATTCTGACCATGCACAGACAGTAATTCCATATAATCCTCAAGTCAT
GAGAGTTGGATCAAGTGGTGAAGAAAAAGAGGCAATGAACACCAGGGAAAGTGGCAAAGCTTCA
GTCTAGGTCTCAGGATTTGATTGCTCCGGTAATAGGAAGGAGTTATGCCAAAGTACTGTTGGT
TCGATTAAGGAGCTTATGCAATGAAAGTGTGAAAAAGAGCTTGTAAATGATGATGAG
GATATTGATTGGGTACAGACAGAGAAGCATGTGTTGAGCAGGCATCCAATCATCCTTCTGTTGGG
TGCATTCTGCTTCAAGACAGAAAGCAGATTGTTCTTGTATAGAGTATGTAATGGAGGAGACCTAAT
GTTTCATATGCAGCAGAAAGAAAATCCCTGAAGAACATGCCAGATTCTGCAGAAATCAGTCTA
GCATTAATTATCTCATGAGCGAGGGATAATTAGAGATTGAAACTGGACAATGTATTACTGGACT
CTGAAGGCCACATTAAACTCACTGACTACGGCATGTGTAAGGAAGGATTACGGCAGGAGATAACACAG
CACTTCTGTGGTACTCTAATTACATTGCTCTGAAATTAAAGAGGAGAAAGATTATGGTTCAAGTGTT
GACTGGGGCTCTGGAGTGCTCATGTTGAGATGATGGCAGGAAGGTCTCCATTGATATTGGGAA
GCTCCGATAACCCCTGACAGAACACAGAGGATTATCTCTCCAAAGTTATTGGAAAAACAAATTGCAT
ACCACGTTCTATGTCGTAAAAGCTGAAAGTGTCTGAAAGAGTTCTTAATAAGGACCTAAGGAACGA
TTGGGGTTGTCTCCTAACAGGATTGCTGATATTCAAGGGACACCCGTTCTCGAAATGTTGATTGGG
ATATGATGGAGCAAAACAGGTGGTACCTCCCTTAAACCAATTCTGGGAAATTGGTTGGACAA
CTTGATTCAGTTACTAATGAACTGTCAGCTCACTCCAGATGACGATGACATTGTGAGGAAGATT
GATCAGTCTGAATTGAAAGGTTTGAGTATCATCCTCTTTGATGTCGAGAAGAATGTGTCGAT
CCTCATTTCACCATGTTACTCATGTCGCAATTAAATGCAAGGAAACTTGCTGCAAGCCTGG
ATACAATTAAACCAATTATATTGCAACCTACAAAAAACACCCAAATATCTCTTGAGACTATATGA
ATCAATTATTACATCTGTTTACTATGAAAAAAATTAATACTACTAGCTTCCAGACAATCATGTCAA
ATTTAGTGAACCTGGTTTCAGTTTAAAGGCCTACAGATGAGTAATGAAGTTATCTTTGTTA
AAAAAAAAAAAAAA
```

>gi|10864649|ref|NM_002744.2| Homo sapiens protein kinase C, zeta
(PRKCZ), mRNA

```
ATGCCAGCAGGCCACCCAAAGATGGAAGGGAGCGGCCGCCGCTCCGCCCTCAAGGCCATTACGGGG
GGGACATCTCATCACCAAGCGTGGACGCCGCCAGACCTTCTGAGGAGCTCTGTGAGGAAGTGAGAGACAT
GTGTCGTCGACCCAGCAGCACCCGCTCACCCCTCAAGTGGTGGACAGCGAAGGTGACCCCTGACGGTG
TCCTCCAGATGGAGCTGGAAGAGGCTTCCGCTGCCGCTAGTCGAGGGATGAAGGCCATCATCTACCGCCG
ATGTTTCCGAGCACCCCTGAGCAGCCTGCCATGTCGGGAGAAGACAAATCTACCGCCG
GGGAGCCAGAAGATGGAGGAAGCTGACCGTGGCAACGCCACCTCTTCAAGGCCAGCGCTTAAACAGG
AGACGCTACTGCGGTCACTGCAAGCAGAGGATATGGGGCTCGCGAGGCAAGGCTACAGGTGACATCAACT
GCAAACGCTGGTCATAAGCGTGCACGCCCTGCTGACCTGAGGAAGCATATGGATTCTGT
CATGCCCTCCAAAGGCCCTCCAGTAGACGACAAGAACGAGGACGCCACCTTCCGAGGAGACAGAT
GGAATTGCTTACATTCTCATCCGGAAAGCATGACAGCATTAAAGACGACTCGGAGGACCTTAAGCCAG
TTATCGATGGGATGATGGAATCAAATCTCAGGGGCTGGGCTGCAGGACTTGTACCTAATCAGAGT
CATCGGGCGGGAGCTACGCCAAGGTTCTCTGGTGGGGTGAAGAACAAATGACCAAAATTACGCCATG
AAAGTGGTGAAGAACAGAGCTGGTGCATGATGACGAGGATATTGACTGGTACAGACAGAGAACGACGTGT
TTGAGCAGGCATCCAGCAACCCCTCTGGCGGATTACACTCTGCTTCCAGCAGACGACAAGTCGGTTGT
CCTGGTCATTGAGTACGTCAACGGCGGGGACCTGATGTTCCACATGCAAGAGGAGAGGAAGCTCCCTGAG
GAGCACGCCAGGTTCTACGCCGGAGATCTGCATGCCCTCAACTTCTGCAAGCAGAGAGGGGATCATCT
ACAGGGACCTGAAGCTGGACAACGTCCTCTGGATGGGACGGCACATCAAGCTCACAGACTACGGCAT
```

EX03-053P

GTGCAAGGAAGGCCTGGCCCTGGTACACAACGAGCACTTCTCGGAACCCGAATTACATCGCCCC
GAAATCCTGCGGGGAGAGGAGTACGGGTTCAAGCGTGACTGGTGGCGCTGGGAGTCCTCATGTTGAGA
TGATGGCCGGCGCTCCCCGTTGACATCATCACCGACAACCCGACATGAACACAGAGGACTACCTTT
CCAAGTGTACCTGGAGAACCCATCCGGATCCCCCGGTTCTGTCCGTCAAAGCCTCCCAGTGTAAAAA
GGATTTAAATAAGGACCCAAAGAGAGGCTCGGCTGCCGCCACAGACTGGATTTCTGACATCAAGT
CCCACGCCTTCTCCGAGCATAGACTGGGACTTGCTGGAGAAGAACAGCAGGCGCTCCCTCATTCCAGCC
ACAGATCACAGACGACTACGGTCTGGACAACCTTGACACACAGITCACCAGCAGGCCGTGAGCTGACC
CCAGACGATGAGGATGCCATAAAGAGGATGACAGTCAGAGTCAGAGTCAGGCTTGAGTATATCAACCCAT
TATTGCTGTCACCGAGGGAGTCGGTGTAGGGCGCGTCTGTGCTGGACACGCGTGATTGACCC
TTAACTGTATCTTAACCACCGCATATGCATGCCAGGCTGGCACGGCTCCGAGGGCGGCCAGGGACAGA
CGCTTGCAGGAGACCCAGAGGGAGGGCAGGGCTAGGGAGGAACTGCTGTGCTGCCGCGGATCCGGGGACCC
GCCCGCAGGCAGCTCGTGTGGAGGAACTGCTGTGCTGCCGCGGATCCGGGGACCC
TGCGGAGGGGGCTGTCACTGGTTCCAAGGTGCACATTTCACGGAAACAGAACACTCGATGCACTGACC
TGCTCCGCCAGGAAAGTGAGCGTGTAGCGTCTGAGGAATAAAATGTTCCGATGAAAAAAA

>gi|4759123|ref|NM_004171.1| Homo sapiens solute carrier family 1
(glial high affinity glutamate transporter), member 2 (SLC1A2), nuclear
gene encoding mitochondrial protein, mRNA
GATAGTGTGAAGAGGGAGGGCGTCCAGACCATGGCATCTACGGAAGGTGCCAACAAATATGCCAAGC
AGGTGGAAGTGCAGATGCCAGACAGTCATCTGGCTCAGAGGAACCCAAAGCACCCGCACCTGGGCTGCG
CCTGTGTACAAGCTGGGAAGAATCTGCTGTCACCCCTGACGGTGTGTTGGTGTATCCTGGGAGCAGTG
TGTGGAGGGCTTCTCGTGTGGCATCTCCATCCACCCCTGATGTGGTTATGTTAATAGCCTTCCCAGGGG
ATATACTCATGAGGATGCTAAAATGCTCATTCCTCTAATCATCTCCAGCTTAATCACAGGGTTGTC
AGGCCTGGATGCTAAGGCTAGTGGCCGTTGGGACGAGAGCCATGGTGTATTACATGTCCACGACCATC
ATTGCTGAGTACTGGGGTCATTCTGGCTTGGCTATCCATCCAGGAATCCAAGCTCAAGAACAGCAGC
TGGGGCTGGGAAGAAGAATGATGAAGTGTCCAGCCTGGATGCCCTGGACCTTATTGAAATCTCTT
CCCTGAAAACCTTGTCCAAGCCTGTTCAACAGATTCAAACAGTGAAGAAGTCCTGGTGCACCA
CCGCCAGACGAGGAGGCCAACGCAACCAGCGCTGAAGTCTCTGTTGAACGAGACTGTGACTGAGGTGC
CGGAGGAGACTAAGATGGTTATCAAGAAGGGCTGGAGGTCAAGGATGGGATGAACGTCTAGGTCTGAT
AGGGTTTTTCAATTGCTTTGGCATCGCTATGGGAAGATGGAGATCAGGCCAACGCTGATGGTGGATTTC
TTCAACATTGAAATGAGATTGTAATGAAGTTAGTGTACATGATCATGTTGACTCTCCCTGGGTATCG
CCTGCCTGATCTGTGAAAGATCATTGCAATCAAGGACTTAGAAGTGGTGTCTAGGCAACTGGGGATGTA
CATGGTACAGTGTACATAGGCCATCATCCACGGGGCATTTCTCCCTGGATTTACTTGTAGTG
ACCAGGAAAAACCCCTTCTCCCTTTGCTGGCATTTCCAAGCTGGATCACTGCCCTGGCACCGCTT
CCAGTGTGGAACTTGTGCTCACCTTCGTTGCTGGAAGAAAATCTGGGGATTGATAAGCGTGTGAC
TAGATTGCTCTTCTGTTGGAGCAACCATTAAACATGGATGGTACAGCCCTTATGAAAGCGGTGGCGCC
ATCTTTAGCCAAATGAATGGTGTGCTGGATAGTCTATCACCTCTCAAGCTGAGCTGGATA
CCCTGGCAAGCGTGGCGCGGGCAGTATCCCAGTGGCCGGCTGGTACCATGCTCCTCATCTGACAGC
CGTGGGCTGCCAACAGAGGACATCAGCTTGCTGGTGGCTGGACTGGCTGCTGGACAGGATGAGAACT
TCAGTCAATGTTGTGGGTGACTCTTGGGGCTGGGATAGTCTATCACCTCTCAAGCTGAGCTGGATA
CCATTGACTCCCAGCATCGAGTGCATGAAGATATTGAAATGACCAAGACTCAATCCATTATGATGACAT
GAAGAACACAGGGAAAGCACTTAATCAATGTTGCTATGCTGCACACAACCTGTCATAGTAGATGAA
TGCAAGGTAACTCTGGCAGCCAATGGAAAGTCAGCGACTGCAGTGTGAGGAAGAACCTTGGAAACGTG
AGAAAATAAGGATATGAGTCTCAGCAAATTCTGAATAAAACTCCCCAGCGT

>gi|31543627|ref|NM_004172.2| Homo sapiens solute carrier family 1
(glial high affinity glutamate transporter), member 3 (SLC1A3), mRNA
AGCGGGGTAGTAACCTGCAAGTTCAAGAGCACATGCACTGTCAGGGCTAGCCTGCCCTGCTTACGCCGCC
TGC GGATTGTTGCCGTTGTACCTGCTGGGAATTCAACCTCGTTACTGCTCGATATCTCCACCCCTTA
CAAAATCAGAAAAGTTGTGTTCTAATACAAAGAGGAGGTTGGCTTCTGTTGAGTGTGGGTGATTCCCAGACA
CTGAAGTGCAGGAAAGAGAGACCCCTCTAGAAAAGTAAAATGACTAAAAGCAATGGAGAAGAGGCCAAGA
TGGGGGGCAGGATGGAGAGATCCAGCAGGGAGTCAGTAACGCACACTTTGGCCAAGAACAGGAAAGTGC
GAACATTACAAAGGAGGATGTTAAAGTTACCTGTTGGAAATGCTTGTGCTCACAGTCACCGCT
GTCATTGTTGGTACAATCCTTGATTTACCTCCGACCATACAGAAATGAGCTACCGGGAAAGTCAGTACT
TCTCCTTCTGGGGAACTCTGATGAGGATGTTACAGATGCTGGTCTTACCAACTTATCATCTCCAGTCT
TGTCAAGGAAATGGCGCGCTAGATAGTAAGGCATCAGGGAAAGATGGGAATGGAGCTGTAGTCTATTAT
ATGACTACCACCATATTGCTGTGGTATTGGCATAATCATCCATCTGGGAAGGGCA

EX03-053P

CAAAGGAAAACATGCACAGAGAAGGAAAATTGTACGAGTGACAGCTGCAGATGCCCTGGACTTGAT
CAGGAACATGTTCCCTCAAATCTGGTAGAACGCCTGCTTAAACAGTTAAACCAACTATGAGAAGAGA
AGCTTAAAGTGCCTACCGGCCACGAAACGCTTGTGGGTGCTGTATAAACATGTGTCAGGCCA
TGGAGACTCTTACCGAATCACAGAGGAGCTGGTCCCAGTTCCAGGATCTGTGAATGGAGTCAGGCCCT
GGGTCTAGTTGCTTCATGCTTCGGTTTGTGATTGGAAACATGAAGGAACAGGGGCAGGCCCTG
AGAGAGTTCTTGATTCCTAACGAAAGCCATCATGAGACTGGTAGCAGTAATAATGTGGTATGCCCT
TGGGTATTCTCTCTGATTGCTGGAGATTGTGGAGATGGAAGACATGGGTGATTGGGGGAGCT
TGCCATGTACACCGTACTGTCAATTGTTGGCTTACTCATTACGCAGTCATGCTTGCCACTCCTAC
TTCTTGGTAACACGGAAAACCTTGGGTTTTATTGGAGGGTTGCTGCAAGCAGTCATCACCCTG
GGACCTCTCAAGTTCTGCCACCCATACCTCAAGTGCCTGGAAGAGAACATGGGTGACAA
GCGCGTACCCAGATTCTGTCTCCCGTAGGAGCCACCATTAACATGGATGGACTGCCCTCATGAGGCT
TTGGCTGCCATTTCATTGCTCAAGTTAACAACTTTGAACCTCGGACAAATTATTACAATCAGCA
TCACAGCCACAGCTGCCAGTTGGGAGCTGGAAATTCTCAGGCGGGCTGGTCACTATGGTCATTGT
GCTGACATCTGTCGGCTGCCACTGACGACATCACGCTCATCGCGGTGGACTGGTCTGGATCGC
CTCCGGACCACCAAAACGTAAGTGGGAGACTCCCTGGGAGCTGGGATTTGGAGCACTTGTCAAGCACATG
AACTGAAGAACAGAGATGTGAAATGGTAACTCAGTGAAGAGAACATGAAGAACACATATCA
ACTGATTGCAACAGGACAATGAAACTGAGAAACCCATGACAGTGAACAGATGACTAACATAAG
AAACACTTTCTTGAGGACCAAGGTGTTAAAACATTATAAAATCTTCATCTCATTACAGCTCATCGC
TCCAGCAAGCCCGTCACTTCCCTTCCCTCTGATAAGACTGGAAATAGTCCCTAAAACACAAG
GGAGGATTGGGTGCCAAAGTGTACAATTTCATCCCACAAATTGAAATTAAATCATTTGTTA
GTCTTACCGAATAAGGTACCAAGATCACAAATAGTGTGATCAGATCTACAAAGTTATGTGGCACACAA
TCCTATAATGTGATTTTTATATAAGTTAAAGAGAACAAATAGTAGGCTAAAACATTAAATCAAC
TTTGAAATTAAAATCTTCAGAATACAATTCAAGTTAGTTCAAAATGTTAACAACTTGAAATTACA
ACCGGTTATCAGTTGGACAGTAAGATTATCCCTTCTCTGACTGGTATAACCTATTTCATTAGTAG
CTAGGTGCACATATACATCTAGCACAGCTGTGAGGACAGACAGAAGGCAAAGTTCCATGTGCCCTGAG
CAAGTCCCATCTCACCTCTAGGCTCTAGTGTCTCATCTATAAAATGAGGGACTCCCTAGAAGTCTCA
TGGTCTTCCAGCCAGACATCTGTATGTCATGAAAGCACCTGCCCTGTITCCCTCAGAACACC
CTGTACCATCCATGGAGCACGAGGCCCTCAGAAAAGACACTTCATGGAGTGAACATTCTAACTAAGG
ACAGGATGGCTGTGTGGTACCAGTGTGAGGACAGAAGGCAAAGTGCAGGTATGCAAGTCGCCAGGCAG
GAGGCCATTCCAGGAGTGGGATTATTCAACTCTTGTCCCAGTTCACTCCAAATGGGGAAAGTATTCC
CTTCTTCTACTCTGGGAGAATGTCTCTGCCACTCTCAACTGATGATAGACTCGAAAACAGATGA
GAAGACTAGCAGCTAGCAAGGGTGTGTTGAGTCACACTGTGAAACACTAAAGAGCTAGGAAAGAGTTGAG
CACAGGCAACATTACAAACAAAGGATTGAAAACACCAAGAGTACAGGTCTTCTTAAGGAAGAATAAAA
AAGAAGAGGTTCACTTCTGGCTTTTTTCACTGAAACACTTTTCTCGAGTCCAAAATCATTCCC
CCCGTGAAGTCTGCTTACAAAACATAAGACGACTTATATATTGAAAGAAGTCAAATGAATGAGCTCTC
TAATAGAAGTCCATGAGTTGAGTGGTATTCTTATTTGAAATCCCACCTATCAATCATTCAAAACTTCAGCTGGA
AATGAGGGAAACAAAATATTATTTGAGGAAATCTCAGTCAAGACGCTGAGTGGGAGCTGTGAGGAGT
GTCAATGAGGTTATGAGAAAACAGCAGGGCATTAGTTCAAGGCAAGGCAGCTCCAGGTTAGAGATT
AATTTTACCCCTAAGGAATCTCAGTCAAGACGCTGAGTGGGAGCTGTGAGGAGTACAGCTGTGT
TTGAGTTCTGGCTGAAATGGACTTAATCATGCTAACAAACTGAAAAATCTAGACATAG
ATCCCTGTATACAAATTAGAGATAATTATATAGACCCAAAGCATTCTGTGCAATAAGTTAACATTA
GGCTGTGGTCAGTAACCATTTAATGTGAGGCTTATTCGGAAATACACTACAAATGTTAAAGTACGT
GGCTGTCTCTTAAGACACTAGTAGAGCAAGACTTAATCATCAACTTAATTCTGTTACACAATATGT
GTTTTTTAATATACTAACCATTTCTATGAAAGGTCTGTGGGAGGCCATCATCGCCAAGCCATC
ACAGGCTCTGCATACACATGCACTCAGTGTGACTGGGAAGCATTACTTGTAGATGTTATTTCATG
GAAAAAAATAGTTTACATTAAAAAAAAAAAAAAAAAGAAAAAAAGAAAAAAAGAAAAAAAGAAAAAA

>gi|20070238|ref|NM_006671.2| Homo sapiens solute carrier family 1
(glutamate transporter), member 7 (SLC1A7), mRNA
GGCACGAGGCTGGTCTTACCAACTCCGACCACTGCCCTGCTGAGGGCTAGGCCCTAGGCCAGACCC
TGTCCCCCGGCCGGCTCTCATGCGTGGAAATGGTGTGCCCCCTGCCAGCAGGCCAGGCTACCATG
GTGCCGCATGCCATCTGGCACGGGGAGGGACGTGTGAGGGCAGGCCAGGCTACCATGCGC
TGTCTGTATCGTGGCTGCCCTCGGCTTCTTGTGAGGACCCGGCGCTCTCACACAGGAAATTAG
TTACTTCCAGTTCCCTGGAGAGCTCTGATGAGGATGCTGAAGAGTGTGATGATCTGCCACTGGTGGTCTC
AGCTTGATGTCCGGACTTGCCTCCCTGGATGCCAAGACCTCTAGCCGCTGGGCTCTCACCGTGGC
ACTACCTGTGGACCACCTCATGGCTGTATCGTGGCATCTCATGGTCTCATCCACCCAGGCAG

EX03-053P

CGCGGGCCAGAAGGAGACCACGGAGCAGAGTGGGAAGCCCATCATGAGCTCAGCCATGCCCTGTTGGAC
CTCATCCGAAACATGTTCCCAGCCAACCTAGTAGAAGCCACATTCAAACAGTACCCGACCAAGACCACCC
CAGTTGTCAAGTCCCCAAGGTGGCACCGAGGAGGCCCTCTCGGCGGATCCTCATCTACGGGGTCCA
GGAGGAGAATGGCTCCCATGTGAGAACACTTCGCCCTGGACCTGACCCGCCGCCCCGAGGTCGTTACAAG
TCAGAGCCGGCACAGCGATGGCATGAATGTGCTGGCATCGTCTCTCTGCCACCATGGGCATCA
TGCTGGGCCATGGGTACAGGGGCCCTGGTCAGCTTCTGCCAGTCAGTCCTCAATGAGTCGGTCAT
GAAGATCGTGGCGTGGCTGTGGTATTTCCCTTCGGATTGTGTTCTCATTCGGTAAGATCCTG
GAGATGGACGACCCCAGGGCGTCGGCAAGAAGCTGGCTTCTACTCAGTCACCGTGGTGTGCCGCTGG
TGCTCCACGGGCTCTTATCTGCCCTGCTCTACTTCATCACCAAGAAGAATCCCATCGTCTCAT
CCCGGGCATCTGCAGGCTCTGCATCGCGCTGGCCACCTCCAGTCAGCCACACTGCCATCACC
TTCAAGTCCCTGCTGGAGAACAAACCATCGACCCGGCATCGCTCGCTTCGTCGCTGCCGTTGGTGC
CCATCAACATGGACGGCACTGCGCTACAGGGCTGTGGCGCCATCTCATGCCAGGTCAACAACTA
CGAGCTGGACTTTGGCCAGATCATCACCATCAGTATCACAGCCACTGCAAGCAGCATGGGCGACTGGC
ATCCCCCAGGCCGGCTCGTACCATGGTCATCGTGTACCTCCGTTGGACTGCCACCGATGACATCA
CCCTCATATTGCCGTTGACTGGCTCTGGACCGTTCCGCCACCATGATTAACGTGCTGGGTGATGCC
GGCAGGGGATCATGGCCATATATGTCGAAGGATTGCCCCGGACACAGGCACCGAGAAAATGCTG
CCCTGCAAGACCAAGCCAGTGAGGCTCCAGGAGATCGTGGCAGCCACAGCAGAATGGCTGTGAAGAGTG
TAGCCAGGGCTCCGAGCTCACCTGGGCCCCACCTGCCACCGATCCGGTTCAAGTGGAGCGGG
TGAGGAGCTGCCGCTGCAGTCTGAACCACCTGACCATCCAGATCAGCGAGCTGGAGACCAATGCTGA
GCCCTGCGAGCTGCAGGGGAGGGCTCCAGGGGAGGTCTGAGGCAACTGACTCTCAA
CCCTCTGAGCAGCCGGCAGGGGGCAGGATCACACATTCTCTCACCCCTTGAGAGGCTGAAATTACCC
GCTTGACGGAAATGTATCTCAGAGAAGGGAAAGGCTGATGGGGAGGCCATCCAGGGAGTGTGG
CCGGCATGGCTGAGGCCCGCTGTGACAGTTCCCCGGTGTGAGCCCGTGAGGGCGCAGGAGGG
TATCCGGCCCACCTTCTGGATGACAGACTTGTGAGGCTCTGAGAGCTGAAAACACTTGTCAAAGGTCTC
GTTAAGGTCAAGACACTAACTCAAATCTTCAAGCCCCCTCTCTCTTGAGGAGACAGGGCAGCCTGCA
GCTGTGTCAGGCCAGGGCCAGGGCCACCCATAACAGTGGCTCAGCCACACAGTTCTCCCAAGGGAGCA
GCCCAAGGCCAAGCCCCTGCCCTCCCCAGGCCACAGTGCCTCCAGTCTCTGCCACGTGTT
TTGCAAAGCTCCTGGATGTGGAGACAGATGTCTTACTAGAGCTGAAAGGCCCCCTTGACACATCC
CCAACCTCCATGGAAATAGTAGGCAAGCCAGGACTCCGGAGGGTGCAGCCAGGATGCTCTGGTGG
AGCTGCCATGGGGCCCTGGTGTCAAGACTCCCCAAAGGCCATGCTGCCAGTGGAGTCAGGTTCTA
TTCTTCTGTGTTGCAAATTCAAGTGTAACTAAAGGTATTTGTTCAAAAAAAAAAAAAAAA
AAA

>gi|21314631|ref|NM_003038.2| Homo sapiens solute carrier family 1
(glutamate/neutral amino acid transporter), member 4 (SLC1A4), mRNA
CCCGCACTCTGCCCTCTCCGCCCTTCTCGCACCTGCTCTGCCAGGCCAGGCCGGAGACCCCCGGGGCG
GCTTCCCAGAACCTGCGGAGCACAACACTGGCCGACCGACCCATTCAATTGGGAACCCCGTCTTTGCCAGAG
CCCACGTTCCCTGCCACCTCTAGCTCGGAGGGGGCTGCCCTCCCCAGGCCACAGTGCCTCCAGTCTCTGCCACGTGTT
CTACCTTGACAGCGCTCAGGGGGCTTCTGCCCTCCCCAGGCCACAGCCTGGTGTGCTCACCGTGTGCTCCGGGTGCTGGCG
CGCGTTGCGCGGGCTTCTGCCCTCCCCAGGCCACAGCCTGGTGTGCTCACCGTGTGCTCCGGGTGCTGGCG
CGGGCCTGGCGCGCGTGTGCGCGGGCTCAGCCTGAGCCGACCGCAGGTACCTACCTGGCTTCCCCGG
CGAGATGCTGCCATGCTGCCATGATCATCTGCCCTGGTGTGCTGCCAGCTGGTGTGCTGGCG
GCCCTCCCTGATGCCAGCTGCCCTGCCGCTCTGGCGGCATCGCTGCTGCCACTTGGCTTCAACAC
TGAGTGCCTGCCGCTGCCGTTGGCTTGTGCTCATCAAGCCAGGATCCGGTGCCAGGCCAC
GTCCAGCGACCTGGGGCTGGAGGACTGGGGCTCTCTGTCCCCAAAGAGACGGTGGACTCTTCTC
GACCTGGCCAGAAACCTGTTCCCAATCTGTGGTGTGAGCTTCCGTACGATGCAACCGATTATA
AAAGTCGTGACCCAGAACAGCAGCTCTGGAAATGTAACCCATGAAAAGATCCCCATAGGCACGTGAGATAGA
AGGGATGAACATTTAGGATTGGCTCTGTTGCTCTGGTGTAGGAGTGGCTTAAAGAAAATAGGCTCC
GAAGGAGAAGACCTCATCGTTCTTCAATTCCCTCAACGAGGCACGATGGTGTGGTCTGGATT
TGTGGTACGTACCTGTGGGATCATGTTCTTGTGGAGCAAGATGTTGGAAATGAAAGACATCATCGT
GCTGGTGAACAGCCTGGGAAATACATCTCGCATCTATATTGGGCATGTTATTGAGGAAATTGTT
CTGCCACTTATTTATTTGTTTCAACGAAAAACCCATTCAAGATCTCTCTGGGCCCTCGCCCCAT
TTGCGACAGCATTTGCTACCTGCTCCAGCTAGCGACCCCTCCCTCATGATGAAGTGCATTGAAGAGAA
CAATGGTGTGGACAAGAGGATCAGCAGGTTATTCTCCCATGGGGCCACCGTGAACATGGACGGAGCA
GCCATCTCCAGTGTGTGGCCGGTGTTCATTGCGCAACTCAACAAACGTAGAGCTAACGCAGGACAGA
TTTCACCAATTCTAGTGAATGCCACAGCGTCCAGTGTGGAGCAGCAGGCGTGGCAGCTGGAGGGTCC
CACCATGCCATTATCTGGAGGCCATTGGCTGCCACTCATGACCTGCCCTGATCCTGGCTGTGGAC

EX03-053P

TGGATTGAGGACCGGACCACCGTGGTGAATGTGAAGGGATGCCCTGGGTGCAGGCATTCTCCACC
ACCTGAATCAGAAGGCAACAAAGAAGGCGACAGGAACCTGCTGAGGTGAAAGTGAAGCCATCCCCAA
CTGCAAGTCTGAGGAGGAGACATGCCCTGTTGACACACCAGAACCCCGCTGGCCCCGTGGCCAGTG
CCAGAACCTGGAATCCAAGGAGTCGGTCTGTGATGGGCTGGCTTGGCTTGCCAGCAGTGATG
TCCCACCCGTTACCCAGCCAGTCATGGACACAGGCACTGCCCTGCCAACCTTACCCCTCCAA
GCAATGCTTGGCCAGTCGCTGGCTGAGGCTTACCTCTGGCACTGGCATGGCTCCCCAGCCGGAA
CTGGTTACAAGGACAAGGACACTCTGACATCGCTTGATCCATGTCAGGTGCAACTGTGTACACC
AGGGATCTGTTGGAAACACCCCTGAGCTGCCAGGCTAAGAAATCATGGACTCACAGGGCTGTG
GGTACATCTGGAAAAAAATGCAGATGTATTCACTCTCCCGTCAGCTCTGCATCAGGTGTTCTGA
GCAAACCAAGGGGTTATAGTCATCTGCGATTGCCCTCGAGTTGCACTTAATTGAAAAAAATGCTCAAAT
TCTTAGCCATGGCTGCCCTTGCTGAGCTGGACTCAGGTGTTAAAGAGTTGTGCTATAGCTAGGTG
GGATAGCTCTGATCCCTGGGTTCTGGGAGACTGCAGGTGCCGACATTGTCAGGTTAAAGAGTTAGAAATACTCCAG
GTGGGTTAGCACTGTGGTGTCTGGTCCACAGCCTAGGTAAACAACTTAGATTCTGAGGTCAAAG
AAAAAAAGGAGAGGGAAATGCAGCCTTGTTGGGGAGAAGCAGGGCAGAGGGTCTCTAATCTAACAGGACA
GGACAGGTTCAATAACAATTGCTCCAGTCGCATCCCAGCCCTGGGGACTTTCTGCTTCCCTCCAGA
GGCCTGGGCTCTGATAACACTTGGCTTTCTCCATTACGCTGATTGGCAAAGGCCAGAGATGGG
CCTCTTCCCTGGGAGGTGTGATGTAGTTACATTAGGACCTGTGATTATCATCTATTATTT
GAATTCAACTGGACACTCTGTAAGTGTGCACTGCAGCAAAACAAACCACCAACCCAGAGAAAAA
CCATGTACTAATTGGAGTGGGGTACCCCATTCACAGGTCCCAGGTTCCCTGGCTTGCTGATTTCAA
AATATAGAGCCCTTCTGCCAGTACATCCAAGTTAAATTATCAGCGAAATGGTCCATGTTTCCAA
TTACCTGCTGACAGGTTCTAAGCTAAGTGAAGGGAGATCTGAGAGCCTGTTGATTTGCTGTTGAT
GCATATTCTGATGTAACAGGTCTGGGCTCACTTACCCATTGTAAGGTTGGCTAATGTCACCT
GCCCTTACCTACCTCAGAGGGATTGGTGAAGCAAACGTAAATCTGAAAACGACCATTCACTTCT
TGGATATCAAGTGTAAACCCAGTATGTTCTTCTTTATGTAAGGGACAGCTTGGAGAAAGGACTGCT
CTGTGGAGCAGACTCTGCTGGTGGAGACAGCATTCTGAGCAGGGTTGTTCTATGTCATT
AGGACTTTATCATGCCCTGTTCTGTGTTAGTTACTTGACAGCATCAAATGCCCTCTCCTAATGT
CCTCAAGTTTCTGAACTAGCAACCCACCTCCACCATGGTCTGGCGCTGATTTGCTGACT
CCCAGACCAGCCACTGTTCTGCCACCCCTGTAACAGGCCATTAAAGCTCCCCAGTGTCAAGCCTCC
ACTCCCTGTTTCCCTGTTGCTATGTCACCTGGGCCCTACAGACAGGGCACAGCTTATGGATGTG
TGTACCAATTGAGATGAGAATGGTAGATGGAACGGAGACCATCAAGGCCACACCCCTTCTAAAATGGG
GACATGAGCCTGAGCAGAAAGGGTGAAGAAGAGCCATGGGACACAGAGTTGACCCAGCCAGGGGAAAGC
CCAGCTCTTTAACCCAGCTAACCCATTCCAGTCCTGTGAAGCAAAAGGGACAGGAACCGTGCAA
AGGAAACTGGAAACTTTCCCCGCTGGTAGAGCATGTTGCTGATACTCTCTGTTTCAAGGGAAACAA
TCACATTGTTGATTCAAATGGTAAATGAACACTCACTATTCTCAGGCTTCAGTAAATCTTTTCT
TCCCTCATATATATACACAACACACACATATGTTATCTATACACACATGTGTTGTTGTTGATAT
GCATGTGTGTGTGCTGCTGCTGTTAGCTTCTGCTGAGGCTTCTGTTGATTTCCCATTCTAAAGATGAATT
GGAACTTAACTTAAACTACAAGTTGTTGATGTGCTGTTGCTGTTGATCTGTTCTGTTTCAAGGGAAACAA
CACAAAGCCATAAACCGTGAATAGAGCTGGACTTAAGACTCATGGCCGACATCTGCTGTTGCT
TGGCCCTGAGTAAGAAGCGTGTCTGGGCTGGAGAAGGGCTTCCGAGAGTGTGAGGTGGCCCTTCC
CCTTGGAGGCAGAGAGAGAATGTGCTGTTGCTATCTCTGTTTCAAGTCCACAGACTGGTAGACCA
GGGTTACGTGACTGGGAAATCTCACATCTCTGTTGCTGAAAACATTCCCCGCTGTTCTTCTAA
CATGTTGTTGAAATCTGTTGCTGACTCTGACTGTTGTTGACATGTGACAATGCTTAAAC
CTAGCACAGTCCTAGAAATGAATACCGTGTGTTCCACTGGAAAAAAAAAAAAAA
AAAAAAAAAAAA

>gi|4827011|ref|NM_005071.1| Homo sapiens solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6 (SLC1A6), mRNA
GATAGACCATGAGCAGCCATGGCAACAGCCTGTTCTCGGGAGAGCAGGCCAGCGCTGGCCGGGTGG
CTGGCTGCAGCGCTGCAGGAACGCTGCAGCAGAGACACTGCGCACGCCCTGCCAGACCATG
ACCCCTGAGCACGTCTGCTGCTTCCCTGCCGAAACGCCATTCTGCTGACGGTCAGGCCGTGGTCA
TTGGGGTCAAGCCTGCCCTTGCCCTGCCCATATCAGCTCACCTACCGCCAGATCAAGTACTTCTCTT
TCCTGGAGAGCTCTGATGAGGATGCTGCAGATGCTGGTTACCTCTATTGTCAGGCCCTGGTCACA
GGTATGGCATCCCTGACAACAGGCCACGGGGGAGGGGATGGGGATGCCAGCTGTGACTACATGGTGA
CCACCATCATCGCGGTCTTCATGGCATTCCATGGTACCCATGCCATCCGGGAAGGGCTCAAGGA
GGGGCTGCACCGGGAGGGCCGGATCGAGACCATCCCCACAGCTGATGCCCTCATGGACCTGATCAGAAAT
ATGTTCCACCAAAACCTTGTTGAGGCTGCTTCAACAGTCAAGACGCACTGACAGCACGAGGGTGGTAA
CGAGGACCATGGTGGAGGACAGAGAACGGGCTGAGCCGGGTGCCCTCATGCCCTCCATTCTCAGTGGA

EX03-053P

GAACGGAAACCAGCTTCTGGAAAATGTCACTCGGGCTTGGTACCCCTGCAGGAGATGCTGAGCTTGAG
GAGACTGTACCCGTGCTGGCTCCGCAATGGCATCAACGCCCTGGGCTCGTGGCTTCTCTGTGGCCT
TTGGGCTGGTATTGGTGGCATGAAACACAAGGGCAGACTCTCAGGGACTTCTTCGACAGCCTCAATGA
GGCTATTATGAGGCTGGTGGCATCATTATCTGGTATGCACCTGTGGCATCCTGTTCTGATTGCTGG
AAGATTCTGGAGATGGAAGACATGGCGTCTGGGGGTCACTGGCATGTACACCCCTGACCGTCATCG
TGGGCTGTTCTCCATGCCGCATTGCTTCCCCTCATCTACCTCTCGTACACTACCCGAACCCCTT
CCCCCTCATGGGGCATGCTACAAGCCCTCATCACCGCATGGGCACGCTTCCAGCTGGCAACGCTG
CCCATCACCTCCGCTGCCCTGGAGGAGGGCTGGGTGTGGACCGCCGATCACCAAGGTCGTCCTGCCG
TGGGCGCACGGTCAACATGGATGGCACTGCCCTCTACGAGGCCCTGGCTGCCATTTCATTGCTCAAGT
TAACAACTAGAGCTAACCTGGTCAAGATCACAACCATCAGCATCACGCCACAGCAGCCAGTGGTGG
GCTGCTGGCATCCCCCAGGGGGCTGGTACCATGGTCAATTGTGCTTACGTGGTCGGCTTGCCCACGG
AAGACATCACGCTCATCATGCCGTGGACTGGTCTCTGACCGGCTTCGACAATGACCAACGTACTGG
GGACTCAATTGGAGGCCGTATCAGCACTTGTCTCAGCGGGAGCTGGAGCTTCAGGAAGCTGAGCTT
ACCCCTCCCAGCCTGGGAAACCTACAAGTCCCTCATGGCACAGGAGAAGGGGCATCCGGGACGGG
GAGGCAACGAGAGTGTGAGGGGCTCCAGCTCTG

>gi|31543625|ref|NM_004170.3| Homo sapiens solute carrier family 1
(neuronal/epithelial high affinity glutamate transporter, system Xag),
member 1 (SLC1A1), mRNA
AGCGGAGGAGCCGGGCGCGCTGCCACGCAAACACTACCGGGCTGGCAGGGCGGGCGCGGTGCGCGAT
CCCGGGTGGCGCGGCAACGGCGGTGGTGAACGGCGGCGACTGCAGGGCGGCTCTCACCTCTCCCTGT
GCACCCGATCTCGCCGCGCCGAGCAGCCAGCAGTCCCCGGGTCGCCCAGCCACGCGCGCACGGCC
GAGCCCAGCGACAATAGCGGCACAGCCATGGGAAACCGGGAGGAAAGGATGCGAGTGGAAAGCGCTT
CCTGAAGAATAACTGGGTGTTGCTGTCCACCGTGGCGGGTGTGAGGATTCACACAGGAGTCTTG
GTTCGAGAACACAGCAACCTCTCAACTCTAGAGAAATTCTACTTTGTTCTGGAGAAATTCTAATGC
GGATGCTAAACTCATCATTGCAATTAAATTATATCCACCATGATTACAGGTGTTGCTGCACTGGATT
CAACGTATCCGAAAAATTGGTGTGCGCGTGTGTGATTATTCTGTACCACCTCATTGCTGTTATT
CTAGGTATTGTGCTGGTGGTGAACATCAAGCCTGGTGTACCCAGAAAGTGGTGAATTGCGAGGACAG
GCAGCACCCCTGAAGTCAGTACGGTGGATGCCATGTTAGATCTCATCAGGAATATGTTCCCTGAGAATCT
TGTCCAGGCCTGTTTCAGCAGTACAAACTAAGCTGAAGAAGTGAAGCCTCCAGCGATCCAGAGATG
AACATGACAGAAGACTCCTCACAGCTGTCACTGACAATTCCAAGAACAAAAGGAATACA
AAATTGTGGCATGTATTCAAGATGGCATAAACGCTCTGGCTTGATTGTCTTTGCTTGTCTTGGACT
TGTCAATTGGAAAAATGGAGAAAAGGACAATTCTGGGATTTCTCAATGCTTGAGTGAAC
ATGAAAATCGTTCAAGTCATCATGTGTTATGCACTAGGTATTGTTCTGATTGCTGGGAAGATCA
TAGAAGTGAAGACTGGGAAATATTCCGCAAGCTGGCTTACATGCCACAGCTCTGACTGGCTTG
AATCCACTCCATTGTAATTCTCCCGTGTGATATTCTCATAGCTGTACGAAAGAACCTTCCGATTG
ATGGGAATGGCCCAGGCTCTCCTGACAGCTCTCATGATCTCTCCAGTTCAAGCAACACTGCC
TCCGCTGCTGAAGAAAATAACCAAGGTGGACAAGAGGATCACTGATTGGTGTACCCGTTGGTGAAC
AATCAACATGGATGGGACTGCGCTCTATGAAAGCAGTGGCAGCGGTGTTATTGACAGTTGAATGAC
GACTTGGCATTGGCAGATCATCACCACATCAGTATCAGCCACATCTGCCACGATCGGAGCTGCTGG
TGCCCCAGGCTGGCTGGTGAACATGGTATTGTGCTGAGTGGCGTGGGCTGCCGCCAGGATGTCAC
CTGATCATGCTGACTGGCTCTGGACCGGTTAGGACCATGGTCAAGCTCTTGGTGTGCTT
GGGACGGCATTGTGGAAAAGCTCTCCAAGAAGGAGCTGGAGCAGATGGATGTTCTATCTGAAGTCAACA
TTGTGAATTCCCTTGGCTTGGAAATCCACAATTCTGACAACGAAGACTCAGACACCAAGAAGTCTTATGT
CAATGGAGGCTTGCACTAGACAAGTCTGACACCATCTCATTCAACCCAGACCTCACAGTTCTAGGG
TGGCTGAGATGACTGGAAACAAGGAAGGACATTCTGGTGTAGAGTCACTCTAAACACTGCTTAAGGAAA
GAGAAACACTAATGCCAAGTGTACATTGATTGATATACAGACCTCCAGATTATTCTATATTG
TTCACAGCCTTGGCTCTGGGTTTGGGATTGGGTGTGGGTAAGTTGAAGGGAAATCAATTAAAGG
AAAGTTCTATTATCTGGGTTTGAAGAAATTCTATAAGAGACAAGTTGGAGTACATAAAAGTAATAACTG
TTAGAATTAGGTAATGGATATGAAAGAGAAAATGCTTCTCATGCAAGACAAGTGTGTTGGTTAA
AAAAAATATTCTGTCATTGGTACAAATTCTACTCAGGCTTCTATTGGCATGGATTCTTGTGAC
TCACCTTTTATAAATTATAATGCACTAAACACCTGTCCCCAGTTAATGTGCCAAATGTCAATT
AACTTATCTCCAGCCAATTCAAGAAAACAGACAGCATAGTCTGCAATAACAGTTTAAGATGGCA
TAGGTTGGAAAGAAAGAGAGAAGGATTCTTCAATGACTGTTGAGTGGACGCTGGTAAC
CCAGTGTTCAGCATAGAGCTATATATATATATGTTATTGTTCTATATAATTG
CAGAGATCAGAATTGAACCGTCAATGTGAAATAAGAGTTCTCTTGTACTTGAAATAAAACCAC
CAACCCAGGTCTGCTTGGGCTTATCAGAACTCCTTCTAAGGAGCACTAGAATGAGAAATCATGTTG

EX03-053P

TCGATCGTTCACATCTGTATATCAGCTCTAAAGCAGAGATGTATTATGGTGATACTCCAAGGTGGCATA
GCCATTCACTTACAACCTCCAGATTGAGCTGCCTGGAGGAAATCCATATCAGCTCTGCATAAGATTATA
TACAAAGCTGCACTCACAAAAGGCTGGATGTGTTTCACTCAACTGGAAGGCTTATTCTTCCAAGTTC
ATTCAACTCAAAGAGGCCAGTACTTGCATCCTGCACCTTCTGTATCAGGGCCAAATAACAGTGG
CAAGCTACCAACTAAGTTGATTAAATAAAGATTCCATGGGTTGAACAAGCCACGTTGCAGAAAAAGAG
CTTCCCCCTAACCTGGGTGTTGCAGAGTAAATCCCACGACATAAGCTGGTATCAGTGGTCCGGGGAAAT
AGTICCATCTATGACTCTTGTCTCTCCTCCAGGAGGACTGTTCTAAGTAGTAACTCTTGGCCCTATTCA
TTACATCCTCTGCTGTCACTCTGCTAATTATGAAGATAGTTATTATAGTCTGACTTCAGTCTCAT
CTTGTAAATAATGCTAACATAAACTGTACTTACACTGAAATCCAAAATAGTCATGTTCTGAGTATT
CTGTAGCCAACCTAACCTGTGCTTCACTGTTAACAAATGAGAAATGTGCCAAAGATAGCAGAAGAGT
AGATAAGTGTCACTGATTGACGACCTACATCTGAAATCTAACACATAATGATACTGAATTGTATGAAA
CATCATAAAATAGTAAATAATGATTCAATGTGAATTAAATGCAAATATTGCTATTGTTATAGGAAAT
AAATCTAAATATAAACGAAAAAAAAAAAAAA

>gi|5032092|ref|NM_005628.1| Homo sapiens solute carrier family 1
(neutral amino acid transporter), member 5 (SLC1A5), mRNA
GTAACCGCTACTCCCCGACACCAGACCACCGCCCTCCGTACACAGGGCCGCATCCCACCCCTCCGGAC
CTAAGAGCCTGGGTCCCCCTGTTCCGGAGGTCGCCTCCGGCCCCAGATTCTGGCATCCCAGCCCTCA
GTGTCCAAGACCCAGCAGCCGGTCCCCCGCTCCCGGATCCAGGCGTCCGGGATCTGCGCACCAGAA
CCTAGCCTCTGCAGACCTCCGCATCTGGGGGACTCAACCTCTGGAGGCAAGGGCCACGTCCCAC
CCAGAGAAACTCTGTATTCCAGCTCCCTAGGGCAAGGAACCCGGGCGCTCCGAACCTCCAGCTTCGG
ACATCTGGCACACGGGCAGAGCAGAGAAGCTCAGGCCAGCCTGGGAATTAAACACTCCAGCTTCC
AAGAGCCAAGGAACCTCAGTGTGAACCTACAACACTCTAAAGGAGCCCTCCAAAGTCCAGTCTCAGGT
GCTGTTACTCAACTCAGTCCCTAGGAACGTCGGGTCTGGGAAGGAGCCAAAGCGCTCCAGCCAGCTTCC
AGGCCTAAAGAAACCCGGTGCTTCCCATATGGTGGCCGATCTCCCTCGAGACTCCAAGGGCTCGCAG
CGCGGAGCCCACGCCAACGGGGCCTGGCGCTGGCCTCCATCGAGGACCAAGGCGCCAGCAGGGG
CTACTCGGTTCCCGGACCAGGTGCGCCGCTGCCCTCGAGCCAACCTGCTTGTGCTGCTGACAGTGGTG
GCCGTGGTGGCCGGCGTGGCGCTGGGACTGGGGGTGTGGGGGCGGGGGTGCCTGGCGTTGGGCCCCGG
AGCGCTTGGCGCTTCGTCTCCGGCGAGCTGCTGCGTCTGCTGCGGATGATCATCTTGGCGCT
GGTGGTGTGAGCTTGTATGGCGCCGGCCAGCTGGACCCGGCGCTCGGGCGTCTGGCGCTGGCGCTGG
GGCGCTGCTTTTCTGGTACACGCTGCTGGCGTCCGGCTCGAGTGGCTTGGCGCTGGCTCTGC
AGCCGGGCCGCCCTCCGCCCATCAACGCCCTCCGTGGGAGCCGGCAGTGGCAGGGAAATGCCCGCAG
CAAGGAGGTGCTGATTGCTTCTGGATCTTGCAGAAATATCTTCCCTTCAACCTGGTGTAGCAGCC
TTTCGCTCATACTCTACACACTATGAAGAGAGGAATATCACCGAACCCAGGGTGAAGGTGCCGTGGGG
AGGAGGTGGAGGGGATGAACATCTGGCTTGGTAGTGTGTTGCCATCGCTTGGTGTGGCGTGGGAA
GCTGGGGCTGAAGGGGAGCTGCTTATCGCTTCTTCAACTCTTCAATGAGGCCACCATGGTCTGGC
TCCTGGATCATGTGGTACGCCCTGTGGGACATCATGTTCTGGTGGCTGGCAAGATCGTGGAGATGGAG
ATGTGGGTTACTCTTGGCCCTTGGCAAGTACATTCTGCTGGCTGGCTGGGACATCCATGG
GCTCCTGGTACTGCCCTCATCTACTCTCTTCACTCCACCGGAAACCCCTACCGCTTCTGTGGGGCATC
GTGACGCCGCTGGCACTGCCCTGGGACCTTCCAGTCCGCCACGCTGCCGTGATGATGAAGTGC
TGGAGGAGAATAATGGCGTGGCAAGCACATCAGCGTTCATCTGGCCCATGGGCCACCGTCAACAT
GGACGGTGGCCGCTTCCAGTGCCTGGCCGAGTGTCAATTGCACAGCTCAGGCCAGCAGTCTTGGAC
TTCGTAAGATCATACCATCTGGTACGCCACAGCGTCCAGCGTGGGGGAGCCGGGATCCCTGCTG
GAGGTGCTCTACTCTGGCCATCATCTCGAAGCAGTCAACCTCCGGTGCACCATATCTCTGATCCT
GGCTGTGGACTGGCTAGTCGACCGGTCTGTACCGTCTCAATGTAGAAGGTGACGCTGTGGGGCAGGA
CTCCCTAAAATTATGTGGACCGTACGGAGTCAGAGAAGCACAGAGCTGAGTTGATACAAGTGAAGAGTG
AGCTGCCCTGGATCCGCTGCCAGTCCCCACTGAGGAAGGAAACCCCTCTCAACACTATCGGGGCC
CGCAGGGGATGCCACGGTCGCCCTGAGAAGGAATCAGTCATGTAACCCCCGGGAGGGACCTCCCTGCC
CTGCTGGGGGTGCTTTGGACACTGGATTATGAGGAATGGATAATGGATGAGCTAGGGCTGTGGGG
CTGCTGCCACACTCTGGGAGCCAGGGGCCAGCACCTCCAGGACAGGAGATCTGGGATGCCCTGGCTG
CTGGAGTACATGTGTTACAAGGGTACTCTCTAAACCCCTACGTTCTCACTCATGTCCCCACTCAAGG
CTAGAAAACAGCAACATGGAGAAATAATGTCTGCTGCCACCGTGCACCTGCCCTGGCTGCCCTGG
CTCAGGGAGCAGGTACAGGTACCATGGGAATTCTAGCCCCACTGGGGGAGGGCTGAGGACAAATACCTG
TGGTTATTTGGCGCTGTAGTTGTGGGGGGATGTGTGTCACGTTGTGTGTGTGTGTGTGTGT
TGTGTGTGTGTGTGACCTCTGCCCCATGGTACGTCCCACCCCTGTCCCCAGATCCCCTATTCCCTC
ACAATAACAGAAAACACTCCCAGGGACTCTGGGGAGAGGCTGAGGACAAATACCTGCTGTCACTCCAGAG
GACATTTTTGTGCAATAAAATTGAGTGTCAACTATTAAAAAA

>gi|4507046|ref|NM_003045.1| Homo sapiens solute carrier family 7 (cationic amino acid transporter, y⁺ system), member 1 (SLC7A1), mRNA
CGATCCTGCCGGAGCCCCGCCGCCGGCTGGATTCTGAAACCTTCCCTGTATCCCTCCTGAGACATC
TTTGCTGCAAGATCGAGGCTGTCCTCTGGTGAGAAGGTGGTGGAGGCTTCCCCTCATATTCCAGCTCTGAA
CAGCAACATGGGGTCAAAGTCTGCTCACACATTGGGCAGCAGATGCTGCCGCCGGAAAGGTGGTGGACTGT
AGCCGGGAGGAGACGCCGCTGTCGCCCTGAACACTTTGATCTGGTGGCCCTCGGGGTGGCAGCA
CACTGGGTCTGGTGCTACGTCCTGGCTGGAGCTGTCGGCTGGCCCTGTGCTATGGCAGTTGGTGCTCGGGTC
CTCCCTCTGATCGCTGCCCTCAGTGCTGGCTGGCCCTGTGCTATGGCAGTTGGTGCTCGGGTC
CCAAGACGGGTCAGCTAACCTACAGCTATGTCACCGTTGGAGAGCTCTGGCCCTCATACCGGCT
GGAACTTAACCTCTACATCATCGGTACTTCAAGCGTAGCGAGGGCTGGAGCGCCACCTCGACGA
GCTGATAGGCAGACCCATCGGGGAGTTCTACGGACACACATGACTCTGAAACGCCCGGCTGGCT
GAAAACCCGACATATTGCACTGATCATAATTCTCATCTTGACAGGACTTTAACTCTGGTGTGAAAG
AGTCGGCCATGGTCAACAAATATTCACTTGATTAACGTCCTGGTCTGGGCTTCATAATGGTGTGAGG
ATTTGTGAAAGGATCGGTTAAAACGTCACGGAGGAGGATTGGGAAACACATCAGGCCGTC
TGTGAAACAATGACACAAAAGAAGGGAAAGCCCGGTGTTGGGATTATGCCCTTCGGGTTCTGGT
TCCCTGCGGGGGCAGCGACTTGCTTCTATGCCCTCGGCTTGTGACTGCATGCCACCACAGGTGAAGA
GGTGAAGAACCCACAGAAGGCCATCCCCGTGGGATCGTGGCGTCCCTTGTATGCTTCATGCCCTAC
TTTGGGGTCTGGCTGCCCTCACGCTCATGATGCCCTACTCTGCTGGACAATAACAGCCCCCTGCCG
ACGCCCTTAAGCACGCTGGGCTGGGAAGGTGCAAGTACGCACTGGCGTGGGCTCCCTGCGCTCTTC
CGCCAGTCTCTAGGTTCCATGTTCCATGCCCTCGGTTATCTATGCCATGGCTGAGGATGACTGCTA
TTAAATTCTTAGCAACGTCATGATAGGACAAAACACCAATAATGCCACATTAGCCTGGGTGCCG
TTGCTGCTGTGATGGCCTTCCTTGTACCTGAAGGACTGGTGGACCTCATGTCCTGGCATTGGCA
GGCTTACTCGTTGGTGGCTGCCCTGTGTTGGTCTTACGGTACAGCCAGAGCAGCCTAACCTGGTATAC
CAGATGGCCAGTACTCCGACGAGTTAGATCCAGCAGACACAAAATGAATTGGCAAGCACCACATGATTCC
AGCTGGGGTTTTACAGAGGAGAGATGTTCTTTGAAAACACATCTCACCAACATGGAGCC
TTCCAAAATCTCTGGCTAATTGAACTTCAACCAGCTTATAGCTGTTCTCATCATCACCTCTGC
ATTGTCACCCTGCTTGGAAAGGGAGGCTCTACCAAAGGGCGCTGGCAGTCTTCTGCTCGCAGGGT
CTGCCCTCTCTGTGCCGTGGTACGGCGTACGGCGTACGGCGTACGGCGAGAGCAAGCACCACGCTCATT
TAAGGTTCCCTTCCCTGCCAGTCTCCCCATCTGAGCATCTCGTGAACGTCATCTCATGATGCA
GACCAGGGCACCTGGGCTGGTTGCTGTGGATGCTGATAGGCTCATCATCTACTTGGCTATGCC
TGTGGCACAGCGAGGAGGCGTCCCTGGATGCCGACCAAGCAAGGACTCCTGACGGCAACTGGACCAGTG
CAAGTGACGCACAGCCCCGCCCCCGAGGTGGCAGCAGCCCCGAGGGACGCCAGAGGACCGGGAGG
CACCCCCACCCCTCCCCACCACTGCAACAGAAACCACTGCGTCCACACCTCACTGCA

>gi|4507048|ref|NM_003046.1| Homo sapiens solute carrier family 7 (cationic amino acid transporter, y⁺ system), member 2 (SLC7A2), mRNA
GAATTCCGGCTCTAAATTCTATAGAATCAAGATAGAACCTTATGATGTCACACGAAACTAGCAA
CTGGAATGAAGATAGAACAAAGTGGTTATAACTCAGACAAACTAAATTGTCGAGGGTTATTGGAAACACC
TGCCCCACCGGTTTGGCACANAAAGTTCTCCTGTCGCCCTCGTCAGACGTCAGAATGATTCCCTGCAAGAG
CCGCGTACCTTGGCGATGTCGATCGGAGAAAAATCGTGACCCCTGGACAGCTAGAACACACCAA
ATTATGCCGCTGTTATCCACCATGGACCTCATGGCCCTGGCGTTGGAAAGCACCCCTGGGGCGGGGTT
TATGTCCTCGCTGGGGAGGTGGCAAGGCAGACTCGGGCCAGCATCGTGGTGTGCTTCCCTCATGCTG
CCCTGGCTTCAGTGATGGCTGGCTCTGCTATGCCAATTGGGGCCGTGTTCCAAGACGGGGTCTGC
ATATTGACACCTACGTGACTGTCGGAGAGCTGTGGGCTTCATCAGTGCAATCTCATTTTATCG
TATGTCGATAGGTACATCAAGTGGTCAAGAGCCTGGAGTGGCACCTTGATGAACTCTAACAAACAGA
TTGGTCAGTTTTGAGGACATACTTCAGAATGAAATTACACTGGTCTGCAAGATATCCGATTTTTGC
TGTGTCCTTATATTACTCTAGCAGGTCTTGTCTTTGGAGTAAAGAGTCGTTGGTGAATAAA
GTCTTCAGCTGTTAATTCTCGTCCTCTGTGTTGTGATGGTTGTGCTGGGTTGTGAAAGGAAATGTGG
CAAACGGAAAGATTAGTGAAGAGTTCTCAAAATATACAGCAAGTGCAGAGAGGCCACCTCTGAAAA
CGGAACAAGTATCTATGGGCTGGCTTATGCCCTATGGCTTACGGGAACGTTGGCTGGTCTGCA
ACCTGCTTTATGCCCTTGCGGAGTTGACTGCATTGCAACAACTGGTGAAGAAGTTCGGAATCCCCAGA
AAGCTATTCCCATTGGAAATTGTCAGCTTGTGCTTGTGTTATGGCTATTGGGGTCTCTGCA
TTAACACTTATGATGCCGTACTACCTCTCGATGAAAAAGCCCCCTCTGTAAGCTTGAATATGTG
GGATGGGGCTCTGCCAAATATGTCGTCGCAGCTGGTTCTCTGCGCCCTGTCAACAAGTCCTCTGGGCT
CTATGTTCTTACCCGAATTCTGTTGCCATGGCCGGGATGGCTTACTGTTAGATTCTTGCCAG
AGTGAGTAAGAGGAGTCACCACTGCTGCCACGTTGACTGCAGGGTCAATTGCTTTGATGGCCTT

EX03-053P

CTGTTGACCTGAAGCGCTTGGACATGATGTCATTGGCACACTCATGGCTACTCTCTGGTGGCAG
CCTGTGTTCTCATCCTCAGGTACAGCCTGGTTATCTTACGACCAGCCAAATGTTCTCTGAGAAAGA
TGGTCTGGGATCGTCTCCAGGGAACCTCGAAGAGTGAGTCCCAGGTACCATGCTGCAGAGACAGGGC
TTCAGCATGCGGACCCCTTCTGCCCTTCTGCCAACACAGCAGTCAGCTCTCTCGTGAGCTTTC
TGGTAGGATTCTCTAGTTCTCGTGTGGGCTGAGTGTCTGACCACTTACGGAGTTCATGCCATCAC
CAGGCTGGAGGCCTGGAGCCTCGCTCCTCACGCTGTTCTTGTTCTTCGTTGCCATGTTCTCAC
ATCTGGAGGCAGCCCCAGAACATCAGCAAAAGTAGCCTCATGGTTCCATTCTTACCATTTTGCCAGCGT
TCAGCATTTGGTGAACATTACTTGATGGTCCAGTTAAGTGCAGACACTTGGTCAGATTCAAGCATTTG
GATGGCAATTGGCTTCTGATTTACTTTCTTATGGCATTAGACACAGCCTGGAGGGTCATCTGAGAGAT
GAAAACAATGAAGAAGATGTTATCCAGACAACTGTCATGCAGCAGCAGAAGAAAAATCTGCCATTCAAG
CAAATGACCATCACCCAGAAATCTAGTTACCTTCATATTCCATGAAAAGACAAGTGAATTCTAAC
CTTGCAGGAGCAGAT

>gi|31543640|ref|NM_032803.3| Homo sapiens solute carrier family 7
(cationic amino acid transporter, y⁺ system), member 3 (SLC7A3), mRNA
GCCTGAGCGCCGAACTCGGAGCTCCAACCAACTCGCTTAACCTCCGCCTCACCGAGGCCAGTCCAAG
ACTCTGTGCTCCCTAGGTTGCAACAGCTCTGTATCATCTTCATAATTCTGCTAGGATGCCGTGGCA
AGCATTTCGAGATTGGTCAAAGCTGGTACGCAGACGTACACTGGAGTCAGGCATGGCTGAGACTCGC
CTTGGCAGATGCCCTAACGACCCCTGGATTAGTGGCCCTGGGTGTTGGCAGCACATTGGGTGCAAGGCGTGT
ATGTCTTAGCTGGCAGGTGGCAAAGATAAGCAGGGCATCCATTGTATGCTGCTTTGGTGGCTG
CCTGTCTCTGTTGGCTGGGCTGTGCTATGGGAGTTGGTGCCTGGGTTCCCGTTCTGGTCCGCA
TATCTCTACAGCTATGTCAGTGTTGGGTGAACCTCTGGGCTTCACCACACTGGCTGAAACCTCATCCTCTCC
ATGTCATTGGTACAGCCAGTGTGGCCCGGGCTGGAGCTCTGCTTGTACAACCTGATTGGAACCCAT
CTCTAAGACTCTGCAGGGTCCATTGCACTGCACGTGCCCCATGTCTTGCAAGATAATCCAGATTCTTT
GCTTGGGCTCGTGTGCTGCTACTGGATTGGCTCTCGGGCTAGTGAATGGGCTTACCA
GAGTGTTCACAGGGTGAACCTTTGGTTCTGGGCTCATGATCTGGCTTCTGGCTTAAGGGGAGCT
GCACAACTGGAAGCTCACAGAAGAGGACTACGAATTGGCATGGCTGAACCTCAATGACACCTATAGCTTG
GGTCCTCTGGCTCTGGAGGATTGTGCTTCTGGCTTCGAGGGATTCTCCGGAGCAGCGACCTGTT
TCTATGCATTGTTGGTTCGACTGTATTGTAACCACTGGAGAAAGACCCAGATCCCCAGCGTCCAT
CCCGATGGGCATTGTGATCTCACTGTCTGCTCTGGCTTCTGGCTATTGGCTCTCTGCACTCACC
CTGATGATGCCCTACTACCAGCTCAGCCTGAGAGCCCTTGTGCTGAGGCAATTCTACATTGGATGGG
CTCCCTGCCGCTATGGTGTGGCTGGCTCCCTGTGCTCTTCTACAGCTCTGGCTCCATGTT
CCCCATGCCCTGGGTGATCTACGCATGGCAGAGGATGGCTCTGTTCCGTGACTTGCTCGGATCCAC
ACCGGCACACGCCACCCAAATCATGCCACCGTGGTCTGGCAATTGCACTGGCATTTCGAGCATTCA
TCAAACACTGATCTTGTGGACCTCATGTCATTGGACCTGCTTGTACTCCCTGGTGTGATTG
TGTTCTCATCTCAGGTATCAACCTGATCAGGAGACAAAGACTGGGAAGAAGTGGAGTTGCAAGGAGGAG
GCAATAACTACTGAATCAGAGAAGTGAACCTATGGGACTATTTCACCACTCAACTCCATCCCCACTC
CACTCTGGCAAATTGTCTATGTTGTCCTCATGTCATTGGACCTGCTTGTACTGCTCTTGCTGGT
GCTGGCCCAGTGGTCAGTCCATTGCTTCTGGAGACCTGGTGTGACTGCAGTGGTTGTGCTGCTCC
CTGCTCATTATTGGATCATTGTCATGGAGACAGCCACAGAGCTCCACTCCCCACTTAAAGG
TGCCTGCTTGCCTCCTCCACTAATGAGCATCTTGTGAATATTACCTTATGATGCAGATGACAGC
TGGTACCTGGGCCCATTGGGCTGGATGCTGATTGGCTTGTCTACTCTGGCTATGGGATCCAG
CACAGCTGGAAAGAGATTAAGAGTAACCAACCCCTCACCGAAGTCTAGAGCCAAACTGTA
CCGGCACTCTCATGTCCACTCAGTTGACATCGTCACACCTAAATGCTGCTGGTCCCTGACAATAA
TGGAGAGTACTCCGTACCCAGTGACAGCTAGCCCTCCCTGTATGGTGTGGAGACTAATACAGT
TCTGTACGATGTGAAGGATGTGCTTGTCTATTCTTGCTATTAAACCGCTGCTTCTAAATGATGT
CTAGCTGCTTACCAACTTTAAAAAAATGATATTAAAAGAAAGTAGAAAAAATAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>gi|29789099|ref|NM_018837.1| Homo sapiens similar to glucosamine-6-sulfatases (SULF2), mRNA
GGGCCATTCTGGACAAACAGCTGCTATTTCACTTGAGCCAAAGTTAATTCTCGGGGAGTTCTCGGGCG
CGCACAGGCAGCTCGTTGCCCCCGTGTGAGCTCGGGGTCGCGGCCGGCGCCGCTCTCCAATGGCA
AATGTGTGTGGCTGGAGGCGAGCGCAGGGCTTCGGCAAAGGCAGTCGAGTGTGAGCAGACGGGGCGAG
TCCTGTGAAAGCAGATAAAAGAAAACATTATTAAACGTGTCAATTACGAGGGGAGCGCCCGGCCGGGGCTG
TCGCACTCCCCGCGGAACATTGGCTCCCTCAGCTCCTAGAGAGGAGAAGAAGAAAGCGGAAAAGAGGC
AGATTCACTGCTTCCAGCCAAGTGGACCTGATCGATGGCCCTCCTGAATTATCAGATATTGATTT

EX03-053P

ATTAGCGATGCCCTGGTTGTGTTACGCACACACACACGTGCACACAAGGCCTGGCTCGCTTCCCTC
CTCGTTCCAGCTCTGGCGAATCCCACATCTGTTCAACTCTCGCCGAGGGCGAGCAGGAGCGAGA
GTGTGTCGAATCTCGAGTGAAAGGGACGAGGGAAAAGAAACAAAGCCACAGACGCAACTTGAGACTCC
CGCATCCCAGAAGAACCGACAGATCAGCAAAAAAGAAGATGGGCCCCCGAGGCTCGTGTGCTTGC
TGTCCGCAACTGTGTTCTCCCTGCTGGGTGGAAGCTCGGCTTCCCTGTCGACCCACCGCTGAAAGGCAG
GTTTCAGAGGGACCCAGGAACATCCGCCCCAACATCATCCTGGTGTGACGGACGACCAGGATGTGGAG
CTGGGTTCCATGCAGGTGATGAAACAAGACCCGGCGCATCATGGAGCAGGGCGGGCGCACTTCATCAACG
CCTTCGTGACCACACCCATGTGTCGCCCTCACGCTCTCCATCCTCACCGCAAGTACGTCCACAACCA
CAACACCTACACCAACAATGAGAACTGCTCTCGCCCTCGCAGGACAGCAGAGGCCACCTTT
GCCGTGACCTCAATAGCACTGGCTACCGGACAGCTTCTCGGAAAGTATCTTAATGAATACAACGGCT
CCTACGTGCCACCCGGTGGAGGAGTGGGTGGACTCCTTAAAACCTCCGCTTTATAACTACACGCT
GTGCGGAACGGGGTGAAGAGAACGACGGCTCGACTACTCCAAGGATTACCTCACAGACCTCATCACC
AATGACAGCGTGAAGCTTCTCCGACGTCAAAGAAGATGTACCCGACAGGCCAGTCCATGGTCA
GCCATGCAGCCCCCACGGCCCTGAGGATTAGCCCCACAATATTACCGCCTTCCCAAACGCATCTCA
GCACATCACGCCGAGCTACAACATCGCGCCAACCGGACAAACACTGGATCATGCGTACACGGGGCCC
ATGAAGGCCATCCACATGGAATTCAACCATGCTCCAGCGGAAGCGCTTGAGACCCCTCATGTCGGTGG
ACGACTCCATGGAGACGATTACAACATGCTGGTTGAGACGGCGAGCTGGACAACACGTACATGTTA
CACCGCCGACCACGGTTACCATCGGCCAGTTGGCTGGAAAGGAAATCCATGCCATATGAGTT
GACATCAGGGTCCCGTCTACGTGAGGGCCCCAACGTGGAAGCGCTGTCTGAATCCCCACATGTC
TCAACATTGACCTGGCCCCCACCATCCTGGACATTGCAAGGCCGGACATACCTGGGATATGGACGGGAA
ATCCATCCTCAAGCTGCTGGACACGGAGCGCCGGTGAATCGTTCACTTGAAGAAGAAGATGAGGGT
TGGCGGGACTCCTTCTGGTGGAGAGAGGCAAGCTGCTACACAAGAGAGACAATGACAAGGTGGACGCC
AGGAGGAGAACTTCTGCCCCAGTACCGCGTGTGAAGGACCTGTGTCAGGCTGTGACTACAGGCC
GTGTGAGCAGCTGGACAGAAGTGGCAGTGTGAGGACGCCACGGGAAGCTGAAGCTGCATAAGTGC
AAGGGCCCCTGCGGCTGGCGCAGCAGAGCCCTCTCAACCTCGGCCAAGTACTACGGGAGGCC
GCGAGGCTGCACCTGTGACAGGGGACTACAAGCTCAGCCTGGGGAGCAGCCGGAAAAACTCTTCAA
GAAGAAGTACAAGGCCAGTATGTCGCAGTCGCTCATCGCTCATGGCCATCGAGGTGGACGGCAGG
GTGTACACGTAGGCCGGTGTGCGGCCAGCCCCGAAACCTCACCAAGCGCAGTGGCCAGGGCC
CTGAGGACCAAGATGACAAGGATGGTGGGACTTCAGTGGCACTGGAGGCCCTCCGACTACTCAGCGC
CAACCCATTAAAGTGCACACATCGGTGCTACATCCTAGAGAACGACACAGTCCAGTGTGACCTGGACCTG
TACAAGTCCCTGCAAGGCCGGTGGAAAGACCACAAGCTGCACATCGACACAGGAGATTGAAACCCCTGCA
AAATTAAAGAACCTGAGGGAAAGTCCGAGGTACCTGAAGAAAAAGCGGCCAGAAGAATGTGACTGTCA
AAATCAGCTTACACACCCAGCACAAGGCCGCTCAAGCACAGAGGCTCCAGTGTGACATCCTTCAGGAAG
GGCCTGCAAGAGAACAGGACAAGGTGTGGCTGTTGCGGGAGCAGAAGGCCAGAACACTCCGCAAGCTG
TCAAGCGCTGCAAGAACACGACACGTGCAGCATGCCAGGCCACGTGCTCACCCACGACAACCAGCA
CTGGCAGACGGGCCCTTCTGGACACTGGGGCTTCTGTGCGCTGACCAAGCGCCAACAATAACAGTC
TGGTGCATGAGGACCATCAATGAGACTCACCAATTCTCTTGTGAAATTGCAACTGGCTTCTTAGAGT
ACTTTGATCTCAACACAGACCCCTACAGCTGATGAAATGCACTGAAACACTGGACAGGGATGTCTCAA
CCAGCTACAGTACAGCTCATGGAGCTGAGGAGCTGCAAGGGTTACAAGCAGTGTAAACCCCGACTCGA
AACATGGACCTGGGACTTAAAGATGGAGGAAGCTATGAGCAATACAGGCAAGTTCAGCGTCGAAAGTGGC
CAGAAATGAAGAGACCTTCTCCAATCACTGGGACAACACTGTGGGAAGGCTGGGAAGGTTAAGAAACAA
AGAGGTGGACCTCCAAAAACATAGAGGCATCACCTGACTGCACAGGAATGAAAACCATGTTGGTGA
TCCAGCAGACCTGTCTATTGGCCAGGAGGCCGTGAGAAGCAAGCACCGACTCTCAGTCACATGACAGA
TTCTGGAGGATAACCCAGCAGGAGCAGAGATAACCTCAGGAAGTCCATTGGCCCTGCTTTGCTTGG
ATTATACCTCACCAAGCTGCACAAAATGCAATTTCAGTCAAAAGTCACCAACTACCCCTCCCCAGAA
GCTCACAAAGGAAACGGAGAGAGCGAGCAGAGGAGATTCTGAAATTCTCCCAAGGGCGAAAGTC
ATTGGAATTTTAAATCATAGGGAAAGCAGTCCTGTTCAATACCTCTTATCTTTGGTTGTCA
AAGAAGGAACTAAGAAGCAGGACAGAGGCAACGTGGAGAGGCTGAAACAGTGCAGAGACGTTGACA
GAGTCAGTAGCACAAAAGAGATGACATTCTACGATATAAACCTGGTGTGCTGAAACTGCT
TCATTGTATATATGTGACTATTACATGTAATCAACATGGGAACTTTAGGGGAACCTAATAAGAAATCC
CAATTTCAGGAGTGGTGTCAATAAACGCTCTGTGGCCAGTGTAAAAGAAAAAAAAAAATTGTG
GACATTCTGTTCTGTCCAGATACCATTCTCTTAGTATTCTTGTGTTATGTCAGAAGACTGATGTTT
TTTTTAAGGTACTGAAAGAATGAAGTGTGATGTTGAAACTGTATTTGAA
AAAATTGTAGTTAAGTATTGTCAACAGTGTCAAAACCCAGCCAATGACAGCAGCTGGTATGAA
GAACCTTGACATTGTAAAAGGCCATTCTGGGAAAAA
AAAAAAAA

EX03-053P

>gi|29789063|ref|NM_015170.1| Homo sapiens sulfatase 1 (SULF1), mRNA
GGAGTCTCAGACCTCCAGTTCAAGCCCTGCCCTCAGCTCCAATCGTAAGAGACACCCAGCCCCAGCA
ATTGGATTGGCAGCCGCTTGACACACCCTGTGCTGAGTGCTGAGGACGTGTTCAACAGATGGTT
GGGGTTAGTGTGTCATCACATTGAGTGGGGATTAAGAGAAGGAAGGCTGCCTTGCTGGAGCTGTG
GTCTCTCCAAGTGAGAGTCGCAAGGAACTAGAACACTTGTCTTGAGGAAAGGAGGAATTCAATT
CAGCAGACACAAGAAAAGCAGTTTTTCAGGGATTCTTCACTTCCTTGAGAACAGGAACACTCAG
AGACTAACACAAGGAAGTAATTCTTACCTGGCATTATTAGTCTACAATAAGTCATCCTCTTCA
TGTGACCAGTAATTCTCCCATACTCTGAAGAGAGCATAATTGGAATGGAGAGGTGGTGTGACGGCC
ACCCACCATCTAAAGAAGATAAAACTTGGCAAATGACATGCAGGTTCTCAAGGCAGAATAATTGAG
AAAATCTCAAAAGGACCCATCTGAGATGTCTGAATACCTCTGAGAACAGAGATTGATTATTCAACCA
GGATAACCTAACTCAAGAACCTCAGAAATCAGGAGACGGAGACATTGTCAGTTGCAACATTGGACCA
AATACAATGAAGTATTCTGCTGTGCTGGTTGGCTGTGCTGGGACAGAATTGCTGGGAAGGCCTCT
GTTCGACTGTCAAGATCCCCGAGGTTCAAGAGGACGGATAACAGCAGGAACGAAAAACATCCGACCC
TATTCTGTGCTACCGATGATCAAGATGTGGAGCTGGGTCCCTGCAAGTCATGAACAAAAGAGAAAG
ATTATGAAACATGGGGGCCACCTCATCAATGCCTTGACTACACCCATGTGCTGCCGTACGGT
CTCCATGCTCACCGGAAGTATGTCACAATCACAATGCTACACCAACAAGAGAACTGCTCTTCCCC
CTCGTGGCAGGCCATGATGAGCTCGGACTTTGCTGTATATCTAACAAACACTGGCTACAGAACAGCC
TTTTTGAAAAACCTCAATGAATATAATGGCAGCTACATCCCCCTGGGTGGCGAGAATGGCTTGGAT
TAATCAAGAATTCTGCTTCTATAATTACACTGTTGTCGAATGGCATCAAAGAAAAGCATGGATTG
TTATGCAAAGGACTACTTCACAGACTTAATCACTAACAGAGAGCATTAAATTACTTCAAATGCTAAGAGA
ATGTATCCCCATAGGGCCGTTATGATGGTGTGACGCCACGCTGCGCCCCACGGCCCCGAGGACTCAGGCC
CACAGTTCTAAACTGTACCCCAATGCTCCAACACATAACTCCTAGTTATAACTATGCACCAAATAT
GGATAAAACACTGGATTATGCACTACAGGACCAATGCTGCCCATCCACATGGAATTACAACATTCTA
CAGCGAAAAGGCTCAGACTTGTGATGTCAGTGGATGATTCTGTGGAGAGGCTGTATAACATGCTCGTGG
AGACGGGGAGCTGGAGAAACTTACATCATTTACACGGCCGACCATGGTACCATATTGGCAGTTGG
ACTGGTCAAGGGAAATCCATGCAATGACTTTGATATTGCTGTGCCCTTTTTATTGCTGGTCCAAGT
GTAGAACCGAGGATCAATAGTCCCACAGATCGTTCTCAACATTGACTTGGCCCCACGATCTGGATATTG
CTGGGCTGACACACCTCTGATGTCAGGGCAAGTCTGCTCTCAAATTCTGGACCCAGAAAAGCCAGG
TAACAGGTTCTGAACAAACAAGAAGGCCAAATTGGCTGATACATTCTAGTGGAAAGAGGCAAATT
CTACGTAAGAAGGAAGAATCCAGCAAGAATATCCAACAGTCAAATCACTTGGCCAAATATGAACGGGTCA
AAGAACTATGCCAGCAGGCCAGGTACCGAGACAGCTGTGAACAACGGGGCAGAAGTGGCAATGCAATTGA
GGATACATCTGGCAAGCTTCGAATTCCAAGTGTAAAGGACCCAGTGCACCTGCTCACAGTCCGGCAGAGC
ACGCGAACCTCTACCGCTCGCGCTTCCATGACAAAGACAAAGAGTGCAGTTGTAAGGGAGTCTGGTTACC
GTGCCAGCAGAAGCCAAAGAAAAGTCACCGCAATTCTGAGAAACCAGGGACTCCAAGTACAAGCC
CAGATTGTCATACTCGGAGACACGTTCTTGCTCCGTGCAATTGAGGTGAATATATGACATAAAAT
CTGGAAGAAGAAGAAGATTGCAAGTGTGCAACCAAGAAGAAACATTGCTAAGGCTCATGATGAAGGCCACA
AGGGGCCAAGAGATCTCCAGGCTCCAGTGGTGGCAACAGGGCAGGATGCTGGAGATAGCAGAACG
CGTGGGCCACCTACCAACTGTCAGTGCACACAAAGTGTATTCTTCAAGGAGAATGACTCTACATTGT
GAGAGAGAACTGTACCAATGGCAGAGCGTGGAGAGGACATAAGGCATACATTGACAAAGAGATTGAAG
CTCTGCAAGATAAAATTAAAGAATTAAAGAGAAGTGAAGGACATCTGAGAGAGAAGGAAGGCTGAGGAATG
TAGCTGCAAGTAAACAAAGCTATTACAATAAAAGAAAGGTTAATGAGGAAAGGAAATTAAAGAGCCAT
CTTCACCCATTCAAGGAGGCTGTCAGGAAGTAGATGCAAACACTGCAACTTTCAAGGAGAACACCGTA
GGAGGAAGAAGGAGAGGAAGGAGAAGAGACGGCAGAGGAAGGGGGAGAGTGCAGCCTGCCCTGGCCTCAC
TTGCTTCAGCATGACAACACACTGGCAGACAGGCCGTTCTGGAAACCTGGGATTTCTGTGCTTGC
ACGAGTTCTAACAAACACCTACTGGTTGCGTACAGTTAATGAGGAGCATAATTCTTCTGTG
AGTTGCTACTGGCTTTGGAGTATTGATGAAATACAGATCCTTATGAGTCACAAATACAGTGC
CACGGTAGAACGGCATTGAAATCAGCTACAGTACAACATAATGGAGCTCAGAAGCTGTCAAGGATAT
AAGCAGTGCACCCAAAGACCTAAAGAATCTGATGTTGAAATAAGATGGAGGAAGCTATGACCTACACA
GAGGACAGTTATGGGATGGAGGGAAAGGTTAATCAGGCCGCTCACTGCAGACATCAACTGGCAAGGCC
TAGAGGGACTACACAGTGTGAATGAAAACATCTATGAGTACAGACAAAACATCAGACTTAGTCTGGTGA
CTGGACTAATTACTTGAGGATTAGATAGAGTATTGCACTGCTGAAGAGTCACATGAGCAAATAAA
ACAAATAAGACTCAAACGCTAAAGTGAACGGGTTCTGGTTGCTCTGCTGAGCACGCTGTGCAATGG
AGATGGCCTCTGCTGACTCAGATGAAGACCCAGGCATAAGGTTGGAAAACACCTCATTTGACCTTG
AGCTGACCTCAAACCCCTGCAATTGAAACGGCAGCAACATTAGTCCAGAGAGTAAACTTGAATGGAATAAC
GACATTGCAAGGTTAATCATTGAAATTCTGAAACACTGGAGAAAAACGGAAAAATGGACGGGGCATGAAG
AGACTAACATCTGGAAACCGATTCTGAGTGGCAGTGCAGAGAGCTAGAGCTCGGGGCCAGCCCCAG
GCTGCAGCCCATTGCAAGGCACCCGAAAGAACCTCCCCAGTATGGTGGCTTGGAAAGGACATTGGAA

EX03-053P

GATCAACTATATCTTCTGTGCATTCCGATGGAATTTCAGTTCATCAGATGTTACCCATGGCCACCGCAG
AACACCGAAGTAATTCCAGCATAGCGGGAAAGATGTTGACCAAGGTGGAGAAGAAATCACGAAAAGGAGAA
GTCACAGCACCTAGAAGGCAGGCCCTCTTCACTCTCTGATTAGTGAACACTGTTACCTTACCC
AAACACAGTATTTCTTTAACTTTTATTTGTAACATAAAAGGTAATCACGCCACCAACATTCA
AGCTACCCCTGGGTACCTTGTGCAGTAGAAGCTAGTGAGCATGTGAGCAAGCGGTGTGACACCGGAGACT
CATCGTTATAATTACTATCTGCCAACAGTAGAAAGAAGGCTGGGATATTGGTTGGCTTGGTTTG
ATTTTTGCTTGTGTTGTTGTTGACTAAACAGTATATCTTTGAATATCGTAGGGACATAAGTAT
ATACATGTTATCCAATCAAGATGGCTAGAATGGTCTTCTGAGTGCTAAAACCTGACACCCCTGGTA
AATCTTCAACACACCTCCACTGCCCTGCGTAATGAGTTGATTCAACACTGGAAATTTC
ATGCCGTCACTTCACTGAGTGAATTGCACTTGTGATTAAGGCTATGCTATTGATTAGTCTTA
TTTTTTATTTTACAGGCTTACAGTCTACTGTTGGCTGTCATTGTGACAAGTCAAATAACCCCCA
AGGACACACACAGTATGGATCACATATTGTTGACATTAAGCTTGTCCAGAAAATGTTGCACTGTT
TACCTGACTTGTCTAAAATGATTAGCAGAAAGGCTGGTAATAATGTTGGTGTGAAAATAAATAAAT
AAGTAACAAAAATGAAGATTGCCCTGCTCTCTGTGCCCTAGCCTCAAAGCGTTCATCATACTACACCT
TTAAGATTGCTATTTGGGTTATTTCTTGACAGGAGAAAAGATCTAAAGATCTTTATTTACATCT
TTTTGTTTCTTGCATGACTAAGAAGCTAAATGTTGATAAAATATGACTAGTTGAAATTACACC
AAGACTCTCAATAAAAGAAAATCATGAATGCTCCACAATTCAACATACCAAGAGAAGTAAATTTC
TTAACATTGTGTTCTATGATTATTGTAAGACCTTCACCAAGTCTGTGATATCTTTAAAGACATAGTCA
AAATTGCTTTGAAAATCTGATTCCTGAAAATATCCTTGTGTGATTAGGTTTAAATACAGCTAA
AGGATTACCTCACTGAGTCATCAGTACCCCTCTATTCACTGCTCCAGGATGATGTTGTTTGTCTTACCC
AAGAGAGGTTTCTCTTATTTAGATAATTCAAGTGTCTAGATAAATTATGTTTCTTAAGTGTGTTA
TGGTAAACTCTTTAAAGAAAATTAAATATGTTAGCTGAATCTTTGGTAACTTAAATCTTATCA
TAGACTCTGTACATATGTCCTGAAATTAGCTGCTTGTGATGTGTTGATCATGGTGGGATGACAGAACAA
ACATATTATGATCATGAATAATGTCCTGTTGAAAAGATTCAAGTATTAGGAAGCATACTGTGTT
TTAACATGTATAATATTCCATGATACTTTATAGAACAAATTCTGGCTCAGGAAAGTCTAGAACAAATA
TTCTTCAAAATAAAAGGTTAAACTT

>gi|27597095|ref|NM_173355.1| Homo sapiens uridine phosphorylase-2
(UPase-2), mRNA
GCCGCCGCCACGGGTGAGTGCCAGGGACTTCACCAAGTGTGCCATGCTGGCCCCAGGCTGTGAGTTGG
ACCCAGACCAAGAAGTGGTGGAGGACAAGGCCGTAAGATGTCCTGCTCCCATTCACTTCAACCATGAT
TGTAAGTGTCTGAGGCCCTCCAGCCATGCTCTGTACAGCCTGTGGAACCTGTGACTTTCACTAGTA
GAGAGAATGGCTCAGTTACCTGCTTACTGGATTGATGAGTGAACAGATCTGACAGGAATACATAATGTTGGAA
AAAGGTTGTTACGTTAAACATCTTACTGGATTGATGAGTGAACAGATCTGACAGGAATACATAATGTTGGAA
GGGAACAAAAACACACAACTACCAAGCAATGTTGAGATGTAAGTTGCTGTGTCGGTGGAGGCC
AACAGAAATGAAAGCATTGCACTGTTATGACAAGGAGCTGGGTTGAGGAAGCTGAAGAAGACATAA
AAGACATCTGTGCTGGACAGACAGATACTGTATGTCACAAACCGGGCTGTGCTGCCATCAGTCACGG
CATGGCATCCCTCATTCTATTGCTCATGAACTCATCAAATTACTCCACCATGCACGGTGTG
GATGTCACTTATTAGAATCGGTACATCAGGGAAATAGGATTGCACTGGGACTGTTGTAATAACGG
ATATAGCTGTAGACTCTCTTAAAGCCGGTTGACAGGTCATTGGACAACATTGTCAACCCGAAG
TACTGAACGGACAAAGAAACTGTCTGAAAGAACTGTTCACACTGTAGCAAAGAAATCCCAACTCCCAACC
CTCGTGGACATACAATGTGTAACCTATGATTTTATGAAAGCCAAGGGCACTAGATGGAGCACTGTGCT
CCTTTCCAGAGAAAAAGTTAGACTACTGTGAAAGAGCAATTAAAGCTGGTGTGAGGAATATTGAAAT
GGAATCTACAGTGTGTTGCACTGTGTCAGTGTGACTCTGTGCTTAAAGCTGCTGTGGCTGTGACACTT
CTCGACAGACTGACTGTGATCAACTGCTCATGATGTGCTGGAGTACCGACAGGCC
AGCTCTAAATCTCAACTCATGACAGCGGGTGGACTAGACCTCTAACTGGGAGGCC
AACCTCCCTGCAAGTTGTAAGTGTAAATGTAAGCTTATTTGAGGTTGCACTGAGCATTAAAGCTC
TAGTTCTCATCCACATGCTAAATGAAAGACTTTATGAAATCTCTCTTAAAGGAATTATTGTA
AAAGAAACTCACACTAAATTCAAAATTCTGTTAGAATAAGTTAACTAAATCAGTCAATAATT
AAAATTAAACTCCTGGATTATGACATTGGAGTTTCATATGCAAGCTTAAAGCTC
TAGACCAGCCATTGCACTAGTTACCAAGTCACTCTGTTGAAACCAATCCAGAAATTCACTGTTAGAA
CATTGTCAGGCACTCTAGGTATTGGACAAGTGCAGAAACTGATCATCCATATTCAAAATATTACAGA
AAAAAGTGTCAAGTGAATGTAGGTCTATATGAAAGTACCTAGGAAATATGGCCATACTGCTTT
TTACCCCTGCACTATTTCAGTGCACCACAGAACAGGATTGAGATTACATATGCCCTGTTGATT
TCTCAGAAATATAACAACTCTGGATTACATTTCCTCTCAACTGAAACCCCTCAGTAATGCAAAGAAAGCC
CTTCCTTTCTCAGAATCACAGTACTAAATTGCCCTAGCATTTTCTGTAAAGGAAAGTGT
TTGAGGAGGCTGTATTTCATTCATATTACCAAAATAGGCTGAGAACATTCACTAGCAATTGAA

EX03-053P

TTAAGACTTGAGTCAGATGTTAAAGGAATCCTTGTATGACTTGCCAGACCGGCCTATTGCCCTAC
CCGTTTGTATTCTCTGGGAGGCATGGTGCCTCTGGCTGCACATGCTCTGTGAACGTGATCGCATCTT
GGGTTCTCTCAATTGACATACTTGGGAGTCGGAAATGACTGGATGGGGATGGGTAGAGGATGACTGGC
ACACTTGATAGTATGTAATGTTGTACATATTATTTATGGTTGTGGCTCAAATAAGTTAATTCC
AACACAAAAAAA

>gi|31742506|ref|NM_003364.2| Homo sapiens uridine phosphorylase (UP), transcript variant 1, mRNA
GGTCAGCTGAGTCGCCGGCCCAGGGCAGGGGGCCGAGCCTAGCGGTAAACCCCCGGGCAGGGCGGGG
CCGCTCGCAGACTCCATATGAGATTCACTCCGAGGTGGTCCCTCATCGAGTGCCTCCGGCCACAGAC
CCGCGCCCCGCGTCTCGAGGCCCTCCGAGAGCCGTCCTCGCAGGCGCTCTCGCAGGCCAGTGGGGCCAGAGA
CCGGTGTGCGAGTGCAGGATGGCGCGCGGGTGTAGCGGCTCTCGCAGGCCAGTGGGGCCAGAGA
AGCGAGGAACCTCGCAGCTCGACACGTCTCGTCTCTGTCCAATTCAAGGGCTTGGTAGGGTACTC
GCGGTGCGGGGTGACTCGCCGGCAGGACACTGCCTGGAACGCCCTGGAGCGCCCTCCACTGCAGACGTCTG
TCCGCTCCAGCCGCTCTCTGACGGTCTGCCTCAGTTGGCGGAATGGCGGCACGGGAGCCAATG
CAGAGAAAGCTGAAAGTCACAATGATTGCCCCGTCAAGACTTTAAATCAAACATAGCAAAATGAAAGA
AGATATTCTCTATCATTCAATCTACCACAGCACAAATTCCAGCCTTGGAGATGTGAAG
TTTGTGTGTGTTGGTGAAGCCCCCTCCGGATGAAAGCCTTCATCAGTGCCTGGTAGAGCTGGCC
TTGACTGCCAGGTAGAGACTATCCAAACATCTGTGCGGAACTGACCGCTATGCCATGTATAAAGTAGG
ACCGGTGCTGCTGTCAGTCAGTGTGATGGCATTCCCTCATCTCAATCATGTCATGAGCTCATAAAG
CTGCTGTACTATGCCGGTGTCCAACGTCACATCATCCGATTGGCACTTCTGGTGGGATAGGTCTGG
AGCCCGGCACTGTGGTCAAAACAGAGCAGGCAGTGGATACTGCTTCAGGCAGAGTTGAGCAGATTGT
CCTGGGGAAAGCGGGTCATCCGAAAACGGACCTTAACAAGAAGCTGGTGCAGGAGCTGTTGCTGTGTTCT
GCAGAGCTGAGCGAGTTCACCACAGTGGTGGGAACACCATGTGCACCTTGGACTTCTATGAAGGGCAAG
GCCGTGGATGGGCTCTGTCTACACGGAGAAGGACAAGCAGGGTATCTGGAGGCAGCCTATGC
AGCCGGCTCCGAATATCAGAGATGGAGTCCCTCGGTGTTGCCCATGTGCAGCGCCTGCCCTCAA
GCGGGCGTGGTGTGTCACCCCTCTGAAACGCCCTGGAAAGGGGACAGATCAGCAGCCCTGCAATGTGC
TCAGCGAGTACCGAGGCCGAGCGGCTGGTAGCTACTTCATCAAGAAGAAACTGAGCAAGGCCCTG
AGCGCTGCCCTGCACCTCCGAGACCTGCTGTGATGACTTGCATTAAAAGCATGTCCAATCCCCTG
TTGAGTGGACTTTGAGCACACTTACACAAGAATCTAGAAAATCAGATCGGATTAAGAGACAGAGAATC
TTGGATTAACCGCATGGAGATGTTCTCCTTTGAAGTTCAATTGAGCATTTCATGATGTTAGCCT
GATTTGGGTTCTCAAGAACATTCTACCAAATTGGTACTATTCTAGGGAAATTTCAGACTTTA
AAATTCTAATGGTAGTCAGATTCATGTCATAAACAGAAATCTGACAATAGTGCAGGAAACTAATT
CCTGATAACATTAAAAAAATTCCATGCAAAAAAAAAAAAAAA

>gi|20127508|ref|NM_006834.2| Homo sapiens RAB32, member RAS oncogene family (RAB32), mRNA
GGGGGCCGAGCACTGGCGGGTTCTGGGTCTGTGACCCGTCAGGGGGGTCAAGGGGGGGGGGGAGG
GCTGGCCGGCCTCGGGGAGTTCCGCGGCCGGCCGGGGCGCAGAGCGCGAGGCCGGCAGGGGG
GCCAGACTCGGAGTCAGGCCGCCCCGACAGCCGAGCCCTCATGGGGGGGGAGGCCGGGGACCCG
GCCTGGGGCGGCCGCCAGGCCAGACCCGAGACCCGAGCACCTCTCAAGGTGCTGGTATGGCGA
GCTTGGCGTGGCAAGACAGCATCAAGCGTACGCCACAGCTCTCTCCAGCACTACCGGCC
ACCATGGGGTGGACTTCGCCCTCAAGGTCTCAACTGGGACAGCAGGACTCTGGTGCCTGCAGCTGT
GGGACATCGCGGGCAGGAGCATTGGCACATGACCCGAGTACTACAAGGAAGCTGTTGGCTTT
TGTAGTCTTGATATCAAGAAGTTCCACATTGAGGCAGTCTTAAATGGAAAAGTGATCTGGATAGT
AAAGTTCATCTCCAATGGCAGCCCTATCCCTGTCCTCTTGGTAACAAATGTGACCAGAACAGG
ACAGTAGCCAGAGTCCTCCCAGGTGGACCAATTCTGCAAAGAACATGGCTTGGGAGTGGTTGAAAC
CTCTGCAAAGGATAACATAAACATAGAGGAAGCTGCCGGTTCTAGTGGAGAAGATTCTGTAAACCAC
CAAAGCTTCTAATGAAGAAAAGCATGTGGACAAAATTAAAGCTAGATCAAGAGACCTTGAGAGCAGAGA
ACAAATCCCAGTGGTGTGATATATGGCTTGTCTTGTGTGTCCTCAGCTCTGAAGAAGTTCCT
GAGAATGGGTTACAGATGTGATGTTAGCTGGAGTCTTCCCACATGTGGCACTTCAAAAGGAGCACCAC
TGGGCGCTGCACTTATTGAAAATGGAACCTTGGGAGAAGTATCCCTGCTAGTGGCTCTGTAACCTAAC
AGATGACAATTAGGCTTTGTGATTGTCATGTCAGTGGAGATAATGTTACATCCTTTAAACATT
TTATATGACAATTCTCAGGATTGGTAAGGCTTCAAGTTGTAGCTTGTAGTGTAAAGTGCCTGGGGTGGT
AATTTGTTACCTGCAAAAAAAAAAAAAAA

EX03-053P

>gi|11641236|ref|NM_022337.1| Homo sapiens RAB38, member RAS oncogene family (RAB38), mRNA
GGCTGCCCTTCCCTGGTCAGGCACGGCACGTCTGGCGGGCGCCAGGATGCAGGCCCGCACAAAGGAGCA
CCTGTACAAGTTGGTGATTGGCAGCTGGCGTGGGAAGACAGTATCATCAAGCGCTACGTGCAC
CAGAACTTCTCCTCGCACTACCGGGCCACAATCGCGTGGACTTCGCGCTCAAGGTGCTCCACTGGGACC
CGGAGACTGTGGTGCCTGCAGCTGGGATATCGCAGGTCAAGAAAGATTGAAAACATGACGAGGGT
CTATTACCGAGAAGCTATGGGTGCAATTATGGTCTTCGATGTCAACCAAGGCAAGCCACATTGAAGCAGTG
GCAAAGTGGAAAAATGATTTGGACTCCAAGTAAGTCTCCCTAATGGCAACCGGTTCAAGTGGACCTGAA
TGGCCAACAAATGTGACCAGGGGAAGGATGTGCTCATGAACAATGGCCTCAAGATGGACCAAGTCTGCAA
GGAGCACGGTTCTGTAGGATGGTTGAAACATCAGCAAAGGAAAATAAACATTGATGAAGCCTCCAGA
TGCTGGGAAACACATACTTGCAAATGAGTGTGACCTAATGGAGTCATTGAGCCGGACGTGCGTAAGC
CCCATCTCACATCAACCAAGGTGGCCAGCTGCTCTGGCTGTGCCAAATCCTAGTAGGCACCTTGCTGGT
GTCTGGTAGGAATGACCTCATTGTCACAAATTGTGCTCTATTTTACCATTTGGTAAACGTCAGG
ATAGATATACCACATGTGCAAGCCAAGATCTATGCCCTGTGTTTCATGAGAGAGAAATAGCAAAT
GTTCTTTCTATGCTTCCCTACCATCATCACAGTGTAACTTCAAAACTTTGAAAATATTAGTCGTTACAA
ACTTCTGTATGTAGCTGACCAAATCCTGCAAGGGCACAGTCGGACTGTTATTGCTTCTTTAATCA
GCAAAGGCTCAAGTCTAAAATAAGGGGAGAAGAACAAACTAGCTGTCAAGTCAAGGACTGGCTTTC
ACCTTGCCCTGGTGTCTTTCAAGATTCATATATTCTCTGATGGCTGACAGGCCTATTAAGTAGAT
GTGATATTTCCTCAAGATGACCTCATTCTCGGCAGACCTAAGAGTTGCCCTGTAGTTAGCTCTTGG
AAATCGTAACACAGGTGTGCTATATTGCTCTGTCTAACTGTCACCTGCCATGGCTGAATGTTGGCTT
AACTGAATATTGTATGAAAAGACATGCCCTCATATGTGCTTCTGTAGCTCTTGTACTCAAGCTGT
GGGCTCCTCTATACATGCTATACATGTAATATATATTATATTGCAAGTGAACAATAAACAT
TAAAAGATAAAA

>gi|4506374|ref|NM_003929.1| Homo sapiens RAB7, member RAS oncogene family-like 1 (RAB7L1), mRNA
CCACACTTCCCCTCCCTAAACGACACCCCCGCTAGCCATGGGCAGCCGCACCACCTGTCAAAGTG
CTGGTGGGGGGACGCCAGTGGCAAGACGTCGCTGGTGAGCGATATTCCCAAGGACAGCTCAGCA
AACACTACAAGTCCACGGTGGAGTGGATTGCTCTGAAGGTTCTCAGTGGCTGACTACGAGATAGT
GGGGCTTCAGCTGTGGGATATTGCAAGGCAAGGCGCTTCACCTCTATGACACGATTGTATTATGGGAT
GCCTCTGCCCTGTGTTATTGTTGACGTTACCAATGCCACTACCTCAGCAACAGCCAGAGGTGGAAAC
AGGACCTAGACAGCAAGCTCACACTACCCAAATGGAGAGCCGGTGCCTGCTCTGGCAACAAAGTG
TGATCTGCCCCCTGGGCAGTGAGCCGGGACCAGATTGACCGGTTCAAGTAAAGAGAACGGTTACAGGT
TGGACAGAAACATCAGTCAGGAGAACAAAATAATTAGGAGCTATGAGACTCTCATTGAAAAGATGA
TGAGAAATTCCACAGAAGATATCATGTCCTTGCCACCCAAAGGGACTACATCAATCTACAAACCAAGTC
CTCCAGCTGGCTCTGCTGCTAGTAGTTGGCTTATTTCATCCAGTTCTGGGAGGTCTTTAAGTC
TCTTCCCTTTGGTTGCCACCTGACCAATTATTAAAGTACATTGAAATTGCTCTGACTACTGTCCAGT
AAGGAGGCCATTGCACTTAGAAAAGACACCCATTGGAACCCATGTGCAATTCTGCATCTCTGGATTAGCC
TTTCACATGTTGCTGACTCACATTAGTGCCAGTTAGTGCCTTCGGTGTAAAGATCTCTCATGCCCTCA
ATTGATCCGAATTGTTGAGAAGGATTAGAAATCAGCACCTGGCTTTAGAGATCATAATTCTCAC
CTACTCTGAGCTTATTTCATGAAATTGATATTGCAATTGACTACATGACTTCAATTGAGAGGAAATGAGA
TCAAATGTCATTCCAAATTCTTGAGGCCGTTGTTCAAGATTCTCTGCTTGGAAATGAAACATC
TGATTCTGGAATGCAAGAAGGAGGGCTGGCATCTGGTGGATTGGCTACTAGAAGTGTCCCAGAAGT
CACTGTATTTTGAAACTCTAACGTCTAAAGTTCTCTGCTTGGCATCAAGAATAGTCAGTT
TTTGGCCGGCATGGTGGCTCATGCCCTGAATCCCAGCACTTGGGAGGCCAAGGCAGGGGATCACAT
GAGGCCAGGAATTGGAGACCAACCTGGTCAGCATGGCAAACCCCCGCTCTACTAAAAGTACAAAATTA
GCCAGGGTGTGGCACGTGTAATCCAGCTACTCTGGAGACTGAGGTGGAGAATGCCCTGAGAC
TGGGAGGGAGAGGTTGCAAGTGAACCGAGATCATGCCACCGCACTCAGCCTGGGTGACAGAGAACAGTC
CGTCTCAAAAAAAAAAGAAAAAGAACATAGTCATTAAACTACCTATCTCATGCAATGAAAGCATTTC
TTCCACAAAGAGCTTAATCCTCATGATAGGATTGCCCTAGTGTCTCCATTGCAAGGTTCTGGGTTGATG
CTTTAATGCTATAACTGCAAGTGACATCAGCTGGCTGTGATGCTTCGAAATAGGTCTGCTCTCACAGC
TTTGGGAATCTGAATGGAAGAAGAAAAGAGAGAACGTTAACACCTCCACTGGGCAACTTTGTAACATG
TAGGCACCTAGTCAGGAAACATATTATGTGCAAGGTCTAGGCCCTGGGTAGGAAAGTAGATAGACAGAA
AATCATTAGGTAATTAAAGTACTAAATTGGCAGGGCTTTAGTATCAAATCAGTACTAGACCGTTAA
TTTGTAAATTATCTCTAGGATGGTGAATTATAACCTACCCAAAGTTACGATATTCTTACTAAACTCTG
AGGCCTGAAGTTCTGTGATAGACCTTAAATAAGTGTCTAACGTCAAGTCAAGTGGTTCCAAATCTGCTGGTGG
GAATACCTGGGAAGTTGTTAAAATTTTAAAATGTTAAGATTGGTCTGAGCCAGGGTGG

EX03-053P

TGGCTCACACCTGTAATCCCAGCACTTGGGAGGCTGAGGCAGGTGGATGCCCTGAGGTCAAGGAGTTCAA
GATCAACCTGGCCAACATACTGAAACCCCCCTCTACTAAAAATAAGAAAATTAGCTGGGCGTGGTGGC
GGGCACCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCACTGAACCTGGGAGTTAGAGGTT
GCAGTGAGCTGAGATCACACCATTGCGCTTCAGCCTGGCAACAAGAGTGAACACTCCATCTCC

>gi|8923041|ref|NM_017633.1| Homo sapiens open reading frame 37 (C6orf37), mRNA

ACAACTGCTAAAGCTCCAGAGACAGCAGCGTGTGGCAGCAAGAGCCAGTTCGGGACCAACCGCAGC
TGGGGTGGCAGCGGGCAGGGGGTGCAGGGGGGGAGGGTGGCAGGCAGGGGGCTGGGAAA
GACGAAGTCGCTATTGCTGCTGAGCGCCTCGCAGCTCTGGAAAGTGTGCGCCCTCTCGGTTTCGCT
CTCGCTCGCTCCCTAGAAGGGGGGGCCCTCAGGACTGACCAAGGGCAAGTGGCGCTCGGCGGG
CACTACATGGCGGAGGGTGAAGGGTACTTCGCCATGCTGAGGACGAGCTGGCCTGCAGCCCCAACATCC
CCCTAGGCGCGACTTCGGCGCCGACTTCGGCGCCGACTTCGGCGCCGACTTCGGCGCCGACTTCGGCGCG
CGACTTCGGCGGTGGCGCAGCTCGGTGGGACTATTGCGAAAGCCCTACGGCGACTGC
AATGTGCTGAACGGAGCAAGTGCAGCGGCTGGACGGCATCTGAGTGAGACCATTCCGATTACGGGC
GCGGCAACTTCCCCACGCTCGAGCTGCAGCCAGGCCTGATCGTGAAGGGTGTGCGGCGCCTGGCCGA
GAAGCGCATTGGCGTCCGCGACGTGCGCCTCAACGGCTCGGAGCCAGCCATGCTGCACCAGGACAGC
GGCCTGGCTACAAGGACCTGGACCTCATCTCGGCCACCTGCCGGGGAAAGGGAGTTCAAGACTG
TGAAGGACGTCGTGGACTGCCTGTTGGACTTCTTACCGAGGGGGTGAACAAAGAGAAGATCACACC
ACTCACGCTCAAGGAAGCTTATGTGCAAGAAAATGGTAAAGTGTGCAATGACTCTGACCGATGGAGTCTT
ATATCCCTGTCAAACAAACAGTGGAAAAATGTGGAACGTGAAATTGTGGATTCCCTCCGGAGGCAGTTG
AATTCACTGAGATTCTTCAAATCAAATTAGACTCTCTCTGCTCTTATGAATGTTCAAGAGAACCC
AATGACTGAGACATTCAACCCCCACAATAATCGGGGAGACCGCTATGGCATTTCAGGAAGCCTTTGAT
CACCTTGTAAACAAGATCATTGCCACCAGGAACCCAGAGGAATCCAGGGGGAGGCCTGCTTAAGTACT
GCAACCTTGGTGGGGCTTACGGCCCTCTGATGAAATCAAGGCCCTCAAAGGTACATGTGTT
CAGGTTTTCATCGACTTCAGACATTGGAGAGCAGCAGAGAAAATGGAGTCTATTGAGAAC
TTTGTGGATTGGAAAGACCGCAAGTATGAGTATCTCATGGAGTGTAAATGAGAGCACAG
TGTGCGCTGATGGGACATGAAAGAAGACAGACTTTAAACCTTATCACCAGTGTGGTATCCGGGTGTTAGC
TGACCAAAATGTCAATTCTAAATGTGCTAATGTCACTTGCTATTACAGCCAGCCCCCTATGTAGCAGAT
GCCAACTTACGAAATTACTACATGACAGGTTCAAGCCAGTATTACGTCAGTGCAGAACAGACACTCCA
CTTGGCTACCCCTGCAATTAAAGAATCATTAAAAATGTCTGTGGGAAGCCATTACAGACAAGACAGGAG
AGAAAAAAAAAAAAAA

>gi|8923191|ref|NM_017709.1| Homo sapiens hypothetical protein FLJ20202 (FLJ20202), mRNA

TCTCTCACTCGGTGGCGTGCCTAGGGGCTGTAGAGGTGCGGCCGCTCCTGCTGGGGCTGCCACGCCA
AGGACCTGCCCTGCGCTCCCTCTTCTATTGCCAGTTTCCCCAGCCAGAACATCCCCTGAAGATGGCA
GAGGAGAGCAGCTGACCGGATTGCACTGCTGAGGCAACTTCCAACCTGGAGATAACTCTGAA
ATGAGGTCTCACTGAAAGTTGTACCTATCCACGGACGAGGCAACTTCCAACCTGGAGATAACTCTGAA
GGACATCGTCCAGACCGTCCGCACTCGGCTGGAGGAGGCAGGCATCAAAGTGCACGACGTCCGGCTGAAT
GGCTCCGCACTGGCACGTTGGTCAAAGATAATGGCTGGGCTGCAAAGACCTGGACCTAATCTTCC
ATGTGGCTCTTCAACAGAGGCAAAATTCACTGAGTGGTAGAGATGTGGTCTGTGTTCCCTCTGAACCT
CCTGCCAGAGGGTGTGAACAAGCTAAATCAGTCCAGTCAGTGAAGGAGGCATATGTGAGAAGCTA
GTGAAGGTTTGCACGGACACTGTCCGCTGGAGGCTGATCTCCCTCTCAACAAAGACGGGAAGAACGTGG
AGCTGAAGTTGTCACTCCATTGGCGTCAGTTGAGTTCACTGTGTTGACTCTTCCAATCATCCTGGA
TTCTTGCTTTCTCTATGACTGTTCCAATAATCCAACTCTGAGCACTTCCACCCACCGTGAATTGGG
GAGAGCATGTACGGGACTTTGAGGAAGCTTGACCATCTGCAGAACAGACTGATGCCACCAAGAAC
CAGAAGAAAATCAGAGGCGGGGACTCTCAAGTACAGCAACCTCTGTGCGGGACTTCAGGCCCCACAGA
CCAGGAAGAAAATCAAACAGAGCCTACATGTGCTCCAGGTTCTCATCGACTTCCGGACATCCTT
GAACAGCAGAGGAAGTTGGAGACTTACCTCAAAACACTCGCTGAAGAAGAGAGAAGCAAGTACGACT
ACCTCATGATCTTCGCAAGGGTGGTGAACGAGAGCACCGTGTCTCATGGGGCATGAACGCCAGGCAGAC
TCTGAACCTCATCTCCCTCTGGCTTGTGCTGGCGAACAAACATCATCCCCAGTGCACCAAC
GTCACCTGTTACTACCAGCCGGCCCTACAGTCAGTGAATGGCAACTCAGCAACTACTACGTTGCCCATC
CTCCAGTCACCTACAGCCAGCCTTACCCCTACCTGGCTGCCCTGTAACTAACCTTGAGACCTGAGGGTTTC
CACAGTGGAAACCCCAATAGGGCTAGGGCTCAGGTAGGGAGGCCCTCTAGATGTAGGCATTGG
TTTTAAAGGGAACTCAGCTGATTCTGCTTTTTTTTTCTCTTGTGACCCATTGGAAATGG
TCTACAGTGATCATGAGCCAACCTCAAGGACCGTATTACAGTGCACGTTGGAAAACGCTACAGGA

EX03-053P

AGCATGACCTATCCACATCTTCCAAGATAGACACTAACATGTCATGTCCCACATTAGCACGTGGGG
TTGAGCTCTGTGCAGTAATCGAGATTGGGAGAATTGGCAGCGCGTGAAGTGCTAAAGCTACTTGT
TCTCACTTGAGCCCCGGTAGGCTGTGTTGCCCTCACTTGGGATTCTCAGCAGTTACATGAAAGTTGT
TGATAATCTCTTCTTGTACCAATTAGTCAGGCAGAAAATGGTAAACATGAGGGTGTCTGTGACT
TAATTGGTTCAAGGGACTAAATTGCTTATGTTTATTCCCTGTCAGCGAGTGGAGAATGTCAATTCA
AATAAACCAAAGCCAATAGCTGGAGAATTGAGATCTGGTTGAAAGTGGTTATGGTTACATGCTGT
ATCCTGAGGAATTGGAGAATTGCTGAGGGAAAAAAATGACCTTTCTTGAATGTAACGTGAAAA
CAAAATAAAATGTGGAACATAAAAAAAAAAAAAAA

>gi|16418426|ref|NM_052943.1| Homo sapiens hypothetical protein
MGC16491 (MGC16491), mRNA
GGCACGAGGGTTAGTCGTGCCGTCTGAGGTGTTCCCTGGCTTGTCTCGCCGTGTTGCCGCCCGTCC
CTGCCCTCGTGCCCCCGCCTGGCCCTGCCAGCGCTCTCCCTGTCCTCCCTCCCTTAACCACCCCC
ACGGTTCTGCGTGGGGCCGGGGCCGGGCGGATGATGCCGTGAGAGCGGGAGCTGACGCCAGGG
CCGGCGGCTGTCAGGTGGGACGGCTGCCACGGCGTGGCCACGGCAGCCCCGGCAGGGCGGG
CCCGACCCGGAGGCCTTATGCCCTCCCCGACGGCACCTGAGTGGCTGAGCTGGCCACAGGTGAAGC
GACTGGACGCTTCTGAGCGAGCCATTACGGCGCGCAACTTCCACGGCGCGCAACTTCCACGCTGAGCGT
GCCCCGGCAGATCGTGCAGGTGGTCCGCAGCACCCCTGGAGGAGCAGGGACTACATGTCACAGTGT
CTGCATGGTTCAAGTGTGCCAGGCCACGTGCTGACCCCTGAGAGTGGCTGGGCTACAAGGATCTGGACCTGG
TGTTCGGGTGGACCTGCGCAGTGAGGCATCTTCCAGCTGACCAAGGCAGTGGTGTGGCTGCCTGCCTACT
AAGCTTCCCTGCCGGCCGGTGTAGCCGGGCAAGATCACGCCACTGACACTCAAGGAGGCATACGTGCAG
AAGCTGGTAAAGTGTGCACAGACTGGACCGCTGGAGGCTCATCTCACTGTCCAACAAGAGCGGCAAGA
ACGTGGAGCTCAAGTGTGGACTCGGTGAGAGCAGCTTGAATTAGCATAGACTCCTTCAGATCAT
CTGGACTCCCTGTTGCTCTTGCCAGTGCTCGTCCACTCCATGTCAGGCTTCCACCCAAACGGTC
ACAGGCAGAAAGCCTGTACGGGGACTTCACCGAGGCCCTGGAGCACCTGCCACCGTGTATGCCACGC
GCAGTCCCGAGGAGATCCGAGGTGGTGGCCTCTCAAGTACTGCCACCTCCGGTGGGGCTTCCGGCC
CCGGCCACCGATGTGCGGCCCTGAGCGCTACATGTCCTCCGCTTCTCATGACTTCCAGAC
CTGGTGGAGCAGCGGCCACCCCTAGAGCGCTACCTGGAGGCCACTTCGGTGGGAGATGCAAGCCCGCC
GTTACGCTGCCTGGTACACTGCAACGGGGTGGTCAACGAGAGCACCGTGTGCCTCATGAACCACGAGCG
CCGCCAGACGCTGGACCTCATTGCCACTGCCGTGCAAGGCACTGGTGTGAGCAGGGCCAGCTGCCACT
GCCGCCCTGGCCTGGGCCCTCCAGGCACTGACGGGTTGTGCCAGGCCACTGTCAATTACTACGTGACCC
CCGTGCAACCTCTCTGGCTCACGCCCTATCCACCTGGCTGCCCTGTAAGTCACTGACTCAGACCTGGCCAGA
AGGGAAAGGGACTGGGCCACGGGGTGGGGCTTCAAGAGTGTGTGGAGGACATGACCAAGAGCG
CAGAATGTGCCAGGAGGCCACGCACTGCAAGGGTTGGGCCCTTGATTAACAGACAGACTTCCCGAGCA
CGAGGCCCTGTGGGCTTAATGCCAGGCCCTGGGCTCTCAGGCCAGGGCTTCAGGCCACCTGGTATTGCA
TTTGAGGACAGCATGCCGTGGGGCTGCCAGGCCATTTGCTTGGAAAGTCATTTCTCAGGAGACAAA
GCAAGTTGGGGTGGTAGCCTTAATGCCAGCACCTGGATTTGATTCCTCATGGCTAAGAGGGCTTTT
GACTAAGGCCAGGCTGTGGTGAATCCCAGCAGCTTGGCTCAGGCCACCTGGGCAACTGGGTA
GTATGTTACAGGGACTTGTCACTTTGGATCAGGCTGGGCACTACAGGCCACCTGGGTA
ATCACTGGAGGGAGGAAACTGAGGGCCCGAGGCAGATACTGGGTTGGGGCTGGGTTAGCCCGG
TTCTCTGAACATACCCCCAGCTGTGAAGGCCCTCTGAGGCTGCACTCTTCCCCCTTGTGTTGCA
CCAAGCAGCCCAGGGGGTCGAGGCCAGGCCCTTCAAGGGTGCACCTCTTCCCCCTTGTGTTGCA
AGGAGCCCTCTGCCCTGGAGCTGGTCTTGGAAAGGTGCTGAGCCTGAATTGCCACAGTCAGTCAC
GTTCCCACCCCAGCTGGCTGGTACAGGGCTCTCACATGGGTAGGGGAGCCACTTCCCACCCCTTG
GTATTCCCCCTGGGTTGGTGAATTTTGACTCTTAACACCTGCCAATAAGACGGTCTACACTGAAAA
AAAAAAAAAA

>gi|22749286|ref|NM_152630.1| Homo sapiens hypothetical protein
MGC26999 (MGC26999), mRNA
AGCGGGAAATGTGTGGAGATCAGGTGATGCAGAACTCTGTAAGGATGTTAGTCTTCAGAGTAAGACTGT
TAAATTCAAGCAAAGTCACTATCAGAAGACAGTTTCTGGTTGGTGTATTACTTTATTCACTGATAAT
ATGAAAATTACTATCTTCACTGAAGGATCTACTGAATAATCATTAACTCAACTATATTGCAATTCTTGA
AAGCAATCTTCAATTGATCTACTGACTTCACAATGTCAGGATTCACCAATCTCACTGGGAT
CAAGTTATAACACTGGATCAAGTGTAGATGAAGTAATTCCAATTGAAAGGGAAATTCCCCACAA
TGGAGGTTAAACCAAAAGACATCATTGATGGTGTGAAAGATCAACTCATAGGGCAAGGAATTATTGTTAA
AGATGCCAGATTGAATGGGTTCCGTAGCAAGTTACATCTGCAAGGCCACAATGAACTAGCTATAAGGAT
CTGGACGTTATTTGGTGTGAGCTTCCAGGTAAACGAAGAATTTCAGGTTGTTAAAGATGCAAGTTCTAG

EX03-053P

ACTGTCTACTTGACTTTTACCAAAAGATGTAAGAAGGAAAAGCTCTCCCCAGATATCATGAAAGACGC
TTACGTACAGAAATTGGTCAAGGTTGCAATGGCATGATTGGAGCTTATCTCCCTTCATAAAC
ACTGGGAAGAATTAGAACCTAAATTTGTGACTTCACAGCAGGCCAGTTGAATTAGTAGATTCT
TTCAAAATTGTTGATCCCAGTGTAGACTTCTACAGTGACAAAAATGCCAAGCTAACCAAAGAAC
TCCTGTTGTTAGCTGAAAGCATGTATGGAGACTTCCAGGAAGCAATGACACATTGCAACACAAGCT
ATATGTACCAGGAAACCTGAAGAGATTAGAGGTGGCTCTGAAGTACTGCAGCTTGCTGGTTCATG
GCTTCAGGCCAGCTGTAGTGACTGAAACCTAGAACGTTATATGTGCTCTAGATTCTTATTGA
TTTCCTCATATAGAAGAACAGCAAAAGAAAATTGAATCATACCTCCACAACCATTTCATAGGTGAAGGA
ATGACCAAGTATGACTACCTTATGACCTTGATGGAGTTGTGAATGAAAGCACTGTTGCCTCATGAGTT
ATGAAAGAAGACAGATTCTCACCTGATCACCATGATGGCTTGAAAGTACTGGAGAACTAAATATTCT
ACCCAATACACAAAAGGTAACTTGCTTTTATAGCCTGCTCCGTACTTTGCGAGCTGAGGCAAGGTACCC
ATTTATGTAATACCTGAGCCACCCCCCGTTAGCTTCCAGGCATACCAACCCACTGCACATTGCTGGATCAA
ATGGTATGAGTTAAAAAATACACATGCAACCATAAGAAACTTTGATTAAACACCAATTAAAGCAA
GTTTCCAAATGTAATTCAAGATCTGTTTATTGGTACAGTTACCAATTATTCAATTACAGTT
ATGGAATAGTAGTTACCAACTATTTGATCAATTAGCCTCATAGTAAATACAATATCTATAAAACCAA
CCACTTTAAATGTTTCAACGTTATTGACTAGCTATAAACTTTCAATGTTGTTCCCTTGAAAG
TGATTTCAATCTTTGACTACTTGACTTTCAAAATTACTGTGACAAATATATTAGAGATGCCTGCA
TCTTGACTATAACATAAAAGGACAGATTGTTAAATTAGATGTACAGTGAAGTATCAAATT
TTATATTCACTGAGTTCTTGTACATTAGTTCTTCTATTGAACAATACCATCAATAATGTT
CAGTACTAACAGAAATGCCATTICAAAAGCAACAGATTGAGACATTAAACCTGGACTTTCA
AGCATTTTTTTGACAATTAAATTGGTTGGATACAAAATCCTACTATAGTTAAAGGAATACTGGAA
AAAATGGTCTGGAAAGCCCTGGACATTAGTAATTGTCATCTATATAATAAAACATTAGTTAATTG
TGGATTGAAATAACATACCATACAGCTGCAACTACTGAGATCAGATACAGGGTTTGTGCCCCT
AAAAATAAGTTAAACGAATGAAATGACCAGCTCTGAATGTGAAAGCTTCTATCATCTACTACAA
AGAGACTCTAAATGCCAACAGGAAAAAACAGGCAGAGGTTATAGCCATAGCATTACCATTTATGG
CTTATTGAAAAACATCTTATGTTGAGAACATTCCATTCACTGTAAGTTAAATATTTCATGTAACT
AAATGAAGCAGGTTTCAATTGCTTACAAAGATCATTCTAACATGCCACTCAAGTGCCTCTTC
GTGTGAATTGGTGTGCAACACTATAATTATTCAACAACGTATACCTTACAGTATATCTAAATATATA
CTTACTACATCGAGTACTGCTAGAAAAATCTACCGTGGATTAAAATGTATTCTCCATAATG
AAAATAATTCACTGACCAATTACCTGAGTGTCAAGAGGAGCTGCTTAAATTAAATGGATCAGGC
CATGGAAAATTCAGTATTCCACTTGGTTATGATTGTTGTGAGTTCCATTCACTGTTTATTGACC
ATCACGTTTCTATCACAACATGACCTGACAGTTGTATCCGATAATTGCGAGTTAGACTGTGCTTA
TCTTCACTGTATTACAATATTGGACAGAAGTACACCAAAATGGCATTTCAAATAACCAATTCTGA
GATGTTTATACCAACAGCACAAGTGGCATAGTATTTAAAGAATTATATCACAGAACCCCTGAG
GCTTAAACACTATGGACTTACCACTTCTGACAAAGATTGTAATTACAATAAAATTTAGAAAT
GAAAGGCAAAAAAAAAAAAAAA

>gi|22212711|gb|AAM94374.1|AF497517_1 adenylate cyclase type V [Homo sapiens]
TNAQDQFLKQLVSNLIFSCTNIVGVCTHYPAEVSRQRQAFQETRECIQARLHSQRENQQERLLLSQLP
RHVAMEMKADINAKQEDMMFHKIYIQLHDNVSILFADIEGFTSLASQCTAQELVMTLNELFARFDKLAAE
NHCLRIKILGDCYYCVSLPEARADHAHCCVEMGMDMIEAISLVRVTGVNVNMRVGIIHSGRVHCGVLGL
RKWQFDVWSNDVTLANHMEAGGKAGRHIITKATLNYLNGDYVEPGCGGERNAYLKEHSIETFLIRCTQ
KRKEEKAMIAKMNQRQRTNSIGHNPPHWGAERPFYNHLLGGNQVSKEKRMGFEDPKDKNAQESANPEDEV
EFLGRAIDARSIDRLRSEHVRKFLLTFREPDLKEKKSKQVDRFGAYVACSLVFLFICFVQITIVPHSI
FMLSFYLTCSLLTLVVFVSVIYSCVKLFPSPLQTLSRKIVRSKMNSTLGVFTITLVFLAFVNMFCTN
SRDLLGCLAQEHNISASQVNACHVAESAUNYSLGDEQFCGSPWPNCNFPEYFTYSVLLSLLACSVFLQI
SCIGKLVLMLAIELIYVLIVEVPVGTLDNADLLVTANAIDFFNNGTSQCPEHATKVALVUTPIIIISVF
VLALYLHAQQVESTARLDFWLQLQATEEKEEMEELQAYNRLLHNIPLKDVAAHFLAREERRNDELYYQSC
ECVAVMFASIANFSEFYVELEANNEGVECLLNEIIIAFDDEIISEDRFRQLEKIKTIGSTYMAASGLND
STYDKVGKTHIKALADFAMKLMQMKYINEHSFNNFQMKGIGLNIGPVVAVGIGARKPQYDIWGNTVNAS
RMDSTGVPDRIQVTTDMYQVLAANTYQLECRGVVKVKGEMMTYFLNGGPPLS

>gi|10181096|ref|NP_056085.1| adenylate cyclase 6 isoform a [Homo sapiens]
MSWFSGLLVPKVDERKTAWGERNGQKRSRRRGTRAGGFCTPRYMSCLRDAEPPSPTPAGPPRCPWQDDAF

EX03-053P

IIRRGGPGKGKELGLRAVALGFEDTEVTTAGGTAEVAPDAVPRSGRSCWRRLVQVFQSKQFRSAKLERLY
QRYFFQMNQSSLTLLMAVLVLLTAVLLAFHAAPARPPQPAYVALLACAAALFVGLMVNCNRHSFRQDSMWV
VSYVVLGILAAVQVGALAADPRSPSAGLWCPFFVYIAYTLLPIRMRAAVLSGLGLSTLHLILAWQLNR
GDAFLWKQLGANVLLFLCTNVIGICHTYPAEVSRQAFQETRGYIQARLHLQHENRQERLLSVLPQHV
AMEMKDINTKKEDMMMFHKIYIQKHDNVSILFADIEGFTSLASQCTAQUEVMTLNELFARFDKLAAEH
LRIKILGDCYYCVSGLPEARADHAKHCCVEMGVDMEIAISLREVTVGNVNMVRGIHSGRVHCGVLGLRKW
QFDVWSNDVTLANHMEAGGRAGRIHITRATLQYLNGDYVEPGRGGERNAYLKEQHETFLILGASQKRK
EEKAMLAKLQRTRANSMEGLMPRWPDRASFRTKDSKAFRQMGIDDSKDNRGTDALNPEDEVDEFLSR
AIDARSIDQLRKDHVRRFLLTQREDLEKKYSRKVDPRPGAYVACALLVFCFCIFCIFQLLIFPHSTMLGI
YASIFLLLITVILCAVYSCGSLFPKALQRLRSIVRSRAHSTAVGIFSVLLVFTSAIANMFTCNHTPIR
SCAARMLNLTPADITACHLQQLNYSGLDAPLCETMPTCSFPEYFIGNLLSLLASSVFLHISSIGKLA
MIFVGLIYLVLLLGPPATIFDNYDLLLGVHGGLASSNETFDGLDCPAAGRVALKYMTPVILLVFA
LHQHQVESTARLDFWLQLQATGEKEEMEELQAYNRRLLHNILPKDVAAHFLAREERRDELYQSCECVAV
MFASIANFSEFYVELEANNEGVECLRLNEIIADFDEIISEERFRQLEKIKTIGSTYMAASGLNASTYDQ
VGRSHITALADYAMRLMEQMKHINEHSFNNFQMKIGLNMGPVAVGIGARKPQYDIWGNTVNSSRMDST
GVPDRIQTTDLYQVLAAKGYQLECRGVVKVKGKGEMLTYFLNGGPSS

>gi|4557257|ref|NP_001106.1| adenylyl cyclase 8; Adenylyl cyclase-8,
brain [Homo sapiens]
MELSDVRCLTGSEELYTIHPTPPAGDGRSASRPQRLLWQTAVRHITEQRFIHGHRRGGSGSGGGSGKASD
PAGGGPNHHAPQLSGDSALPLYSLGPGERAHSTCGTKVPERSGSGSASGSGGGDLGFLHLDCAPNSD
FFLNGGYSYRGVIFPTLRSFKSRDLERLYQRYFLGQRRKSEVMNVLDVLTKLTLVLHLSLASAPMDP
LKGILLGFFTGIEVVICALVVVKDTSHTYLQYSGVVTWVAMTTQILAAGLGYGLGDGIGYVLFTLFA
TYSMLPLPLTWAILAGLGTSSLQVILQVVIPIRALVISINQVVAQAVLFMCMNTAGIFISYLSDRAQRQAF
LETTRRCVEARLRLETEENQRQERLVLSQLPFRVYLEMINDMTNVEDEHLQHQFHRUYIHRYENVSILFADV
KGFTNLSTTLQAQELVRMLNELFARFDRLAHEHHCLRIKILGDCYYCVSGLPEPRQDHAHCCVEMGLSM
KTIRYVRSRTKHDVDMRIGIHSGSVLCVGLRKWQFDVWSWDVDIANKLESGGIPGRIHISKATLDCLN
GDYNVEEGHGKERNEFLRKHNIETYLIKQPEDSLLSPEDIVKESVSSSDRRNSGATFTEGWSPELPFD
NIVGKQNTLAALTRNSINLLPNHILAQALHVQSGPEEINKRIEHTIDLRSGDKLREHIKPFSLMFKDSSL
EHKYSQMRDEVFKSMLVCAFIVLLFITAIQSLLPSSRVMPTIQFSILIMLHSALVLITTAEDYKCLPLI
LRKTCCWINETYLARNVIIFASILINFGLGAILNILWCFDKSIPLKLNLTTFNSAVFTDICSYPEYFVFTG
VLAMVTCAVFLRLNSVLKLAFLIMIAIYALLTETVYAGLFLRYDNLNHSGEDFLGTKEVSLLLMMFLL
AVFYHGQQLEYTARLDFLWRVQAKEEINEMKELREHNNEMLRNILPSHVARHFLEKDRDNEELYSQSYDA
VGVMFASIPGFADFYSQTEMNNQGVECLRLNEIIADFDELLGEDRFQDIEKIKTIGSTYMAVSGLSPEK
QQCEDKWGHLCALADFSALTESIQUEINKHSFNNFELRIGISHGSVAVGIGAKPQYDIWGKTVNLASR
MDSTGVSGRIQVPEETYILKDQGFADYRGEIYVKGISEQEGKIKTYFLLGRVQPNPFILPPRRLPGQY
SЛААВЛГЛВQSLNRQRQKQLLNENNNTGIKGHYNRRTLLSPSGTEPGAQAEGTDKSDLP

>gi|7661962|ref|NP_055585.1| centaurin, gamma 1; centaurin gamma 1;
phosphoinositide 3-kinase enhancer; Arf GAP with GTP-binding protein-
like, ANK repeat and PH domains 2; GTP-binding and GTPase activating
protein 2 [Homo sapiens]
MHAQRQFVVAAVRAEVRRHEVAKQALNRLRKLAEVDDPELQDSIQASLDSIREAVINSQEWTLSRSIPE
LRLGVLGDRASGKSSLIHRFLTGSYQVLEKTESEQYKEMLDGQTHLVLIREEAGAPDAKFGWADAVI
FVFSLEDENSFQAVSRLHGQLSSLRGEGRGLALALVGTQDRISASSPRVVGALARALCADMKRCSYYE
TCATYGLNDRQFQEVAKVVTLRKQQQLAAACKSLPSSPSHSAASTPVAGQASNGGHTSDYSSSLPSSF
NVGHRELRAAAAAGLSTPGSLHRAAKRRTSLFANRRGDSEKRSLSRGETTGSGRAIPIKQSFLLKR
SGNSLNKEWKKYVTLSSNGFLYHPSINDYIHSTHGKEMDLLRTTVKPGKRPRAISAFGPSASINGL
VKDMSTVQMGEGLEATTPMPSPSPSLQPPPDQTSKHLKPDRNLARALSTDCTPSGDLSPSLREPPP
SPMVKKQRRKKLTPSKTEGSAGQAEENFEFLIVSSTGQTWHFEAASFEERDAWVQAIQESQILASLQCC
ESSKVKLRTDSQSEAVAIQAIRNAKGNSICVDCGAPNPTWASLNGLALICIECGIHRNLGTHLSRVRSL
DLDDWPRELTLVLTAGNDTANRVWESDTRGRAKPSRDSREERESWIRAKYEQLLFLAPLSTSEEPLGR
QLWAAVQAQDVATVLLLAHARHGPLDTSEDPQLRSPLHAAELAHVVITQLLLWYGADVAARDAGRT
ALFYARQAGSQLCADILLQHGCPGEGGSAAATPSAATPSITATPSRRSSAASVGRADAPVALV

EX03-053P

>gi|7662484|ref|NP_055729.1| centaurin, gamma 2; Arf GAP with GTP-binding protein-like, ANK repeat and PH domains 1; GTP-binding and GTPase-activating protein 1 [Homo sapiens]
MNYQQQLANSAAIRAEIQRFESVHPNIYSIYELLERVEEPVLQNQIREHVIAIEDAFVNSQEWTLSRSP
ELKVGIVGNLASGKSLAVHRYLTGTYVQEESPEGGRFKKEIVVDGQSYLLIRDEGGPPEAQFAMWDAV
IFVFSLEDEISFQTVYHYSRMANRNTSEIPLVLVGTQDAISSANPRVIDDARARKLSNDLKRCYYET
CATYGLNVERVFQDVAQKIVATRKQQLSIGPCKSLPNSPSHSSVCSAQSAVHSQTSNGGSSLSDYSS
SVPSTPSISQKELRIDVPPANTPTPVRKQSRRSNLFTSRKGSDPDKEKKLESRADSIGSGRAIPIKQ
GMLLRSGKSLNKEWKKKVTLCDNGVLTYHPSLHDYMQNVHGKEIDLRTTVKPGKRPPRATSACAPI
SSPKTNGLSKDMSSLHISPNSDTGLGDSVCSSPSISSTTPSKLDPPPSPHANRKHHRRKKSTSNSFKADGL
SGTAEEQEENFEFIIVSLTGQTWHFEATTYEERDAWQAISEQILASLQCESSKNSRLTSQSEAMALQ
SIRNMRGNSHCVDCTQNPNWASNLGALMCIECGIHRNLGTHLSRVRSLDLDDWPIELIKVMSSIGNE
LANSVWEESSQGRTPKPSVDSTREEKERWIRAKYEQKLFLAPLPCTELSLGQHLLRATADEDLRTAILLA
HGSRDEVNETCAGEGDGRTALHLACRKGNVVAQLLIWYGVDTARDAGNTALAYQASSQECIDVLLQ
YGCPCDERFVLMATPNLSRRNNNNRNNSGRVPTII

>gi|16799069|ref|NP_114152.2| centaurin, gamma 3; MRIP-1 protein [Homo sapiens]
MFHQAGGGQSPQQQQQLAGGPPQQFALSNSAAIRAEIQRFESVHPNIYAIYDLIEREDLALQNQIREHV
ISIEDSFVNSQEWTLSRSPPELKVGIVGNLSSGKSALVHRYLTGTYVQEESPEGGRFKKEIVVDGQSYLL
LIRDEGGPPELQFAAWVDAVVFVFSLEDEISFQTVYNYFLRLCSFRNASEVPMLVGTQDAISAANPRVI
DDSRARKLSTDLCRKYETCATYGLNVERVFQDVAQKVVALRKQQLAIGPCKSLPNSPSHSAVSAASI
PAVHNQATNGGSAFSYSSSPSTPSISQRELRIETIAASSTPTPIRKQSKRRSNIFTSRKGADLDRE
KKAEECKVDSIGSGRAIPIKQGILLKRSGKSLNKEWKKVYTLCDNGLLTYHPSLHDYMQNIHGKEIDL
RTTVKPGKRLPRATPATAPGTSRANGLSVERSNTQLGGGTGAPHASSASLHSERPLSSAWAGPRPE
GLHQRCSCVSSADQWSEATTSLEPPGMQHPASGPRAEVLSSSPKLDPPPSPHSNRKHHRRKKSTGTPRDGP
SSATEEAEESFEFVVVSLTGQTWHFEASTAEERELWVQSVQAQILASLQGCRSAKDTRLGQNAALAVQ
AVRTVRGNSFCIDCDAFPNDWASLNLCALMCIECGIHRHLGAHLSRVRSLDLDDWPPELLAVMTAMGNA
LANSVWEAGLGGYSKPGPDACREEKERWIRAKYEQKLFLAPLPSSDVPLGQQLLRAVVEDDLRLLVMLLA
HGSKEEVNETYGDGDGRTALHLSSAMANVFTQLLIWYGVDRSRDARGLTPLAYARRAGSQECADILIQ
HGCPGEGCGLAPTPNREPANGTNPSAELHRSPSLL

>gi|5453840|ref|NP_006377.1| DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 isoform 1; probable RNA-dependent helicase p72 [Homo sapiens]
MRGGGGFGRDRDRDRGGFGARGGGGLPPKKFGNPGERLRRKKWDLSELPKFEKNFYVEHPEVARLTPYEV
DELRRKKEITVRGGDVCVKPVPFAFHANFPQYMDVLMQHFTEPTEPIQCQGFPLALSGRDMVGIAQTGS
GKTLAYLLPAIVHINHQPYLERGDGPICLVLAPTRELAQVQOVAADDYKGCSRALKSTCIYGGAPKGQIR
DLERGVIEICIATPGRLIDFLESQGKTNLRRCTYLVLDEADRMLDMGFEPOQIRKIVDQIRPDRQTLMSATW
PKEVRQLAEDFLRDYTQINVGNLELSANHNIQIVDVCMESEKDHLIQLMEEIMAENKTIIIFVETKR
RCDDLTTRMRRDGWPAMCIHGDKSQPERDWLNEFRSGKAPILIATDASRGLDVEDVKFVINYDYPN
EDYVHRIGRTARSTNKGTAYTFPGNLKQARELIKVLEEAQINAQPKLQLVDHGGGGGGGRSRYRT
TSSANNPNLMYQDECDRRLRGVKDGGRRDSASYRDRSETDRAGYANGSGYGSNSAFGAQAGQYTYGQGT
YGAAAYGTSSYTAQEYAGTYGASSTTSTGRSSQSSQQFSGIGRSGQQPQPLMSQQFAQPPGATNMIGY
MGQTAYQYPPPPPPPSRKK

>gi|4758138|ref|NP_004387.1| DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; DEAD box-5 [Homo sapiens]
MSGYSSSDRDRGRDRGGFAPRFGGSRAGPLSGKKGFGNPGEKLVKKWNLDLPLKFEKNFYQEHPDLARRTA
QEVE TYRRSKEITVRGHNCPKPVLNFYEANFPANVMDVIARQNFTPTAIQAOQGPVALSGLDMVGVAQT
GSGKTLSYLLPAIVHINHQPYLERGDGPICLVLAPTRELAQVQOVAEYCRACRLKSTCIYGGAPKGQ
IRDLERGVIEICIATPGRLIDFLECQGKTNLRRCTYLVLDEADRMLDMGFEPOQIRKIVDQIRPDRQTLMSA
TWPKEVRQLAEDFLDYIHNIGALELSANHNIQIVDVCHEKDEKLIRLMEEIMSEKENKTIVFET
KRRCDELTRKMRRDGWPAMGIHGDKSQQERDWLNEFKHGKAPILIATDASRGLDVEDVKFVINYDYPN
SSEDYIHRIGRTARSTKGTAYTFFTPNNIKQVSDLISVLREANQAINPKLLQLVEDRGSGRSRGGMK
DDRRDRYSAGKRGGFNTFRDRENYDRGYSSLLKRDGFAKTQNGVYSAANYTNGSGFSNFVSAGIQTFSRT
GNPTGTYQNGYDSTQQYGSNVPNMHNGMNQQAYAYPATAAAPMIGYPMPTGYSQ

EX03-053P

>gi|8922581|ref|NP_060643.1| hypothetical protein FLJ10665 [Homo sapiens]
MKAEGPPHEGPLQGLVASRIETYGRHRASAQSTTGRLYPRGYPVLDPSRRRLQQYVPFARGSGQARGLS
PMRLRDPEPEKRHGGHVAGLLHSPLKELTKAHELEVRLHTFSMFGMPRLPPEDRRHWEIGEGGDSGLT
IEKSWRRELVPGHKEMSQELCHQQEALWELLTELIVYRKLIKIMTDLLAAGLLNLQRVGLLMEVAETLFG
NVPSLIRTHRFSFWDEVLGPTLEETRASGQPLDPIGLQLQSGFLTFQRFHPYVQYCLRVKQT MAYAREQQET
NPLFHAFVQWCEKHKRSRGQMLCDLLIKPHQIRITKYPLLHLHAVLKRSPEARAQEALNAMIEAVESFLRHI
NGQVRQGEEQESLAAAQRIGPYEVLEPPSDEVEKNLRPSTLDLTSPMLGVASEHTRQLLLEGPPVRVKE
GREGKLDVYLFLFSDVLLVTKPKQRKADAKAKVIRPPLMDKLVCQPLRDPNSFLLIHLTEFQCVSALLVH
CPSPPTDRAQWLKEQTQQAQAAQKQLKAEEYVQQKRELLTLYRDQDRESPSTRPSTSLEGSQSSAEGRTP
FSTIIPLHVVTDEDAPLPVDTSDDSGYGTLPGPTGSRSPLSRLRQRALRRDPRLTFSTLELRDIP
LRPHPPDPQAPQRSAPELPEGILKGGLSPQEDPPTWSEEDGASERGNVVVETLHRARLQGQLPSSPTH
ADSAGESPWESSGEEEEEGPLFLKAGHTSLRPMAEDMLREIREELASQRIEGAEEPRDSRPRKLTRAQL
QMRMGPPIIQLDTPLSASEV

>gi|29728516|ref|XP_030970.8| similar to hypothetical protein FLJ10665
[Homo sapiens]
MNSVLTKHGSPRSWLSCLSGTDDQSPAEEKGLRCQNAPACMDKGRAAKVCHADCQQLHRRGPLNLCEAC
DSKFHSTMHYDGHVRFDLPPQGSVLARNVSTRSCPRTSPAVIDLEEEEESVDGKGDRKSTGLKLKSKKK
ARRRHTDPSKECFTLKFDLNVDIETEIVPAMKKKSLGEVLLPVFERKGIALGKVDIYLDQSNTPLSLTF
EAYRGGGHYLRVKAPAKPGDEGKVEQGMKDSKSLSLPILRPAGTGPPALERVDAQSRRESLDILAPGRRR
KNMSEFLGEASIPGQEPPTPSSCSLPSSGSSNTGDSWNRAASRFSGFFSSGPSTSAGFREVDKMEQL
EGKLHTYSFLGQLPRLPRGLRFHDSEEEYDEDEDENACRLREDSWRELIDGHEKLTRRQCHQQEAVWE
LLHTEASYIRKLRVIINFLCCCLNQLQESGLCEVEAERLFSNIPETIAQLHRRLWASVMAPVLEKARRTR
ALLQPGDFLKGFKMFGLPKPYIYRCMEEGCMEMYMRGLRNDLFRAYITWAEEKHPQCQRLKLDMLAK
PHQRLTKYPLLKSVLRKTEEPRAKEAVVAMIGSVERFIHHVNACMRQRERQRQRLAAVVSRIDAYEVVES
SSDEVDKLKEFLHLDLTAPIPGASPEETRQLLLEGSLRMKEGKDSDMVYCFLFTDLLLVTAKVKAER
TRVIRPPLLVDKIVCRELDPGSFLLIYLNEFHSAVGAYTFQASGQALCRGWVDTIYNAQNQLQQLRAQE
PPGSQQPLQSLEEEDEQEEEEEEEEEEDSGTSAAASSPTIMRKSSGSPDSQHCASDGSTETLAMVV
VEPGDTLSSPEFDSPGFSSQSDETSLSATTASSATPTSELLPLGPVDRGRCSMDSAYGTLSPTLSQDFVAP
GPMAELVPRAPESPVPSPPPSPRLRRRTPVQLLSCPPHLLSKSEASLLQLLAGAGTHGTPSAPSRSLS
ELCLAVPAPGIRTQGSPQEAGPSWDRCGAPSPGSGPGLVGLAGEPAGSHRKRCGDLPSGASPRVQPEPP
PGVSAOHRKLTALQYRIRTTLLNSTLASEV

>gi|8923496|ref|NP_060334.1| hypothetical protein FLJ20530 [Homo sapiens]
MAAFLNVCLGLEDLQYVFMISSEHLFITLLKDEERKLLDQMQRKRSRPNLICKPVTFSFYDIPASASVN
IGQLEHQILSVDPWRIRQILIELHGMTSERQFWTVSNKWEVPSVYSGVILGIKDNLTSDLVYILMAKGL
HCSTVKDFSHAKQLFAACLELVTEFSPKLRQVMLNEMLLDIHTHEAGTGQAGERPPPSDLISRVRGYLEM
RLPDIPRLRQVIAEECVAFMLNWRENEYLTLOQPAFLQSNSPVVKLGQLLAATCKELPGPKESRTAKDLW
EVVVQICSVSSQHKRGNDGRVSLIKQRESTLGIIMYSELLSFIKKLREPLVLTLIILSLFAKLHNVRDIV
NDITAEHISIWPSSIPNLQSVDFEAIVTKEVLYRTLSINPMNNHSWLIIQADIYPATNQSYAALHYYLQ
AGAVCSDFFNKA VPPDVYTDQVIKRMKCCSLLNCHTQVAILCQFLREIDYKTAFKSLQEQN SHAMD SY
YDVLTWDTVIILEYLTLYHHKRGETDKR OIAIKAIGOTELNASNPEEV LQLAAQRKKKF LQAMAKLYF

>gi|4557601|ref|NP_000798.1| gamma-aminobutyric acid A receptor, alpha 2 precursor [Homo sapiens]
MKTKLNIYNIEFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPGLGDSITEVF
NIYVTSGPVSQDTMNEYTIDVFFRQWKDERLKFKGPMNILRLNNLMASKIWTPTFFFHNGKSVAHNM
MPNKLLRIQDDGTLLYTMRLLTVQAECPMHLEDFPMDAHCSPLKFGSYAYTTSEVTIWTYNASDSVQVAP
DGSRLNQYDLLGQSIGKETIKSSTGEYTVMTAHFLKRKIGYFVIQTYLPCIMTVLSQVSFWLNRESVP
ARTVFGVTTVLMTTLSISARNSLPKVAYATAMDWFIAVCYAFVSALIEFATVNYFTKRGWTWDGKS
NDKKKEKASVMIQNNAYAVAVANYAPNLSKDPVLSTISKATTPEPNKKPENKPAEAKKTFNSVSKIDRM
SRIVFPVLFGTENLWVATYLNREPVLGVSP

>gi|4503861|ref|NP_000801.1| gamma-aminobutyric acid (GABA) A receptor, alpha 5 precursor [Homo sapiens]

EX03-053P

MDNGMFSGFIMIKNLLFCISMNLSHFGFSQMPSTSVDNTIDGGLDGYDNRLRPGLE
RITQVRTDIYVTSFGPVSDTEMETYIDVFFRQSWKDERLRFKGPMQLPLNNLLASKIWT
SIAHNMTPNKLLRLEDGDGLTYMRLTISAECPMOLEDFPMDAACPLKFGSYAYPNSEVVY
KSVVVAEDGSRLNQYHLMQTVGTTENISTSTGEYTINTAHLKRKIGYFVIQTYLPCIMT
LNRESVPARTVFGVTVLMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFAT
WDGKKALEAAKIKKKREVILNKSTNAFTTGKMSHPNPNIKEQTAGTSNTTSVSVK
SISKIDKMSRIVFPVLFGTFLNVWATYLNREPIVIKGAAASKP

>gi|4504019|ref|NP_000162.1| glycine receptor, alpha 1 [Homo sapiens]
MYSFNTLRLYLSGAIFFSLAASKEAAARSATKPMSPSDLKLMGRTSGYDARIRPNFKGPPNVSCN
IFINSFGSIAETTMDYRVNIFLRQQWNPRLAYNEYPDDSDLDPMSLDSIWKPDLFFANEKGAHFHEIT
TDNKLLRISRNGNVLYSIRITLTLACPMDLKNPMDVQTCIMQLESFGYTMNDLIPEWQEQQAVQADGL
TLPQFILKEEKDLRYCTKHNTGKFTCIEARFHLERQMGGYLIQMYIPSLLIVILSWISFWINMDAAPAR
VGLGITVLTMTTQSSGSRASLPKVSYVKAIIDIWMAVCLLFVFSALLEYAAVNFSRQHKELLFRKR
HHKEDAEAGEGRFNFSAYGMGPACLQAKDGISVKGANNNTNPPPAPSKSPEEMRKLFIQRAKKIDKISR
IGFPMAFLIFNMFYWIYKIVRREDVHNQ

>gi|20127457|ref|NP_004121.2| glycogenin [Homo sapiens]
MTDQAFVTLTTNDAYAKGALVLGSSLKQHRTTRRLVVLATPQVSDSMRKVLETFVDEVIMVDVLDGDSA
HLTLMKRPELGVTLTKLHCWSLTQYSKCVFMDADTLVLANIDDLFDREELSAAPDPGWPDCFNSGVFVYQ
PSVETYNQLLHLASEQGSFDGGDQGILNTFFSSWATTDIRKHLPFIYNLSSIISIYSLPAFKVFGASAKV
VHFLGRVKPWNNTYDPKTKSVKSEADPNMTHPEFLILWWNIFTTNVLPLLQQFGLVKDTCSYVNVLSDL
VYTLAFSCGFCRKEDVSGAISHLSLGEIPAMAQPFVSSEERKERWEQGQADYMGADSFDNKRKLDTYLQ

>gi|5453674|ref|NP_003909.1| glycogenin 2 [Homo sapiens]
MSETEFHGAGQAGLELLRSSNSPTASQSGAMTVTDQAFVTLATNDIYCGALVLGQSLRRHRLTRKLVV
LITPQVSSLRVLISKVFDENVLIDSADYIHLAFLKRPEGLTLTKLHCWTLTHYSKCVFLDADTIV
LSNVDELFDRGEFSAAPDPGPWDCFNSGVVFQPSLHTHKLLLQHAMEHGSFDGADQGLLNSFFRNWSTT
DIHKHLPIFYINLSSNTMYTSPAFKQFGSSAKVVFGLGSMKPWNKYKNPQSGSVLEQGSVSSSQHQAAFL
HLWWTVYQNNVLPLYKSVQAGEARASPQHTLCHSDVGGPCADSASGVGEPCENSTPSAGVPCANSPLGSN
QPAQGLPEPTQIVDETLSLPEGRRSEDMIACPETETPAVITCDPLSQSPQPADFTETETILQPKANVKES
VSSEETFEPSQELPAEALRDPQLQDALEVDLAVSVSQTIEEKVKELSPEEERRKWEGRIDYMGKDFA
RIQEKLDRFLQ

>gi|30147855|ref|XP_301113.1| similar to Glycogenin-1 [Homo sapiens]
MTDQVFVLTNTDAYTKGALVLGSSLKQHRTTRRLVMLATPQVSDSMRKVLETFDEIIVVDVLDGDSAA
HLTLMKRPELAFLKVFVGASAKVVFGLGVKPWNYTYDPKTKSVKNESHHPNVTHPEFLILWWNIFTTTVLP
LLQQFGLVKDTSYVNENVSGAISHLSLGGIPAMAQSVPQKNGRSGGNRARPIIWEQIPLTTSRGSLT
LTSSRNNTAFSCGHIFHTSLSVSDT

>gi|4757726|ref|NP_004632.1| myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) ALL1 fused gene from chromosome 10; myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 10 (Homo sapiens)
MVSSDRPVSLEDEVSHSMKEMIGGCCVCSDERGWAENPLVYCDGHGCCVAHQACYGIVQVPTGPWFCKR
CESQERAARVRCELCPHKDGAALKRTDNGGWAHVVCALYIPEVQFANVSTMPEPIVLQSVPHDRYNKTCYIC
DEQGRESKAATGACMTCNKHGRQAFHVTCAQFAGLLCEEENGADNVQCYGYCKYHFSKLKSKRGSNR
SYDQSLSDSSHSQDKHKEKKYKEKDHHQKHKQPEPSPALVPSLTVTTEKTYTSTSNNISGSLK
RLEDTTARFTNANFQEVSAAHTSSGKDVSERGSEGKQKSSAHSSSGQRGRKPQGGRNPGTTVSAASPFPKQ
GSFGSGTPGSVKSSSGSSVQSPQDFLSFTDSLRNDSYSHSQQSSATKDVHKGESGSQEGGVNSFSTLIGL
PSTSATVSPQKSFENSPGDGNSSLPTAGYKRAQTSGIEEETVKEKKRKGKQSKHGPGRPKGNKNQENV
SHLSVSSASPTSSVASAAGSITSSSLQKSPTLLRNGLSQLSVGSSPVGSEISMQYRHGDACPTTFSEL
LNIAIHNRGDSSTLTQKELFIGIYNSNDVAVSPNVSQSGSSTPVSSSHLPQQSSGHLQQVGA
LSPRSPVSSLQIRYDQPGNSSLNLPPVAASIEQLLERQWSEQQFLLEQGTPSDILGMLKSLHQLQVEN
RRLEEQIKNLTAKKERLQLLNAQLSVPFPTITANPSPSHQIHTFSQAQTAPTTDSLNSSKSPHIGNSFLPD
NSLPVLNODLTSSGOSTSSSSALSTPPPAGOSPAQOGSGVSGVQOVNGVTVGALASGMQPVTSTIPAVSA

EX03-053P

VGGIIGALPGNQLAINGIVGALNGVMQTPVITMSQNPTPLHTTVPPNATHPMATLTNSASGLGLLSDQQ
RQILIHQQQFQQLLNSQQLTPVHRRPHFTQLPPTHFSPSMEIMQVRK

>gi|5174577|ref|NP_005928.1| myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6; Myeloid/lymphoid or mixed-lineage leukemia, translocated to, 6; myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 6 [Homo sapiens]

MKEMVGCCVCSDERGWAENPLVYCDGHACSVAVHQACYIVQVPTGPWFCRKCESQERAARVRCELCPH
KDGALKRTDNGGWAHVVCALYIPEVQFANVLTMEPIVILQYVPHDRFNKTCYICEETGRESKAAGACMTC
NRHGCRCQAFHVTCAQMAGLLCEEVEVDNVKYCGYCKYHSKMKTSRHSSGGGGGAGGGGGSMGGGS
GFISGRRSRSASPSTQQEKHPTHHERGQKKSRSRKDERLKQKHKKRPESPPSILTPPVVPTADKVSSASS
SSHHEASTQETSESSRESKGKKSSSHSLSHKGKKLSSKGKVSSFTSASSSSSSSSSSGGPFQPAVSSLQ
SSPDFSAFPKLEQPEEDKYSKPTAPAPSAPPSSPAPEPPKADLFEQKVFSGFGPIMRFSTTSSSGRAR
APSPGDYKSPHVGTGASAGTHKRMPALSATPVADETPTGLKEKKHKASKRSRHGPGRPKGSRNKEGT
GGPAAPSLPSAQLAGFTATAASFSGGSLSVSGGLSSRTFGPSGLPSLSLESPLLGAGIYTSNKDPI
SHSGGMLRAVCSTPLSSSLGGPGTSALPRLSRSPFTSLPSSSASISTTQVFSLAGSTFSLPSTHIFGT
PMGAVNPILLSQAESSHTEPDLEDSCFRCRTSPQESLSSMSPISSLPALFDQTASAPCGGGQLDPAAPGT
TNMEQLLEKQGDGEAGVNIVEMLKALHALQKENQRQLQEQLSLTAKKERLQILNVQLSVPFPALPAALPA
ANGPVPGPYGLPPQAGSSDSLSTS KSPPGKSSGLDNSLSTSSEDPHSGCPRSSSSLSFHSTPPPLPLL
QQSPATLPLALPGAPAPLPPQPQNGLGRAPGAAGLGMAMPMAEGLLGGLAGSGGLPLNGLLGGLNAAAPN
PASLSQAGGAPTLQLPGCLNSLTEQQRHLLQQQEQQLQQLQQLASPQLTPEHQTVVYQMIQQIQQQREL
QRLOMAGGSQLPMASLLAGSSTPLLSAGTPGLLPTASAPPLPAGALVAPSLGNNTSLMAAAAAAAVAA
AGGPPVLTATNPFLSLSGAEGGGGPKGGTADKGASANQEKG

>gi|4505957|ref|NP_002688.1| POU domain, class 2, transcription factor 1; Octamer-binding transcription factor-1 [Homo sapiens]

MNNPSETSKPSMESGDGNTGTQTNGLDFQKQPVPGGAISTAQAQAFGLHLHQVQLAGTSLQAAAQSLNV
QSNSNEESGDSQQPSQPSQPSVQAAIPQTQLMLAGGQITGLTLPAQQQLLQQAAQAAQQLAAAVQOH
SASQQHSAAGATISASAATPMTOPIQLSQPIQIAQDLQQLQQLQQQNLNLQQFVLVHPTTNLQPAQFIISO
TPQGQQQLLQAQNLTQLPQQSQANLLQSQPSITLTSQPATPTRTIAATPIQTLQSQSTPKRIDTPSLE
EPSDLEELQFAKTFQRRRIKLGFTQGDVGLAMGKLYGNDFSQTTISRFEALNLSFKNMCKLKPPLKEWL
NDAENLSSDSSLSSPSALNSPGIEGLSRRRKRTSIE TNIRVALEKSFLENQKPTSEEITMIADQLNMEK
EVIRWFNCNRRQKEKRINPPSSGTSSSPIKAIFPSPTSLVATTPLS VLTSSAATLT VSPVPLTSAAVT
NLSVTGTSDDTSNNATVISTAPPASSAVTSPSLSPSPSASASTSEASSASETSTTQTTSTPLSSPLGTS
QVMVTASGLQAAAAALQGAAQLPANASLAAMAAAAGLNPNSMAPSQAAGGALLSLNPGTLSGALSPAL
MSNSTLATIQLASGGSLPITSLDATGNLVFANAGGAPNIVTAPLFLNPQNLSLTSNPVSLVSAAAASA
GNSAPVASLHATSTSAESIQNSLFTVASASGAASTTTASKAQ

>gi|4505959|ref|NP_002689.1| POU domain, class 2, transcription factor 2 [Homo sapiens]

MVHSSMGAPEIRMSKPLEAEKQGLDSPSEHTDTERNGPDTNHQNPQNKTSPFSVSPGPSTKIKAEPSG
DSAPAAPLPPQPAQPHLPQAQMLTGSQLAGDIQQLLQLQQLVLPVGHHLQPPAQFLLPQAQQSQPGLLP
TPNLFQLPQQTQGALLTSQPRAGLPTQPPKCLEPPSHPEEPSDLLEELQFARTFKQRRRIKLGFTQGDVGL
AMGKLYGNDFSQTTISRFEALNLSFKNMCKLKPPLKEWLNDAEITMSVDSSLPSPNQLSSPSLGFGLPGR
RRKKRTSIE TNVRALEKSFLANQKPTSEEILLIAEQLHMEKEVIRWFNCNRRQKEKRINPCSAAPMLPS
PGKPASYSPHMVTPGGAGTLPQLSQASSSLTTVTTLSAVGTLHPSRTAGGGGGGGAAPPLNSIPS
PPPATTNSTNPSPQGSHSAIGLGLNPSTGPGLWWNPAPYQP

>gi|7657409|ref|NP_055167.1| POU transcription factor; likely ortholog of mouse POU domain, class 2, transcription factor 3 [Homo sapiens]

MVNLESMTDIKMSGDVADSTDARSTLSQVEPGNDRKGLDFNRQIKTEDLSDSLQQTLSHRPCHLSQGPA
MMMSGNQMSGLNASPCQDMAHLPLQQLVLVPGHLQSVSQFLLSQTQPGQQGLQPNNLPPFQQQSGLLLPO
TGPGLASQAFGHPGLPGSSLEPHLEASQHLPVPKHLPSSGGADEPSDLEELKFAKTFKQRRRIKLGFTQG
DVGLAMGKLYGNDFSQTTISRFEALNLSFKNMCKLKPPLKEWLNDAESSPSDPSVSTPSSYPSLSEVFGR
KRKKRTSIE TNIRLTLEKRFQDNPKPSSEEISMIAEQLSMEKEVVRVWFNCNRRQKEKRINCPVATPIKPP

EX03-053P

VYNSRLVSPSGSLGPLSVPPVHSTMPGTVTSSCPGNNSRPSSPGSGLHASSPTASQNNSKAAVNSASSF
NSSGSWYRNHSTYLH

>gi|4506071|ref|NP_002731.1| protein kinase C, iota [Homo sapiens]
MSHTVAGGGSGDHSQVRVKAYYRGDIMITHEPEPSISFEGLCNEVRDMCSFDNEQLFTMKWIDEEGDPCT
VSSQLEEEAFRLYEELNPKDSELLIHVFPVCVERPGMPCPGEDKSIYRRGARRWRKLYCANGHTFQAKRFN
RRAHCAICTDRIWGLGRQGYKCINCKLLVHKCHKLVTIECRHSLPQEPMQMDQSSMHSDHAQTVIPY
NPSSHESLDQVGEKEAMNTRESGKASSSLGLQDFDLLRVIGRSYAKVLLVRLKKTDRYAMKVKKEL
VNDDEDIDWVQTEKHFVFEQASNHPFLVGLHSCFQTESRFFFVIEYVNGGDLMFHMQRQRKLPEEHarfys
AEISLALNYLHERGIYRDLKLDNVLLDSEGHIKLTDYGMCKEGLRPGDTTSTFCGTPNYIAPEILRGED
YGFSDVWWALGVLFEMMAGRSPFDIVGSSDNPQNTEDYLQVILEKQIRIPRSLSVKAASVLSFLNK
DPKERLGCHPQTGFADIQGHPPFRNVDWDMMEQKQVVPPFKPNISGEFGLDNFDSQFTNEPVQLTPDDDD
IVRKIDQSEFEGFEYINPLLMSAECV

>gi|10864650|ref|NP_002735.2| protein kinase C, zeta [Homo sapiens]
MPSRTDPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQHQHPLTLKWDSEGDPCTV
SSQMELEEEAFRLARQCRDEGLIIVFPSTPEQPGPLCPGEGDKSIYRRGARRWRKLVRANGHLFQAKRFRN
RAYCGQC SERI WGLARQGYRCINCKLLVHKRCHGLVPLTCRKHMD SVMPSQEPPVDDKNEDADLPSEETD
GIA YISSSRKHDSIKDDSEDLKPVIDGMDGKISQGLGLQDFDLIRVIGRSYAKVLLVRLKNDQIYAM
KVVKKELVHDDEDIDWVQTEKHFVFEQASNPFVGLHSCFQTSRRLFVIEYVNGGDLMFHMQRQRKLPE
EHARFYAAEICIALNFLHERGIYRDLKLDNVLLDADGHIKLTDYGMCKEGLGP GDTTSTFCGTPNYIAP
EILRGEEYGFSDVWWALGVLFEMMAGRSPFDIITDPDMNTEDYLQVILEKPIRIPRFLSVKASHVLK
GFLNKDPKERLGCRPQTGFSDIKSHAFFRSIDWDLLEKKQALPPFQPQTDDYGLDNFDTQFTSEPVQLT
PDDEDAIKRIDQSEFEGFEYINPLLSTEESV

>gi|4759124|ref|NP_004162.1| solute carrier family 1, member 2;
H.sapiens mRNA for glutamate transporter; glutamate/aspartate
transporter II; excitatory amino acid transporter 2; glial high
affinity glutamate transporter [Homo sapiens]
MASTE GANNMPKQVEVRMPDSHLGSEEPKCHRHLGLRLCDKGKNNLLLT TVFGVILGAVCGGLLRLASPI
HPDVVMLIAFPGDILMRMLKMLIPLISSLITGLSGLD AKASGRLGTRAMVYYSMSTIIIAAVLGVILVL
AIHPGNPKLKKQLQPGKKNDEVSSLD AFDL LIRNLFPENLVQACFQQI QT VTKKVLVAPPD EEA NATA
EV SLLNETVTEVPEETK MVVI KGGLE FKDG MNV LGLIGFFIAFG IAMGKMG DQAKL MVDFFN ILNEIVM
KLVIMIMWY SPLG IACL IC GKII IA KDL EVA RQL GM YM VTVI IGLI I HGG IFLPLI YFVVTRK
NP FSL FAG IF QAW I T AL GTASS AG TL P VTF RC LEEN LGID KRV TRF VLP VGAT IN MDG TAL YEA
AA IF IA QM NGV VL DGG QI TV S LT AT LAS V GA AS I P SAG LV TM L L I TA V GL PT ED IS
LL V A DV W LL DR M RT SV NV V G DS FGA GIVYHLSK SEL DT ID SQ HRV HEDI EM KT QSI YD
DMK NH RES SN QCV YAH NS V IV DECK V T LAANG KS ADCS VEE EPW KREK

>gi|4759126|ref|NP_004163.1| solute carrier family 1 (glial high
affinity glutamate transporter), member 3 [Homo sapiens]
MTKSNGEEPKMGRMERFQQGVRKRTLLAKKKVQNITKEDVKS YL RNA FVLLTV TAVIVG TILGFTLR
P YRMSYREV KYF SF PG ELLMRMLQMLVPLI ISSLV TGMA ALD SKAS GKM GMR AVYY MTTII A VV
GII IV III HPGK GT KEN MH REG KIV R VT A ADA FDL LIR NM FPP NL V EAC FQ KFT NY EK RS F
K VPI QAN ET LV GAVIN NV SEAM ET LTR I TE ELV PV PG SV NGV N AL GLV VFS MC FG FV
IGN MKE QG Q AL RE FF D S L NE A IM R LV AVIMWY AP V G I L F L I A G K I V E
M D G V I G G Q L A M Y T V T V I V G L L I H A V I V L P L L Y F L V T R K N P
W V F I G G L L Q A L I T A L G T S S S A T L P I T F K C L E E N N G V D K R V T
R F V L P V G A T I N M D G T A L Y E A L A A I F I A Q V N N F E L N F G Q I
I T I S I T A A S I G A A G I P Q A G L V T M V I V L T S V G L P T D D I
L I I A V D W F L D R L R T T N V L G D S L G A G I V E H L S R H E L K N
R D V E M G N S V I E E N E M K K P Y Q L I A Q D N E T E K P I D S E T K M

>gi|20070239|ref|NP_006662.2| solute carrier family 1 (glutamate
transporter), member 7; excitatory amino acid transporter 5 (retinal
glutamate transporter) [Homo sapiens]
MVPHAILAR GRDV CRRNG L L ILSV LSV I V G C L L G F F L R T R R L S P Q E I S Y F Q
F P G E L L M R M L K M M I L P L V V S S L M S G L A S L D A K T S S R L G V L T
V A Y Y L W T T F M A V I V G I F M V S I I H P G S A A Q K E T T E Q S G K P I
M S S A D A L L D L I R N M F P A N L V E A T F K Q Y R T K T T P V V K S P K V
A P E E A P R R I L I Y G V Q E E N G S H V Q N F A L D L T P P
P E V V Y K S E P G T S D G M N V L G I V F F S A T M G I M L G R M G D S G
A P L V S F C Q C L N E S V M K I V A V A V W Y F P F G I V F L I A G K I

EX03-053P

LEMDDPRAVGKKLCFYSVTVCGLVLHGLFILPLLYFFITKKNPIVFIRGILQALLIALATSSSATLPI
TFKCLLENHHIDRRIARFVLPVGATINMDGTALYEAVAAIFIAQVNYYELDFGQIITISITATAASIGAA
GIPQAGLVMTMIVLTSVGLPTDDITLIIAVDWALDRFRTRMINVLGDAALAAGIMAHICRKDFARDTGTEKL
LPCETKPVSLQEIVAAQQNGCVKSVAEASELTLGPTCPHVPMVERDEELPAASLNHCTIQISELETNV

>gi|21314632|ref|NP_003029.2| solute carrier family 1, member 4;
glutamate/neutral amino acid transporter;
alanine-serine/cysteine/threonine transporter [Homo sapiens]
MEKSNETNGYLDQAQCPAAGPGAPGTAAGRARRCAGFLRRQALVLLTVSGVLAGAGLGAALRGLSLSRT
QVTYLAFFGEMLLRMLMIILPLVVCSLVSGAASLDASCLGRGGIAVAYFGLTLSASALALVALAFI
PGSGAQTLQSSDLGLEDGPPPVPKETVDSFLDLARNLFPNSLVAAFRTYATDYKVVTQNSSSGNVTHE
KIPIGTEIEGMNIILGLVLFALVLGVALKKLGSEGEDLIIRFFNSLNEATMVLVSWIMWYVPVGIMFLVGSK
I VEMKDIIIVLVTSLGKYIFASILGHVIHGGIVLPLIYFVFTRKNPFRFLLGLLAPFATAFATCSSSATLP
SMMKCIEENNNGVDKRISRFILPIGATVNMDGAAIFQCVAAVFIAQLNNVELNAGQIFTILVTATASSVGA
AGVPAGGVLTIAIILEAIGLPTHDLPLILAVDWIVDRTTVEVGDALGAGILHHLNQKATKKGEQELA
EVKVEAIPNCKSEEETSPVTHQNPAGPVASAPELESKESVL

>gi|4827012|ref|NP_005062.1| solute carrier family 1 (high affinity
aspartate/glutamate transporter), member 6; excitatory amino acid
transporter 4 [Homo sapiens]
MSSHGNSLFLRESGQRLGRVGWLQLQESLQQRALRTRLQTMLEHVLRLRRNAFILLTVSAVIGV
SLAFALRPYOLTYRQIKYFSFPGEMLRMLQMLVLPLIVSSLVTGMASLDNKATGRMGRAVYYMVTTI
IAVFIGILMVTIIHPGKGSKEGLHREGRIETIPTADAFMDLIRNMFPNLVEACFKQFKTQYSTRVVT
MVRTEGSEPGASMPPFSENGTSFLENVTRALGTLQEMLSFEETVPVPGSANGINALGLVVFSAFGL
VIGGMKHGRVLRDFDSLNEAIMRLVGIIIWYAPVGLFLIAGKILEMEDMAVLGGQLGMYTLTVIVGL
FLHAGIVLPLIYFLVTHRNPFPFIGGMLQALITAMGTSSSATLPITFRCLEEGLGVDRRITRFVLPVGA
TVNMDGTALYEALAAIFIAQVNYYELNLQITTISITATAASVGAAGIPQAGLVMTMIVLTSVGLPTEDI
TLIIAVDWFLDRLRTMTNVLGDSIGAAVIEHLSQRELELQEAELTPSLGKPYKSLMAQEKGASRGRRGN
ESAM

>gi|18252049|ref|NP_004161.2| solute carrier family 1, member 1;
excitatory amino acid transporter-3; excitatory amino acid carrier 1
[Homo sapiens]
MGKPARKGCEWKRFLKNNWVLLSTVAAVVLGITGVLVREHSNLSTLEKFYFAFPGEILMRMLKLIILPL
IISSMITGVAALDSNVSGKIGLRAVYYYFCCTLIAVILGIVLVSIPKPGVTQKVGEIARTGSTPEVSTD
AMLDLIRNMFPENLVQACFQQYKTKREEVKPPSDPEMNTEESFTAUMTTAI SKNKTKEYKIVGMYS
DGI NVLGLIVFCLVFGLVIGKMGEKGQILVDFNALS DATMKIVQIIMCYMPLGILFLIAGKIIIEVEDWE
IFRNKLGLYMATVLTGLAIHSIVLPLIYFIVVRKNPFRFAMGMAQALLTALMISSSATLPVTFRC
AEENNQVDKRITRFVLPVGATINMDGTALYEAVAAVFIQALNDLIGQIITISITATSASIGAAGV
PQAGLVMTMIVLSAVGLPAEDVTLIIAVDWLLDRFRTMNVLGDAFGTGIVEKLSKKELEQMDVS
SEVNIVNPFAESTILDNEDSDTKKSYVNGGFADVKSDTISFTQTSQF

>gi|5032093|ref|NP_005619.1| solute carrier family 1 (neutral amino
acid transporter), member 5; neutral amino acid transporter B; RD114
virus receptor; baboon M7 virus receptor [Homo sapiens]
MVADPPRDSKGAAAEP TANGGLALASIEDQGAAAGGYCGSRDQVRCLRANLVLTVVAVVAGVALGL
GVSGAGGALALGPERLSAFVFPGEPLLRLRMIIPLVVC SLIGGAASLDPGALGRLGA
WALLFFLVTTL LASALGVGLALALQPGAAASAAINASVGAAGSAENAPSKEV
LDSFLDARNIFPSNLVSAAFRSYSTTYEE RNITGTRVKVPGQVE
EGMNILGLVVFAIVFGVALRKLGP EGELLIRFFNSFNEATMVLV
SWIMWYAPVG IMFLVAGKIVEMEDVGLLFARLGKYILCCLGH
AIHGLVLPLIYFLFTRKNPYRFLWGIVTPLATAGT SSSSATL
PLMMMKCVEENNGVAKHISRFILPIGATVNMDGAALFQC
VAAVFIAQLSQOSLDFVKIITILVT ATASSVGAAGIPAG
GVLT LAIILEAVNL
PVDHISLILAVDWLVDRSCTLNVEG
DALGAGLLQNYVDRTE SRSTEPELIQVKSELPLDPLPV
PTEEGNPLKHYRG
PAGDATVASEKESVM

>gi|4507047|ref|NP_003036.1| solute carrier family 7 (cationic amino
acid transporter, γ system), member 1; amino acid transporter,
cationic 1; ecotropic retroviral receptor [Homo sapiens]

EX03-053P

MGCKVLLNIGQQMLRRKVVDCSREETRLSRCNTFDLVALGVGSTLGAGVYVLAGAVARENAGPAIVISF
LIAALASVLAGLCYGEFGARVPKTGSAYLYSYVTVGELWAFITGWNLILSYIIGTSSVARAWSATFDELI
GRPIGEFSRTHMTLNAPGVLAEADPDIIFAVIILILITGLLTGKVKESAMVNKIFTCINVVLGFIMSGFV
KGSKVNWQLTEEDFGNTSGRLCLNNDTKEGKPGVGGMPFGSGVLSGAATCFYAFVGFDCAATTGEEVK
NPQKAIPVGIVASLLICFIAYFGVSAALTLMMPYFCLDNNSPLPDAFKHVGWEGAKYAVAVGSLCALSA
LLGSMFPMPRVVIYAMAEDGLLFKFLANVNDRTKTPIIATLASGAVAAMAFDLKDLVDLMSIGTLAY
SLVAACVVLRLYQPEQPVLVYQMASTSDELDPADQNELASTNDSQLGFLPEAEMFSLKTLSPKNMEPSK
ISGLIVNISTSLIAVLIITFCIVTGLGREALTKGALWAVFLLAGSALLCAVVTGVIWRQPESKTKLSFKV
PFLPVLPILSIFVNVYLMQLDQGTWVRFAVVMLIGFIIFYFGYGLWHSEEASLDADQARTPDGNLDQCK

>gi|4507049|ref|NP_003037.1| solute carrier family 7 (cationic amino acid transporter, γ^+ system), member 2; amino acid transporter, cationic 2 [Homo sapiens]
MIPCRAALTFARCLIRRKIVTLDLEDTKLCRCLSTMIDIALGVGSTLGAGVYVLAGEVAKADSGPSIVV
SFLIAALASVMAGLCYAEFGARVPKTGSAYLYTYVTVGELWAFITGWNLILSYVIGTSSVARAWSGTDFE
LLSKQIGQFLRTYFRMNYTGLAEYPDFFAVCLILLLAGLISFGVKESAWVNKVFATVNILVLLFVMVAGF
VKGNVANWKISEEFLKNISASAREPPSENGTSIYGAGGFMPYGFTGTLAGAATCFYAFVGFDCAATTGEE
VRNPQKAIPIGIVTSSLVCFMAYFGVSAALTLMMPYLLDEKSPLPVAFEYVGWGPVAKYVVAAGSLCAL
TSLLGSMFPLPRILFAMARDGLLFRFLARVKRQSPVAATLTAGVISALMAFLFDLKALVDMMSIGTLMA
YSLVAACVVLRLYQPGLSYDQPKCSPKDGLGSSPRVTSKSESQVTMLQRQGFSMRTLFCPSLLPTQQSA
SLVSFLVGFLAFLVGLSVLTTYGVHAIRLEAWSLALLTLFLVLFVAVLTIWRQPQNQQKVAFMVPFL
PFLPAFSILVNIYLMVQLSADTWVRFSIWMAIGFLIYFSYGIHSLEGHLRDENNEEDAYPDNVHAAAEE
KSAIQANDHHPRNLSSPFIFHEKTSEF

>gi|17939406|ref|NP_116192.2| solute carrier family 7 (cationic amino acid transporter, γ^+ system), member 3 [Homo sapiens]
MPWQAFRRFGQKLVRRTLESQMAETRLARCLSTLDLVALGVGSTLGAGVYVLAGEVAKDKAGPSIVICF
LVAALSSVLAGLCYAEFGARVPRSGSAYLYSYVTVGELWAFTTGWNLILSYVIGTASVARAWSSAFDNLI
GNHISKTLQGSIALHVPHVLAEYPDFALGLVLLLTGLLALGASESALVTKVFTGVNLLVLGFVMSIGFV
KGDVHNWLTEEDYELAMEALNDTYSLGPLGSGGFVPGFEGILRGAATCFYAFVGFDCAATTGEEAQNP
QRSIPMGIVISLSCVFLAYFAVSSALTLMMPYVQLOPESPLPEAFLYIGWAPARYVVAVGSLCALSTSLL
GSMFPMRVIYAMAEDGLLFRVLAIRHTGTRTPIIATVWSGIIIAAFMAFLFKLTDLVDLMSIGTLAYSL
VSICVLLRLYQPDQETKTGEEVELQEEAITTESEKLTWLGLFFFPLNSIPTPLSGQIVYVCSSLLAVLLTA
LCLVLAQWSVPLSGDLLWTAVVVLLLLIGIIVVIVIWRQPQSSTPLHFKVPALEPLLPLMSIFVNIELMM
QMTAGTWARFGVWMLIGFAIYFGYGIQHSLEEIKSNQPSRKSRAKTVLDLPGTLVHSV

>gi|29789100|ref|NP_061325.1| similar to glucosamine-6-sulfatases; sulfatase 2 [Homo sapiens]
MGPPSLVLCLLSATVFSLLGGSSAFLSHHRLKGRFQRDRRNIRPNIIVLTDQDQVELGSMQVMNKTRRI
MEQGGAAFINAFVTPMCCPSRSSILTGKYVHNHNTYTNNECSSPSWQAHESRTFAVYNSTGYRTAF
FGKYLNEYNGSYVPPGKEWVGLLKNSRFYNYTLCRNGVKEKHGSDYSKDYLTDLITNDVSFFRTSKKM
YPHRPVLMVISHAAPHGPEDSAPQYSRLEPNASQHITPSNYAPNPDKHWIMRYTGPMKPIHMEFTNMLO
RKRLQTLMSSVDDSMETIYNMLVETGELDNTYIVYTADHYHIGQFGLVKGKSMPPYEFDIRVPFYVRGPNV
EAGCLNPVHLVNLIDLAPTILDIAKLDIPADMDGKSILKLLDTERPVNRFHLLKKMRVWRDSFLVERGKLL
HKRDNDKVDAQEENFLPKYQRVKDLCQRAEYQTACEQLGQKWCQVEDATGKLKLHKCKGPMRLGGSRALS
NLVPKYYGQGSEACTCDSGDYKLSLAGRRKLKKKYKASYVRSRSIRSVAIEVDGRVYHVGLGDAAQPR
NLTKRHWPAGEDQDDKDGDFSGTGGLPDSAANPIKVTHRHYTLENDTVQCQDLYKSLQAWKDHKLH
IDHEIETLQNKKIKNLREVRGHLKKRPEECDCHKISYHTQHKGRLLKRGSSLHPRKGLQEKKDVWLLRE
QKRKKKKRKLKRLQNNDTCSMPGLTCFTHDNQHWQTAPFWTLGPFCACTSANNTNTYWCMTTINETHNFL
FCEFATGFLEYFDLNTDPYQLMNAVNTLDRDVLNQLHVQLMELRSCKGKQCNPRTRNMDLKDGGSYE
QYRQFQRRKWPPEMKRPSKSLGQLWEGWEG

>gi|29789064|ref|NP_055985.1| sulfatase FP [Homo sapiens]
MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIIVLPTDDQDQVELGSLQVMNKTRKIM
EHGGATF1NAFVTPMCCPSRSSMLTGKYVHNHNTYTNNECSSPSWQAHESRTFAVYNNTGYRTAFF
GKYLNEYNGSYIIPPGRWELGLIKNSRFYNYTCSRNGIKEKHFDFYAKDYFTDLITNESINYFKMSKRMY
PHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSNYAPNMDKHWIMQYTGPMPLPIHMEFTNILQR

EX03-053P

KRLQTLMSVDDSVERLYNMLVETGELENTYIYTADHGYHIGQFGLVKGKSMFYDFDIRVPFFIRGPSVE
PGSIVPQIVLNIDLAPTIILDIAGLDTPPDVGKSVLKLLDPEKPGNRFRNTKKAKIWRDTFLVERGKFLR
KKEESSKNIQQSNSHLPLKYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPDLLTVRQSTR
NLYARGFHDKDKECSCRESGYRAARSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVFEGEIYDINLE
EEEELQLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGPPMTVRVTHKCFILPNDSIHCR
ELYQSARAWDKDHKAYIDKEIEALQDKIKNLREVRGHLRKPEECSCSKQSYYNKEGVKKQEKLKSHLH
PFKEAAQEVDSKLQLFKENNRRRKERKEKRQRKGECLSPGLTCFTHDNNWQATFWNLGSFCACTS
SNNNTYWCLRTVNETHNFLCEPATGFLEYFDMMTDPYQLNTVHTVERGILNQLHVQLMELRSCQGYKQ
CNPRPKNLDVGNKDGGSYDLHRGQLWDGWEG

>gi|27597096|ref|NP_775491.1| uridine phosphorylase-2; liver-specific
uridine phosphorylase [Homo sapiens]
MASVIPASNRSMRSRNTYVGKRFVHVKNPYLDMDEDILYHLDLGTKTHNLPAMFGDVKFVCVGGSPNR
MKAFALFMHKELGFEAEEDIKDICAGTDRCMYKTGPVLAISHGMGIPSISIMLHELIKLLHHARCCDV
TIIIRIGTSGGIGIAPGTVVITDIAVDSFFKPRFEQVILDNIVTRSTELDKELEELFNCSEIPNFPTLV
GHTMCTYDFYEGQGRLDGALCSFREKKLDYLKRAFKAGRNIEMESTVFAAMCGLCGLKAAVVCVTLLD
RLDCDQINLPHDVLVEYQQRPQLLISNFIRRLGLCD

>gi|4507839|ref|NP_003355.1| uridine phosphorylase [Homo sapiens]
MAATGANAEKAESHNDCPVRLNPNIAKMKEDILYHFNLTSRHNFPALFGDVKFVCVGGSPSRMKAFIR
CVGAELGLDCPGRDYPNICAGTDRYAMYKVGVLVSOSHMGIPSISIMLHELIKLLYYARCSNTIIRIG
TSGGIGLEPGTVVITEQAVDTCFKAEEFEQIVLGKRVIRKTDLNKKLVQELLCSAELSEFTTVVGNTMCT
LDFYEGQGRLDGALCSYTEKDKQAYLEAAAGVRNIEMESSVFAAMCSACGLQAAVVCVTLLNRLEGDQ
ISSPRNVLSEYQQRPQLLVSYFIKKKLSKA

>gi|5803133|ref|NP_006825.1| RAB32, member RAS oncogene family [Homo
sapiens]
MAGGGAGDPGLAAAAAPAPETREHLFKVLVIGELGVGKTSIIKRYVHQLFSQHYRATIGVDFALKVWNWD
SRTLVRLQLWLDIAGQERFGNMTRVYYKEAVGAFVVFDISRSSTFEAVLKWKSDLDKVHLPNGSPIPAVL
LANKCDQNKDSSQSPSQVDQFCKEHGFAGWFETSAKDNINIEEAARFLVEKILVNHQSPNEENDVDKIK
LDQETLRAENKSQCC

>gi|11641237|ref|NP_071732.1| RAB38; Rab-related GTP-binding protein
[Homo sapiens]
MQAPHKEHLYKLLVIGDVGKTSIIKRYVHQNFSHYRATIGVDFALKVLHWDPETVVRQLQWLDIAGQE
RFGNMTRVYYREAMGAFIVFDVTRPATFEAVAKWKNLDSKLSLPNGKPVSVLLANKCDQGKDVLMNNG
LKMDQFCKEHGFVGWFETSAKENINIDEASRCLVKHILANECDLMESEPDVVKPHLTSTKVASCSCAK
S

>gi|4506375|ref|NP_003920.1| RAB7, member RAS oncogene family-like 1
[Homo sapiens]
MGSRDHFLFKVLVVGDAAVGKTSLVQRYSQDSFSKHYKSTVGVDFAKVLQWSDYEIVRLQLWLDIAGQRF
TSMTRLYYRDASACVIMFDVTNATTFSNSQRWKQDLD SKLTLPGEPVPCLLANKCDLSPWA SRDQID
RFSKENGFTGTWTESVKENKNINEAMRVLIEKMMRNSTEDIMSLSTQGDYINLQTKSSSWSCC

>gi|8923042|ref|NP_060103.1| chromosome 6 open reading frame 37;
retinal expressed gene C6orf37 [Homo sapiens]
MAEGERGYFAMSEDELACSPYIPLGGDFGGDFGGDFGGDFGGGGSFHHCLDYCESPTAHCNV
LNWEQVQRLLDGILSETIPIHGRGNFPTELELQPSLIVKVRRRLAEKRIGVRDVRNLNGSAASHVLHQDSL
GYKDLDLIFCADLRGEGEFQTVKDVVLDCLLDFLPEGVNKEKITPLTLKEAYVQKMVKVCNDSDRWSLIS
LSNNSGKNVELKFVDSLRRQFESVDSFQIKLDSLLLFEYCSENPMETFHPTIIGESVYGFQEAQDFH
CNKIIATRNPEEIRGGGLLKCNLLVRGFRPASDEIKALQRYMCSSRFIDFSDIGEQQRKLESYLQNHFV
GLEDRKYEYLMTLHGVVNESTVCLMGHERRQTLNLITMLAIRVLADQNVIPNVANVTCYYQPAPYVADAN
FSNYYIAQVQPVFTCQQQTYSTWLPCN

>gi|8923192|ref|NP_060179.1| hypothetical protein FLJ20202 [Homo
sapiens]

EX03-053P

MAEESSCTRDCMSFSVLNWDQVSRLHEVLTEVVPIHGRGNFPTLEITLKDIVQTVRSLLEEAGIKVHDVR
LNGSAAGHVLVKDNGCKDLDLIFHVALPTAEFQLVRDVVLCSLLNFLPEGVNKLKISPVTIKEAYVQ
KLVKVCTDTVRWSLISLSNKNGKVELKFVDSIRRQFEFSVDSFQIILDSLLFFYDCSNNPISEHFHPTV
IGESMYGDFEEAFDHLQNRLIATKNPEEIRGGGLLKYSNLVRDFRPTDQEIKTLERYMCSSRFFIDFPD
ILEQQRKLETYLQNHFEEERSKYDYLMLRRAVNESTVCLMGHERRQTLNLISLLALRVLAEQNIIPSA
TNVTCYYQPAPYVSDGNFSNYYVAHPPVTYSQPYPTWLPCN

>gi|16418427|ref|NP_443175.1| hypothetical protein MGC16491 [Homo sapiens]
MPSESGAERRDRAAAQVGTAATAAVATAAAPAGGGPDPEALSAFPGRHLSGLSWPQVKRLDALLSEPIIH
GRGNFPTLSVQPRQIVQVVRSTLLEEQGLHVHSVRLHGSASHVLHPESGLGKDLVLFRVDLRSEASFQ
LTКАVVLACLLDFLPAGVSRAKITPLTLKEAYVQKLVKCTSDRWSLISLSNKSGKVELKFVDSVRRQ
FEFSIDSFQIILDSLLLFGQCSSTPMSEAFHPTVTGESLYGDFTEALEHLRHRVIATRSPEEIRGGGLK
YCHLLVRGFRPRPSTDVRALQRYMCSSRFFIDFPDLVEQRRTLERYLEAHFGGADAARRYACLVTLHRVVN
ESTVCLMNHERRQTLDLIAALALQALAEQGPATAALAWRPPGTDGVPATVNYYTPVQPLLAHAYPTW
LPCN

>gi|22749287|ref|NP_689843.1| hypothetical protein MGC26999 [Homo sapiens]
MSEIRFTNLTWDQVITLDQVLDEVIPIHGKGNFPTMEVKPKDIIHVVKDQLIGQGIIVKNDARLNGSVASY
ILASHNGISYKDLDVIFGVELPGNEEFQVVKDAVLDCLLDFLPKDVKKEKSPDIMKDAYVQKLVKCNG
HDCWSLISLSNNTGKNELELFVSSLRQFEFSVDSFQIVLDPMDFYSDKNAKLTKESYPVVVAESMYGD
FQEAMTHLQHKLICTRKPEEIRGGGLLKYSCLLVHGFKPCMSEIKNLERYMCSSRFFIDFPHIEEQKKI
ESYLHNHFIGEGMTKYDYLMTLHGVVNESTVCLMSYERRQILHLITMMALKVLGELNILPNTQKVTCFYQ
PAPYFAAEARYPIYVIPEPPPVSFQPYHPLHFRGSNGMS

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/026338

International filing date: 12 August 2004 (12.08.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/495,172
Filing date: 14 August 2003 (14.08.2003)

Date of receipt at the International Bureau: 30 September 2004 (30.09.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse